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DEVELOPMENT AND APPLICATION OF NEW DIAGNOSTIC ASSAYS FOR               
THE DETECTION OF BARTONELLA HENSELAE INFECTION IN CATS  
 
 
Many species of the bacteria in the genus Bartonella are well known as zoonotic 
pathogens in humans and are increasingly recognized in a wide range of animals. To date, 
several mammals are known to serve as natural reservoirs of a variety of Bartonella spp.. 
Bartonella henselae is one of the most common species and primarily causes cat-scratch disease 
in humans. The cat plays a role as a predominant reservoir of this organism. Bartonella henselae 
infection in cats is widespread in most countries due to transmission via the cat flea, 
Ctenocephalides felis. Seroprevalence rates as high as 90% and bacteremia rates as high as 80% 
have been reported in flea infested healthy cats. While most infected cats show no signs of 
disease, some develop non-specific manifestations such as fever. Thus, laboratory assay results 
are necessary to aid in the diagnosis of the clinical feline bartonellosis. 
Serology, culture, and PCR assays for the amplification of Bartonella spp. DNA are the 
assays most widely available commercially. Results of the currently available assays are 
commonly reported as positive or negative and because of the high prevalence rates of infection, 
positive assay results are often not associated with the clinical manifestations of B. henselae 
infection. In some infectious disease, levels of bacteremia are associated with clinical 
manifestations of disease. While quantitative B. henselae bacterial culture has been performed in 
some research cats, test results take several weeks to return and quantitative culture has not been 
used to evaluate clinically ill cats in the field.  PCR assay and antigen assay results can be 
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returned quickly.  However, levels of B. henselae DNA or antigen in the blood of cats have not 
been evaluated for association with clinical manifestations of disease, particularly fever. Thus, 
the primary goals of the research described in this dissertation were to develop new quantitative 
diagnostic assays and to apply them to an at-risk cat population in Thailand in order to determine 
if the assays would aid in the diagnosis of fever caused by B. henselae. The 2 diagnostic assays 
developed were 1) a quantitative real-time PCR (qPCR) and 2) an antigen-capture ELISA (AC-
ELISA). Both assays can be used to determine the quantity of B. henselae in feline blood and can 
have results returned within one day.  
The experiments describing the titration of a new qPCR for amplification of the groES 
gene of B. henselae in blood of cats are presented in Chapter 3. The qPCR was shown to have 
high sensitivity and could detect at least 52 CFU/ml of B. henselae in blood accurately. The 
assay was also shown to be highly specific and reproducible.  
The experiments to titrate a new B. henselae AC-ELISA are described in Chapter 4 of the 
dissertation. Rabbit polyclonal antibodies against the CSU-1 isolate of B. henselae were 
produced and purified for specific use in this research. After the AC-ELISA was optimized, the 
assay has shown to be specific for detection of B. henselae antigen and detect at least 1.25 ng/µl 
of B. henselae antigen in feline blood. However, when applied to blood collected from 
experimentally-inoculated cats, the AC-ELISA detected only 50% of cats shown to be positive 
by the qPCR assay and so it was concluded the assay had lower analytical sensitivity.  
The prevalence of several Bartonella spp. infections (B. henselae, B. clarridgeiae, and B. 
koehlerae) that use C. felis as the vector generally correlates to the infestation prevalence. 
Thailand is located in a tropical area where the climate is appropriate for C. felis. However, 
available information regarding Bartonella infection of client-owned cats and C. felis collected 
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from those cats is minimal. Thus, Chapter 5 of the dissertation reports the DNA prevalences of 
Bartonella spp. and other blood borne infections, including hemoplasmas and Rickettsia felis in 
blood and fleas of client-owned cats which lived in Bangkok, Thailand. The prevalence rates of 
Bartonella spp. DNA in blood and flea samples were 17% and 32%, respectively. Bartonella 
henselae and B. clarridgeiae were amplified most commonly. Hemoplasmas were commonly 
found in cats and fleas, as well, but R. felis was absent. The results of this preliminary study were 
used to design the subsequent field study to collect samples from cats with and without fever. 
Fever is the most common clinical sign in cats experimentally infected with B. henselae. 
To determine the clinical utility of the B. henselae qPCR (Chapter 3) and AC-ELISA (Chapter 
4), these assays were applied to the blood samples collected from healthy cats and cats with fever 
of unknown origin in Bangkok, Thailand (Chapter 6). Risk factors that might be associated with 
fever were also determined. Using the qPCR, cats with fever were significantly more likely than 
afebrile cats to have B. henselae DNA in blood supporting the hypothesis that B. henselae is 
associated with fever in naturally infected cats. Cats with fever had 50X higher median bacterial 
counts of B. henselae than those of afebrile cats but the results were not statistically different 
between groups because of the wide range. However, these findings suggest that cats with high 
bacterial loads were more likely to develop fever but a larger sample size is needed. The AC-
ELISA was shown to be less sensitive than the qPCR assay with only about 30% of the qPCR 
positive samples being positive by AC-ELISA. Because of the low overall sensitivity, the AC-
ELISA did not provide enough information to determine an association with fever. However, the 
sample set collected in this chapter and the prototype AC-ELISA results could be used in future 
experiments designing more sensitive assays. 
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The research described in this dissertation raises the knowledge in the field of feline 
bartonellosis. The results provide additional prevalence results for cats in one area of Thailand, 
provides additional information that B. henselae infection in cats can be associated with fever, 
and suggests that use of qPCR results are superior to non-quantitative test results to make an 
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1.1  Taxonomy 
Bartonella spp. are gram-negative bacteria that belong to alphaproteobacteria on the basis 
of 16S rDNA sequences. More than 20 species and subspecies have been discovered in a wide 
range of domestic and wild animals and the number of species identified is still expanding. 
Bartonella spp. are highly adaptive and co-evolved organisms in mammalian reservoir hosts. 
Each species of Bartonella is typically identified and designated in at least one reservoir host 
(Table 1-1). 
 
1.2 Bacteriological Features 
Bartonella spp. are small (0.3-0.6 x 0.3-1.0 µm) aerobic fastidious slow-growing 
pleomorphic bacilli or coccobacilli. Microscopically, B. clarridgeiae and B. bacilliformis have 
flagella, which facilitates erythrocyte invasion, while flagella are not apparent in other 
Bartonella spp., such as B. henselae. The organism in infected tissues can be stained with 
Warthin-Starry silver, and the organism in blood can be evaluated by blood culture. Blood is 
usually frozen to induce red blood cell lysis before being plated onto agar containing fresh blood 
of sheep, rabbit, or horse. An inoculated plate is incubated for at least one week at 35 - 37 C in 
5% carbon dioxide environment. Primary isolates of some Bartonella, such as B. henselae, B. 
clarridgeiae, B. vinsonii, or B. elizabethae have colonies with a white, rough, dry, raised 
appearance and pit the medium (Boulouis et al., 2005). Biochemical profiles of Bartonella, 
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including catalase, oxidase, urease and nitrate reductase are negative except for the production of 
peptidases, which varies slightly among species (Breitschwerdt and Kordick, 2000).  
Table 1-1  Bartonella species and subspecies, primary reservoir hosts, vectors, and known 
accidental hosts (Chomel and Kasten, 2010) 
Species  Primary 
reservoir 
Vector   Incidental host 
B. alsatica Rabbit  Rabbit flea (potential) 
(Spilopsyllus cuniculi) 
Human  
B. bacilliformis Human  Sand fly  
(Lutzomia verrucarum) 
None 
B. clarridgeiae Cat Cat flea 
(Ctenocephalides felis) 
Human, dog 
B. elizabethae Rat  Rat flea 
(Xenopsylla cheopis) 
Human, dog 
B. grahamii Wild mice Rodent fleas Human  





B. koehlerae Cat Cat flea 
(Ctenocephalides felis) 
Human, dog 
B. melophagi Sheep  Sheep ked  
(Melophagus ovinus) 
Human  
B. quintana Human  Body louse 
(Pediculus humanis) 
Cat, dog  
B. rochalimae Canids Fleas (potential) 
(Pulex irritans, Pulex 
simulans) 
Human, dog 




Unknown  Human  
B. vinsonii subsp. 
berkhoffii 
Dog, coyote Unknown Human, cat 
B. washoensis California 
ground squirrel 




Identification of Bartonella strains and species of the isolate can be performed using 
molecular methods by amplification of selected genes such as 16S rRNA, 16S - 23S rRNA 
spacer region, or protein-encoding genes e.g. citrate synthase, followed by restriction fragment 
length polymorphism (RFLP) or DNA sequencing.  
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1.3 Clinical Relevance  
Following the discovery of Bartonella spp., the knowledge of the organism has been 
expanded in numerous publications. Many Bartonella spp. were apparently defined as zoonotic 
pathogens since the early 1990s. At least eight Bartonella species or subspecies, including B. 
henselae, B. koehlerae, B. elizabethae, B. clarridgeiae, B. vinsonii subsp. arupensis, B. vinsonii 
subsp. berkhoffii, B. grahamii, and B. washoensis have been recognized as zoonotic agents in 
humans, and are responsible for a wide spectrum of symptoms in multiple organ systems 
(Chomel et al., 2004). Most reservoir animal hosts typically have subclinical infections or have 
minimal clinical signs, but infections may cause severe disease in incidental hosts. Host 
responses to infection range from subclinical or asymptomatic to significant clinical 
manifestations depending on virulence of the Bartonella spp., host immunity and host 
adaptation. Bartonella bacilliformis and B. quintana are human-specific. Infection with B. 
bacilliformis causes Carrion’s disease that is frequently reported in South America. The acute 
phase, also known as Oroya fever, is characterized by an acute fatal hemolytic anemia, and the 
chronic vasoproliferative phase called verruga peruana, in which the patients develop cutaneous 
nodular vascular eruptions. Infection in animals has never been reported. Bartonella quintana is 
not considered to be zoonotic; but the organism is the etiologic agent of trench fever and 
bacillary angiomatosis (BA), characterized by a vascular proliferative lesion, that is commonly 
observed in immunocompromised patients (Koehler and Tappero, 1993). In addition, B. quintana 
has been an etiology of endocarditis and chronic bacteremia in homeless people (Brouqui et al., 
1999). Infection with B. quintana may have mild illness with low morbidity and limited 
mortality. Humans are also considered the primary reservoir host for B. quintana, which is 
transmitted by the human body louse. However, B. quintana DNA has been identified from 
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blood of animals such as feral cats (Breitschwerdt et al., 2007b), dogs with endocarditis (Kelly et 
al., 2006), healthy Golden Retrievers and Golden Retrievers with lymphoma (Duncan et al., 
2008), and a captive-bred cynomolgus monkey (Macaca fascicularis) (O'Rourke et al., 2005).  
Cats are a major reservoir host for B. henselae and potentially B. clarridgeiae. Bartonella 
henselae is generally isolated or DNA amplified from blood of cats, and most infected cats have 
no clinical signs. Nevertheless, mild to severe clinical signs have been documented in naturally 
and experimentally B. henselae infected cats. In humans, B. henselae infection results in self-
limiting illness as cat-scratch disease (CSD) or severe clinical diseases e.g. BA. Bartonella 
henselae is the primary etiologic agent of CSD, which is commonly characterized by fever and 
localized lymphadenopathy. In typical CSD patients, a papule and then a pustule usually 
develops within 7-12 days after a cat scratch at the inoculation site. A regional lymphadenopathy 
develops within a few weeks after infection and can persist a few weeks to several months. 
Abscessed lymph nodes are reported occasionally. Fever, malaise, and muscle ache are often 
reported. Less than 10% of CSD patients may develop atypical CSD. A broad spectrum of 
disease manifestations of atypical CSD are currently recognized, such as fever of unknown 
origin (FUO), peliosis hepatis, BA, Parinaud’s oculoglandular syndrome, encephalitis, 
neuroretinitis, osteomyelitis, and endocarditis (Florin et al., 2008). Bartonella henselae infection 
was also reported to be a cause of peliosis hepatis in dogs (Kitchell et al., 2000). 
Bartonella clarridgeiae antibodies were reported in a suspect case of CSD, in a patient 
with a chest-wall abscess due to CSD, and in some patients with lymphadenopathy (Kordick et 
al., 1997a; Margileth and Baehren, 1998; Sander et al., 2000). However, significant cross-
reactivity between B. henselae and B. clarridgeiae was identified (Tsuneoka et al., 2004). Based 
upon the serological evidence, B. clarridgeiae may be an infrequent agent of CSD and other 
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clinical syndromes in people. While frequently detected in cats and dogs, associations with 
clinical disease are unclear. 
B. vinsonii subsp. berkhoffii was originally isolated from a dog with endocarditis 
(Breitschwerdt et al., 1995), but the role of dogs for serving as a reservoir host for B. vinsonii 
subsp. berkhoffii or other Bartonella spp., such as B. henselae, or B. clarridgeiae is poorly 
defined. However, there are increasing reports that this organism is associated with clinical 
illnesses in humans. For example, B. vinsonii subsp. berkhoffii was isolated from a patient with 
endocarditis (Roux et al., 2000), and patients with arthritis, fatigue, neurologic or neurocognitive 
problems such as headaches, insomnia, memory loss, or incoordination (Breitschwerdt et al., 
2007a; Breitschwerdt et al., 2008; Breitschwerdt et al., 2010). Most of these individuals had 
animal contact and arthropod exposure as potential risk factors. Recently, B. henselae and B. 
vinsonii subsp. berkhoffii have been isolated or DNA amplified from several body fluids, 
including pleural, pericardial, and abdominal effusions from dogs with idiopathic cavitary 
effusions or constrictive pericarditis (Cherry et al., 2009), synovial fluid from a polyarthritic dog, 
and subcutaneous seroma fluids from a traumatic dog (Diniz et al., 2009b). Although the extent 
to which effusions are caused by B. henselae and B. vinsonii subsp. berkhoffii is unconfirmed, 
the bacteria may be a cause in the development of various effusions (Breitschwerdt et al., 2010). 
Alternatively, it is possible that dogs are previously infected with Bartonella spp., and the 
bacteria accumulate in fluids due to other illnesses. Further studies are required to define the role 
of Bartonella spp. as a cause of effusive disease in dogs. DNA from several Bartonella spp. was 
also amplified from the saliva of healthy and sick dogs (Duncan et al., 2007; Kim et al., 2009). 
Beside B. vinsonii subsp. berkhoffii and B. henselae that have been associated with 
endocarditis in humans, B. elizabethae (Daly et al., 1993), B. koehlerae (Avidor et al., 2004), B. 
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vinsonii subsp. arupensis (Fenollar et al., 2005), B. alsatica (Raoult et al., 2006), which are host 
adapted Bartonella for rat, cat, mouse, and rabbit, respectively, have been documented in 
endocarditis cases so far. Furthermore, B. vinsonii subsp. berkhoffii, B. henselae, and B. 
clarridgeiae (Chomel et al., 2001; Chomel et al., 2009b) have also been reported from dogs with 
endocarditis. Bartonella grahamii for which a rodent is a reservoir has been associated with 
patients of neuroretinitis (Kerkhoff et al., 1999). Recently, several novel Bartonella spp. have 
been isolated from sick patients and animals, such as B. tamiae (rodent reservoir) from patients 
with fever, myalgia, fatigue, and headache (Kosoy et al., 2008), or B. rochalimae (fox reservoir) 
was isolated from a woman with bactermia, fever, and splenomegaly (Eremeeva et al., 2007). 
Bartonella rochalimae has also been isolated from gray foxes, healthy dogs, and a dog with 
endocarditis (Henn et al., 2007; Diniz et al., 2009a; Henn et al., 2009).  
 
1.4 Course of Infection in the Mammalian Reservoir Host  
Bartonella spp. are hemotropic and endotheliotropic organisms. The infection causes 
prolonged bacteremia and periodically induces a relapsing bacteremia in reservoir hosts. The 
presence of B. henselae in erythrocytes of bacteremic cats was first demonstrated (Kordick and 
Breitschwerdt, 1995), and invasion of B. henselae into feline erythrocytes was described a few 
years later (Mehock et al., 1998). The course of Bartonella spp. infection in mammalian 
reservoir hosts was subsequently described in detail by the rat model of B. tribocolum infection 
(Dehio, 1999; 2001; Schülein et al., 2001).  
In the rat model, after animals were infected with B. tribocolum by intravenous 
inoculation, bacteria were rapidly cleared from circulation or maintained below detectable levels 
for about four days. Bacteria might be unable to infect erythrocytes during early stages of 
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infection, but they seemed to colonize a primary niche which is not clearly identified. However, 
it has been suggested that endothelial cells are an important localization of the primary niche 
(Dehio, 2005). After release of B. tribocolum from the primary niche into the bloodstream, the 
organism is competent for erythrocyte interaction. The organism can adhere to mature 
erythrocytes, followed by invasion and replication within a membrane-bound compartment of 
erythrocytes until a critical density is reached. The intraerythrocytic bacteria are sustained for the 
remaining lifespan of the infected erythrocytes (Schülein et al., 2001). Large numbers of B. 
tribocolum are usually released from the primary niche into the blood circulation on 
approximately day five post-inoculation. Bacteria can re-infect the primary niche which triggers 
further bacterial release, and followed by waves of re-infection. These observations suggested 
periodic sequestration in one or more tissue sites followed by re-entry into the vasculature and a 
relapsing pattern of bacteremia. The 5-day period of human trench fever caused by B. quintana is 
probably described by the bacterial re-infection. A relapsing pattern of bacteremia was also 
demonstrated in cats infected with B. henselae by blood transfusion with unpredicted period 
(Kordick and Breitschwerdt, 1997), but this phenomenon has not been confirmed in humans, 
dogs, and other reservoir animals.  
The certain life cycle of Bartonella spp. is different from species to species probably due 
to specific paths of pathogen-host adaptation, but the overall concept of this course of infection is 















Figure 1-1.   Common infection strategy of the bartonellae (Harms and Dehio, 2012). The figure 
illustrates the general concept of reservoir host infections with Bartonella. Following 
transmission by an arthropod vector (a), the bartonellae entry into migratory cells and are 
transported to the primary niche (b) colonize into the vascular endothelium (c), where the 
bacteria persist intracellularly. From the primary niche, the bacteria are seeded into the 
bloodstream (d), where they invade erythrocytes and reinfect the primary niche. After limited 
replication inside the red blood cell (e), they persist in the intraerythrocytic niche (f) competent 
for transmission by a bloodsucking arthropod (g).  
 
Intracellular bacteria seem to have immunological privilege. Therefore, Bartonella spp. 
can persist in the bloodstream for several weeks without causing an abnormality to the 
experimental rat. Lifespan of infected erythrocytes is similar to that of uninfected cells therefore 
immunological responses are unlikely to recognize the infected erythrocytes. Antibodies 
produced by the rat may neutralize bacteria released from the primary niche and protect the 
infection of additional erythrocytes as well as the re-infection of the primary niche. The 
bacteremia level of B. tribocolum in rats decreases below the detectable level after 10 weeks 
post-inoculation. A similar duration of bacteremia has been observed in experimental model of 
B. vinsonii subsp. berkhoffii infection in dogs (Pappalardo et al., 2001), but longer period of 
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bacteremia was observed in experiment cats inoculated with B. henselae feline strain or B. 
clarridgeiae (Yamamoto et al., 2002a; Yamamoto et al., 2003). To date, mechanisms that 
maintain bacterial persistence are not clearly understood. The intracellular colonization within 
erythrocytes and endothelial cells is probably a potential strategy for bacterial persistence, 
evasion from host immune responses, distribution throughout tissues of host, and transmission by 
blood-sucking arthropod vectors (Chomel et al., 2009a). 
Bartonella henselae was demonstrated to infect human CD34 progenitor cells in vitro 
(Mändle et al., 2005). This finding suggests that bacteria may infect bone marrow cells as well as 
the progenitor cells of erythrocytes. An in vitro study indicated that B. henselae can infect 
microglial cells, which are professional macrophages (Muñana et al., 2001). Other 
reticuloendothelial cells, such as dendritic cells, monocytes, tissue macrophages are capable of 
carrying bacteria and migrating through many organs. Infection of these monocytes and 
professional macrophages may allow Bartonella to localize to injured tissues as a component of 
the inflammatory process (Breitschwerdt et al., 2010). Besides red blood cells, the monocytes 
and professional macrophages are also questioned as being the primary niche of Bartonella 
infection, as well (Chomel et al., 2009a). However, further studies are needed for supporting this 
hypothesis. It appears that mechanisms of host adaptation to Bartonella spp., including 
endothelial cell localization and erythrocyte and macrophage infection may be related to the 
diversity of disease manifestations among individual hosts. Bartonella spp. may preferentially 
infect the erythrocytes of a given mammalian host without causing a disease, while endothelial 
cells may become infected and leaded to severe disease or lesion during incidental infection of 
non-reservoir hosts. For example, human infected with cat-specific B. henselae may cause BA 
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lesions where bacteria are identified in close association with proliferating endothelial cells 
(Dehio, 2005). Further studies need to be conducted to confirm this hypothesis. 
 
1.5 Pathogenicity Factors Involved in Adaptation to the Mammalian Host  
The pathogenicity factors of Bartonella spp. have been studied from the complete 
genomic sequences of 4 species of Bartonella, including B. henselae, B. quintana, B. 
bacilliformis, and B. tribocorum. Comparative genome analysis revealed that only 959 genes are 
conserved in all the genomes, which is known as small core genome that reflects specific 
adaptations and preferences of these bacteria to host-integrated metabolism, such as hemin (iron-
containing porphyrin). This substance is enriched in the host niches of Bartonella e.g. the 
intracellular space of erythrocytes and the mid-gut lumen of bloodsucking arthropods. An in 
vitro study documented the requirement of hemin for growth of B. quintana due to the presence 
of multiple genes encoding hemin binding and hemin uptake protein (Alsmark et al., 2004). A 
similar result was observed in the rat model of B. tribocorum infection using a large-scale 
signature tagged mutagenesis screen (STM), in which several of the hemin-uptake genes were 
identified as important for intraerythrocytic infection (Saenz and Dehio, 2005). The STM also 
confirmed that the majority of pathogenicity factors are dependent on the core genome of the 
four available genome sequences. All other genes that are not strictly conserved in all four 
sequenced Bartonella spp. are excluded from the core genome and constitute the accessory 
genome, which are organized in genomic islands. Some of the genome islands, such as type IV 
secretion systems and bacterial adhesins are important for Bartonella-host cell interaction and 




1.5.1 Type IV Secretion Systems 
Type IV secretion systems (T4SSs) are ancestrally related to bacterial conjugation 
machines of gram-negative bacteria that mediate the transfer of DNA and protein among diverse 
species of bacteria and from the bacterial cytoplasm directly into the host cell cytoplasm 
(Christie et al., 2005). In addition to Bartonella spp., T4SSs represent crucial pathogenicity 
factors for many important human pathogens such as Helicobacter pylori, Legionella 
pneumophila, Bordetella pertussis, and Brucella melitensis. T4SSs are recognized prominently 
for its capacity of Bartonella to adapt to their host. The accessory genome of Bartonella encodes 
at least three distinct T4SSs, which all are absent from the genome of B. bacilliformis. Thus, this 
human pathogen is placed an isolated position in the Bartonella phylogeny as the only 
representative of an ancestral lineage. All other species of Bartonella evolve in a separate 
modern lineage and represent highly host-adapted pathogens of limited virulence potential. 
Bartonella spp. of the modern lineage encode at least one of the closely related T4SSs, 
VirB/VirD4, Vbh, or Trw that involves diverse important functions in the colonization, invasion, 
and persistence within either endothelial cells or erythrocytes (Schulein and Dehio, 2002; 
Seubert et al., 2003; Schröder and Dehio, 2005). The bacterial effector proteins associated with 
vascular endothelial cell functions for establishing chronic infection are translocated by the 
VirB/VirD4 and Vbh, which are VirB-like T4SSs (Schmid et al., 2004; Saenz et al., 2007), while 
the interaction with erythrocytes is related to pilus-associate variant surface proteins expressed 
by the Trw (Seubert et al., 2003). Trw produces multiple variant pilus subunits critically 
involved in the invasion of erythrocytes. The adapted T4SSs in modern lineage lead to 




1.5.2 Trimeric Autotransporter Adhesions  
Bacterial adhesins are commonly associated with the pathogenesis of most bacterial 
infections. Adhesins can bind to extracellular matrix proteins of host cells, and assist the 
translocation of effectors from a bacterium into the host cell via T4SSs. The function of 
Bartonella trimeric autotransporter adhesions (TAA) is non-pilus-associated on the bacterial 
surface, and they are orthologous in distinct species, i.e. BadA (340 kDa protein) in B. henselae 
(Riess et al., 2004), and the Vomp family (4 of 100 kDa-proteins) in B. quintana (Zhang et al., 
2004). The Bartonella TAA plays roles in host endothelial cell binding by B. henselae (Riess et 
al., 2004; Kaiser et al., 2008), and in autoaggregation and collagen binding by both B. quintana 
(Zhang et al., 2004) and B. henselae (Riess et al., 2004). Bartonella TAA is known to represent 
significant virulence factors, and they are also immunodominant antigens that are rapidly 
notified by the host immune system (Riess et al., 2004). However, it has been suggested that 
Bartonella spp. escape the immune system of host by an increase in frequency of recombination 
of repetitive DNA sequences in the stalk domains of BadA and Vomp (Linke et al., 2006). For 
example, recombination and deletion of Vomp genes result in generation of altered Vomp 
(antigenic variation; altered the protein expressed), or loss of surface expression of one or more 
Vomp (phase variation; no longer expressed the protein on its surface). These antigenic and 
phase variation strategies can be utilized by Bartonella spp. to bind to different host cell types. 
The bacteria can evade immune system and survive in the host. This strategy facilitates the 
organism to multiply and reach the high density in the bloodstream which is then passed from the 
mammalian host to the hematophagous arthropod vector in order to be transmitted to a new host.  
In addition to the function of host cell binding of BadA and Vomp, they are involved in 
eliciting a proangiogenic host cell response that leads to generating vascular skin lesions known 
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as BA. These lesions are specific to immunocompromised patients with B. henselae and B. 
quintana infections (Koehler et al., 1992). The mechanism of BA angiogenesis is not completely 
described. However, BadA and Vomp expression is thought to be required for activation of HIF-
1 and secretion of proangiogenic cytokines e.g. vascular endothelial growth factor. It is 
hypothesized that the localization of Bartonella in the tissues where hemin is limited induces 
formation of new vessels that would provide this necessary substance. Other virulence factors of 
Bartonella TAA are further studied.  
 
1.6 Strategies Utilized by Bartonella to Escape the Host Immune Response  
In addition to strategy of phase and antigenic variations as described in section 1.5, 
Bartonella spp. are capable of evading the host immune response by their diverse strains and 
species that can co-infect the host. Different species of Bartonella and several strains of B. 
henselae were commonly identified in cats (Gurfield et al., 1997). B. henselae strains of human 
isolates are more relatively limited (Dillon et al., 2002). Based on sequences of 16S rDNA, the 
major strains that infect cats belonged to genotype II (Marseille), but most strains involved in 
CSD patients were within the genotype I (Houston I) (Bergmans et al., 1996; Dillon et al., 2002). 
Recent studies using pulsed-field gel electrophoresis, multilocus sequence typing (MLST), 
multispacer typing (MST), and multiple locus variable number tandem repeat analysis (MLVA) 
support a high level of diversity of feline strains (Iredell et al., 2003; Li et al., 2006; Arvand et 
al., 2007; Monteil et al., 2007; Bouchouicha et al., 2009). Other possible strategies involved in an 
evasion of host immune responses include outer membrane protein variation (Kyme et al., 2003) 
and genetic variation, in which many genetic variants were detected in primary isolates of B. 
henselae from different geographical regions (Berghoff et al., 2007).  
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Host immune responses require humoral and cell-mediated immunity for eliminating 
Bartonella spp. Specific antibodies appears to be important for clearance of bacteria in the initial 
infection with a Bartonella species, but it is suppressed during the relapsing bacteremia (Kabeya 
et al., 2006). Infection in dogs with B. vinsonii subsp. berkhoffii also documented immune 
suppression due to cyclic CD8+ lymphopenia, defects in monocytic phagocytosis, and impaired 
antigen presentation within lymph nodes (Pappalardo et al., 2000; Pappalardo et al., 2001). It 
may be possible that infection with Bartonella spp., particularly in an incidental host, might 
induce systemic and local immune suppression that facilitate the persistent infection (Chomel et 
al., 2009a).  
 
1.7 Zoonotic Implication 
Cats and dogs are considered the relevant reservoir hosts for B. henselae and B. vinsonii 
subsp. berkhoffii, respectively that can infect humans. Because many naturally infected cats have 
subclinical infections, they play a role as efficient carriers that transmit bacteria to humans. Most 
of B. henselae-infected cases in human are primary associated with history of cat scratches 
(Zangwill et al., 1993). However, infection can occur in some patients lacking history of 
scratches. In these cases, transmission from cat to human via a cat bite is questioned. Bartonella 
spp. DNA was recently detected from skin, claw beds, and gingiva of cats from high 
Ctenocephalides felis prevalence area in the United States (Lappin and Hawley, 2009). 
Bartonella henselae DNA was also amplified from saliva and nail samples collected from feral 
cats in Korea (Kim et al., 2009). These findings did not prove the transmission competency 
associated with saliva or biting, and the presence of Bartonella spp. DNA may be caused by 
contamination. However, cares should be taken to avoid bites, scratches, and contamination of 
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saliva of cats into open wounds, particularly in immunocompromised individuals. Bartonella 
spp. DNA was also detected from oral swabs collected from dogs (Duncan et al., 2007), 
therefore people should aware of contaminating wounds with saliva of dogs, as well. Infection 
can occur in some patients that never previously contact with cats. Other arthropod vectors or 
animal hosts may possibly be involved in transmission, but these have not been well-defined.  
Human cases of Bartonella infections are mostly people who are veterinarians or are 
otherwise exposed to animals or arthropods. Due to extensive contact with a variety of animal 
species, careers involving veterinary medicine appear to have an occupational risk of being 
exposed to Bartonella infection. Regardless of unclarified causation data to date, these 
individuals should increase precautions to avoid animal bites or scratches, particularly from 
unknown animals, arthropod bites and feces (fleas, ticks, and lice), and direct contact with blood 
and other body fluids from sick animals. The higher risk of exposure should be concerned 
particularly when people are handling feral or rescued animals. A veterinarian reported 
headaches, fatigue, and intermittent paresthesias after a needle stick during a fine-needle 
aspiration in a dog with diffuse cutaneous masses. Bartonella vinsonii subsp. berkhoffii genotype 
I was amplified from blood of the patient and cultured isolates, and seroconversion to B. vinsonii 
subsp. berkhoffii genotypes I and III were found after 30 days post-infection (Oliveira et al., 
2010). Therefore, veterinary professionals and staffs should avoid even needle sticks and cuts. 
Beside of B. henselae and B. vinsonii subsp. berkhoffii, other bacteria in this genus i.e. B. 
clarridgeiae and B. koehlerae have been detected in cat fleas (Rolain et al., 2003b), and B. 
quintana DNA has been amplified from ticks (Chang et al., 2001), therefore people should also 
aware of arthropod vectors that may possibly transmit these organisms.  
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In 2006, the American Association of Feline Practitioners (AAFP) released a panel report 
on various issues of Bartonella spp. infections (Brunt et al., 2006). The AAFP recommendation 
for avoiding zoonotic bartonellosis and Bartonella spp. infections of cats include:  
 Maintain an appropriate flea-control program year-round. 
 A healthy cat at the age over 1 year and free from fleas can be adopted, by a family that 
has an immunocompromised member. 
 Immunocompromised individuals should avoid contact with cats of unknown health 
status. 
 Scratches and bites should be avoided. 
 Cat claws should be trimmed regularly, but declawing of cats is not required. 
 Cat-associated wounds should be washed promptly and thoroughly with soap and water 
and medical advice sought. 
 Although Bartonella spp. have not been shown to be transmitted by saliva, cats should 
not be allowed to lick open human wounds.  
 
1.8 Feline Bartonellosis  
B. henselae (previously known as Rochalimaea henselae) was first isolated and identified 
from a cat in the 1990’s (Regnery et al., 1992). Currently, four other species, including B. 
clarridgeiae, B. koehlerae, B. quintana, and B. bovis have been known to infect cats (Brunt et al., 
2006). Cats serve as reservoir hosts for three of these five species: B. henselae, B. clarridgeiae, 
and probably B. koehlerae. The DNA of B. henselae and B. clarridgeiae are commonly isolated 
or amplified from blood of cats from various geographical regions. Bartonella koehlerae was 
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previously isolated from two naturally infected cats in northern California (Droz et al., 1999), 
one cat in France (Rolain et al., 2003a), and one cat in Israel (Avidor et al., 2004). Recently, B. 
koehlerae DNA was amplified from blood of two cats in Thailand (Assarasakorn et al., 2012). 
Bartonella quintana was isolated from the dental pulp of a cat (La et al., 2005), and was isolated 
from 2 barn cats (Breitschwerdt et al., 2007b). Bartonella bovis is the host adapted species for 
ruminants that has been isolated from a few cats (Chomel et al., 2004).  
 
1.8.1 Bartonella spp. and Vectors 
Transmission for many Bartonella spp. is primarily related to arthropod vectors, as listed 
in Table 1-1. For B. henselae transmission among cats, the cat flea (Ctenocephalides felis) has 
been known to be the dominant vector.  
 
Ctenocephalides felis   
Ctenocephalides felis is responsible for the transmission of B. henselae, B. clarridgeiae, 
and potentially B. koehlerae among cats. Since B. henselae was first identified from cat fleas 
(Koehler et al., 1994), they were consequently proved as a main vector of B. henselae infection 
in cats (Chomel et al., 1996). In the study of Chomel et al. (1996), specific-pathogen-free (SPF) 
kittens were experimentally infected with B. henselae after infected fleas infested on them. 
Whereas SPF kittens housed with bacteremic kittens in the environment without fleas were not 
infected. A subsequent study (Foil et al., 1998) demonstrated that cats were bacteremic if feces 
of infected fleas were inoculated intradermally, but bacteremia did not occur by infected fleas 
which were deposited in retention boxes or cats were fed with infected fleas. The role of fleas as 
arthropod vector for B. henselae was determined in another experiment (Higgins et al., 1996). It 
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had been shown that B. henselae replicated within the flea gut and survived for up to 9 days after 
infection, while bacteria were shed in the flea feces at the same time. A subsequent study 
confirmed that B. henselae can multiply in the cat fleas (Finkelstein et al., 2002). The bacteria 
level in the flea feces increased and reached the level of detection after the fleas had fed on the 
non-infected recipient cat for 6 days. Bartonella henselae persisted in the flea feces in the 
environment for at least 3 days. Therefore, flea feces seem to be the potential source of infection 
for cats as same as humans, in which flea feces contaminate cat claws and probably inoculated B. 
henselae through skin by scratches. To date, the primary mode of transmission for B. henselae in 
cats suggests that fleas are required for replication of bacteria in the flea gut and excretion in the 
flea feces which preserve bacteria for a few days. A recent study strongly supported that the 
monthly use of topical 10% imidacloprid-1% moxidectin reduced flea infestation and prevented 
flea transmission of B. henselae to treated cats over the period of 84 days when compared to 
untreated cats (Bradbury and Lappin, 2010).  
Although the role of fleas as biological vector and flea feces as the source of bacterial 
transmission has been well documented, other possible routes of B. henselae transmission are 
questioned e.g. flea bite. Further study is needed to determine the possibilities whether B. 
henselae can replicate within the salivary gland of cat fleas and can be spread via saliva during a 
flea bite or blood suckling period.  
Concurrent infection of Bartonella spp. in cats and their fleas has been commonly found. 
DNA of B. henselae and B. clarridgeiae, and co-infection with these two species has been 
reported from C. felis from different locations, including France, United Kingdom, United States, 
Canada, Australia, and Thailand (Rolain et al., 2003b; Shaw et al., 2004; Lappin et al., 2006; 
Kamrani et al., 2008; Barrs et al., 2010; Foongladda et al., 2011; Assarasakorn et al., 2012). 
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Bartonella clarridgeiae was found to be the predominant species amplified from C. felis in 
French Polynesia (Kernif et al., 2011). Bartonella koehlerae was the minor species found in C. 
felis from France and Thailand (Rolain et al., 2003b; Assarasakorn et al., 2012). Increasing 
reports of Bartonella spp. infection in both cats and their fleas support the evolutionary 
relationship between the reservoir host and the arthropod vector, and indicate the risk of 
Bartonella spp. transmission among cats. 
 
1.8.2 Experimental Model of Infection in Cats 
The course of B. henselae infection in cats had been studied by different models of 
experiments. Many experiments demonstrated that cats could be infected with B. henselae by 
intravenous (IV) inoculation, intradermal (ID) inoculation, or flea exposure. Duration of 
bacteremia in experimentally infected cats varied dramatically from weeks to months. Based 
upon sequential blood culture, some cats had a consistent and predictable pattern of bacteremia, 
whereas in other cats, bacteremia occurred in a random fashion. In the study of Abbott et al. 
(1997), kittens inoculated with B. henselae by ID or IV route became bacteremic by 1-3 weeks 
following inoculation, and bacteremia persisted in most cats for 1-8 months. The number of 
infected cats was higher in the group inoculated by ID route than the group inoculated by IV 
route. This might suggest the greater efficiency of the ID route or the low inoculum dose of the 
IV route. One naturally infected cat in this study appeared to be cyclically bacteremic and had 
the stable antibody titer over the period of 24 months. Antibodies could be detected at the same 
time as the onset of bacteremia, a few weeks preceding bacteremia, or several weeks after 
detectable bacteremia. Antibodies subsequently remained a steady titer for several months. 
However, no clinical or hematologic abnormalities were observed in any of the infected cats. In 
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another study, cats were inoculated IV with different inoculum dose of B. henselae. Clinical 
abnormalities, bacteremia, antibodies against B. henselae, histopathologic lesions were observed 
over the 32-week period of postinoculation (Guptill et al., 1997). All inoculated cats were 
bacteremic within 2 weeks. Bacteremia persisted for 16 weeks in most infected cats, but one cat 
remained bacteremic until 32 week after infection. Some cats developed transient fever within 2 
hours and recurrent fever with mild anorexia by 1-3 week after infection. Bartonella-specific 
IgM and IgG were seen in all infected cats. A virulent feline strain (LSU16) of B. henselae was 
documented with apparent clinical signs in cats after infection (O'Reilly et al., 1999). All of the 
cats inoculated ID either with pure culture, infected blood, or flea feces became bacteremic and 
had fever by 1-3 weeks postinoculation. Lethargy and anorexia also developed concurrently 
during febrile periods. Bacteremia peaked at 14 to 28 days post-inoculation in all cats. This study 
demonstrated inflammatory skin lesions associated with B. henselae inoculation and occurrence 
of lymphadenopathy in most cats. The lesions resolved and disappeared in next 2 weeks. All of 
infected cats developed high level of antibodies against B. henselae. The results from the study 
of Yamamoto et al. (2002) revealed different responses of cats to the different strains of B. 
henselae. Cats could be infected with feline strain or Houston 1 strain of B. henselae, however 
only feline strain was able to induce clinical signs, such as fever. Although all infected cats 
developed bacteremia, the duration of bacteremia was much longer in cats inoculated with feline 
strain than the cats inoculated with Houston 1 strain. Recently, cats exposed to B. henselae-
infected fleas were found to develop fever and lethargy, whereas B. henselae-infected cats by IV 
inoculation were clinically normal (Bradbury and Lappin, 2010). One of these cats also 




Based upon data of the experimental infection, humoral and cell-mediated immunity 
plays a role in elimination, suppression, and control of Bartonella spp. infection in cats. As 
shown in a study, activation of cell mediated immune response which was detected by IFN-γ and 
TNF- production, was important in elimination of B. henselae from bacteremic cats (Kabeya et 
al., 2009). Because prolonged or relapsing bacteremia is typically seen in cats, it is believed that 
the natural immunity might only suppress, but not eliminate infection from these cats. Cross-
protection from re-infection with different strains was documented in a challenge study 
(Yamamoto et al., 2003). Cats primarily infected with B. henselae type I were cross-protected 
against the challenge with B. henselae type II, but cross-protection was not observed in cats 
primarily infected with B. henselae type II and subsequently challenged with B. henselae type I. 
The duration of bacteremia in cats primarily inoculated with B. henselae type I was apparently 
shorter than cats inoculated with either B. henselae type II or B. clarridgeiae. Another 
observation in this study was the shorter bacteremia duration and the lower level of bacteremia 
after challenging with different strains from the primary inoculation (Yamamoto et al., 2003). 
The study of Yamamoto et al. (2002b) demonstrated that the duration of B. koehlerae bacteremia 
was significantly shorter than that of cats inoculated with B. clarridgeiae, and a bacteremia 
relapse was not detected.  
 
1.8.3 Prevalence of Bartonella spp. Infection in Cats 
Epidemiological surveys on Bartonella spp. infections in cats have been performed and 
documented in several countries throughout the world i.e. the Americas, Europe, Asia, and 
Oceania (Boulouis et al., 2005). In general, bacteremia was detected by culture of blood and 
subsequently confirmed by PCR assays. Seroprevalence was determined by ELISA or IFA. B. 
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henselae and B. clarridgeiae are the most common Bartonella infections in cats from many 
areas. B. koehlerae is rarely found, and has currently been reported from California, France, 
Israel, and Thailand. Prevalence of bacteremia and seroprevalence of B. henselae varies 
dramatically according to geographical location and cat populations. For example, prevalence 
rate of bacteremia may range from 8.1 - 62.3% in pet and stray cats from 2 different cities in 
France (La Scola et al., 2002a; Rolain et al., 2004b). Seroprevalence may dramatically vary from 
1% (Bergh et al., 2002; Hjelm et al., 2002) to 93% (Nutter et al., 2004). Based on several studies, 
seroprevalence is commonly about double the bacteremia prevalence in the same population 
(Chomel et al., 1995; Guptill et al., 2004). In the United States, an increase in seroprevalence of 
B. henselae likely paralleled an increase of warmth and precipitation (Jameson et al., 1995). It 
has been suggested that climate and humidity are important factors for an increased number of 
potential arthropod vectors (fleas). The prevalence of Bartonella spp. DNA amplified directly 
from blood of cats by PCR assays was commonly higher in feral or stray cats than that of pet cats 
within the same region (Solano-Gallego et al., 2006; Kamrani et al., 2008; Juvet et al., 2010; 
Kelly et al., 2010; Staggemeier et al., 2010). Bartonella clarridgeiae bacteremia in cats has been 
reported from many countries, and prevalence rates of B. clarridgeiae bacteremia are usually 
much lower than B. henselae bacteremia (Boulouis et al., 2005). Co-infection with B. henselae 
and B. clarridgeiae in same cats are usually found in many areas (Gurfield et al., 2001; Lappin et 
al., 2006; Barrs et al., 2010; Juvet et al., 2010; Assarasakorn et al., 2012). 
Bartonella henselae feline isolates are generally differentiated into genotype I (Houston) 
and genotype II (Marseille), based upon variations in the 16S rDNA gene sequence (Bergmans et 
al., 1996; La Scola et al., 2002b). Prevalence rate in cats for each genotype varies among 
different regions and cat populations (Gurfield et al., 1997; Heller et al., 1997; Maruyama et al., 
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2000; Fabbi et al., 2004; Guptill et al., 2004). It has been suggested that B. henselae feline strains 
have higher level of diversity than those that are isolated from humans, and genetic variations 
between isolates may also relate to virulence in people (Dillon et al., 2002; Iredell et al., 2003).  
The multiple-locus variable number tandem repeat analysis (MLVA) has been recently 
developed for B. henselae typing (Monteil et al., 2007). This technique has been demonstrated to 
have the highest discriminatory power compared with other typing techniques proposed (Iredell 
et al., 2003; Li et al., 2006; Arvand et al., 2007). The recent study has shown that genotype I and 
II isolates shared no common MLVA profile (Bouchouicha et al., 2009). MLVA profiles were 
differentiated into group A and B. Group A exclusively consisted of genotype II feline isolates. 
Group B was composed of all human isolates which was further divided in 2 subgroups, Ba 
(exclusively constituted by genotype I isolates, including the strain Houston I) and Bb (belonged 
to genotype II). It was also suggested that genotype I isolates could be phylogenetically derived 
from genotype II isolates located in group B but not in group A. The most recent study showed 
that MLVA profiles can be used as specific geographical markers for feline B. henselae isolates. 
 
1.8.4 Clinical Implication of B. henselae Infection 
Bartonella spp. have been known as stealth pathogens in reservoir-adapted animals. Most 
of cats with natural infection are usually subclinically infected and have limited pathology 
associated with infection. However, a wide variety of disease manifestations associated with B. 
henselae infection may appear in cats. None of clinical signs were documented in either 
experimentally or naturally infected cats with B. koehlerae (Yamamoto et al., 2002b). Based on 
experimental studies, clinical abnormalities, including fever, lymphadenopathy, inflammatory 
skin lesions, lethargy, anorexia, mild neurologic signs, and reproductive disorders had been 
24 
 
developed in cats inoculated with some strains of B. henselae (i.e. genotype II or LSU16). 
However, the pathogenesis of many disease manifestations remains unclear. Fever is the most 
common clinical sign. Self-limiting transient fever can develop within 2 hours after inoculation, 
but usually during 1-3 weeks following infection of cats with B. henselae via needle inoculation 
(Guptill et al., 1997; Kordick et al., 1999; O'Reilly et al., 1999; Yamamoto et al., 2003). Fever 
usually persists less than a week. Development of fever can be delayed to 3 months after cats 
were exposed to infected cat fleas (Bradbury and Lappin, 2010). Skin lesions (erythema, 
swelling, and pustule) at the site of inoculation and localized or generalized lymphadenopathy 
were also found (O'Reilly et al., 1999). Some cats developed transient anemia and transient mild 
neurologic dysfunction, such as nystagmus, tremors, focal motor seizures, and behavior changes. 
Reproductive failure in female cats, including stillbirths, lack of  pregnancy, or pregnancy only 
after repeated breedings was also reported following experimental infection with B. henselae 
(Guptill et al., 1998). In a recent experiment, cats inoculated with B. henselae IV remained non-
clinically ill, but exposure to C. felis resulted in myocarditis in one cat (Bradbury and Lappin, 
2010). This finding suggested that the natural arthropod vector might be important for 
pathogenicity of the organism and disease pathogenesis. In addition to the development of 
clinical abnormalities, cats inoculated with B. henselae and B. clarridgeiae by blood transfusion 
also developed histopathologic findings in various tissues, including peripheral lymph node 
hyperplasia, splenic follicular hyperplasia, lymphocytic cholangitis/pericholangitis, lymphocytic 
hepatitis, lymphoplasmacytic myocarditis, and interstitial lymphocytic nephritis (Kordick et al., 
1999), splenic microabscesses, hepatic abscess, hepatic necrosis, focal pyogranulomatous 
nephritis, and interstitial myocarditis (Guptill et al., 1997). These findings are likely to specify 
the cell-mediated immunologic response following B. henselae infection.  
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Cats that are naturally infected with B. henselae have been found to develop clinical 
abnormalities. For example, B. henselae has been implicated as a potential cause of anterior 
uveitis in cats (Lappin et al., 2000), which was confirmed by the evidence of intraocular antibody 
production against B. henselae and a response to antibiotic treatment. Fever commonly develops 
in experimentally infected cats and the presence of Bartonella spp. DNA in blood of client-
owned cats has shown to be associated with fever (Lappin et al., 2009). Occasionally, B. 
henselae infection associated with endocarditis was described in bacteremic cats (Malik et al., 
1999) or a negative-culture seropositive cats (Chomel et al., 2003). Based on serological studies 
in low-prevalence areas, seropositivity in cats from Switzerland was associated with urological 
diseases and stomatitis (Glaus et al., 1997). Seropositive cats in Japan were more likely to have 
lymphadenitis and gingivitis, especially those co-infected with the feline immunodeficiency 
virus (Ueno et al., 1996). A recent study from a veterinary hospital found that culture results of 
Bartonella spp., but not serologic test results, was strongly associated with gingivostomatitis in 
naturally infected cats (Sykes et al., 2010). However, establishment of a causation of disease 
manifestations in cats from endemic areas is more difficult and usually inconclusive. Due to high 
number of seropositive cats, many studies supported that antibody tests should not be used alone 
to determine the cause of clinical illnesses associated with Bartonella spp. infection in cats. For 
example, detection of antibodies against Bartonella spp. infection by ELISA or western blot was 
not able to predict fever (Lappin et al., 2009), uveitis (Fontenelle et al., 2008), gingivitis, or 
stomatitis in cats (Quimby et al., 2008; Dowers et al., 2010). In addition, PCR results were also 
not associated with stomatitis and uveitis (Quimby et al., 2008; Dowers et al., 2010). Owing to 
neurologic disease induced by Bartonella spp. infection, the seroprevalence against B. henselae 
was high in healthy cats and the cats with or without neurologic disease, and there was no 
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difference among groups (Pearce et al., 2006). The findings of B. henselae DNA and Bartonella 
spp. C values, representing intrathecal antibody production, in cerebrospinal fluid of client-
owned cats with neurologic disease in a subsequent study (Leibovitz et al., 2008) suggest that B. 
henselae infection might involve with neurologic disease in cats. Furthermore, stress is 
questioned to induce the self-limiting fever in B. henselae bacteremic cats following minor 
surgical procedures (Breitschwerdt et al., 2010). Hyperglobulinemia, particularly polyclonal 
gammopathy was recently found to be significantly associated with seropositivity to Bartonella 
species in privately owned cats (Whittemore et al., 2012). An increase in globulin concentration 
by 1 mg/dl was associated with a 4.37-fold increase in the risk of seropositivity. Chronic 
infection and coinfections with more than one Bartonella sp. are speculated to cause 
hyperglobulinemia. 
Clinical signs are rarely reported from cats naturally-infected with B. clarridgeiae. 
However, B. clarridgeiae was recently isolated from a cat with lymphadenopathy and fever from 
Italy (Capitta et al., 2010). Bartonella vinsonii subsp. berkhoffii was isolated from the 
osteomyelitis lesion in a carpal joint of a cat after 18 months of amputation of original 
osteomyelitis lesion in a digit in the rear leg (Varanat et al., 2009). This finding suggests that 
cats, like dogs and human patients, might be more likely to develop clinical disease when 
infected with a non-reservoir-adapted Bartonella spp.  
 
1.8.5 Diagnosis  
Detection of Bartonella spp. infection in cats is commonly performed by many methods 
available in laboratories. Bartonella spp. infection can be identified by isolation method using 
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culture of blood or tissues, or amplification of Bartonella DNA in blood, tissue, and body fluids 
by PCR assays, or detecting Bartonella-specific antibodies in serum.  
 
Culture  
Blood culture is the definitive diagnosis that ultimately proves the active infection in cats. 
Because cats usually have a high level of intraerythrocytic bacteremia, isolation of Bartonella 
spp., e.g. B. henselae, B. clarridgeiae, from blood of cats is much easier than isolation of those 
organisms from other animals that are accidental hosts or do not serve as a reservoir-adapted 
host. Primary culture from blood sample may take from 5 days and up to a few weeks to obtain 
visible colonies and to ensure the growth of the organism. Because of the slow growth of these 
bacteria, standard biochemical testing for identification may not be applicable. Clinical use of 
culture for diagnosis is limited because of the fastidious nature of the organisms, the requirement 
of specialized laboratory equipment, and less sensitivity compared to molecular methods. 
Negative blood culture results are found in many seropositive cats.  In this case, it is possible that 
the infection is absolutely eliminated; the bacteremia is intermittent; the number of organisms is 
below the limit of detection; or the organisms die during the storage of sample. Positive blood 
culture results do not prove the cat is clinically ill from the infection. Currently, an insect-based 
liquid culture medium, also known as Bartonella-Alphaproteobacteria growth medium 
(BAPGM) has been formulated and used for culture of blood of cats, dogs, and humans (Maggi 
et al., 2005). The medium is efficient and supports the growth of at least seven Bartonella spp., 




Polymerase Chain Reaction 
Amplification of Bartonella spp. DNA from blood, body fluids, or tissues of cats has 
been currently used to prove infection due to high sensitivity and specificity. Several PCR assays 
designed to amplify different protein-encoding genes, such as citrate synthase (gltA) (Norman et 
al., 1995), riboflavin synthase (ribC) (Johnson et al., 2003), as well as the 16S - 23S rRNA 
intergenic spacer region (ITS) (Jensen et al., 2000; Maggi and Breitschwerdt, 2005), are 
commonly been used for blood of cats. The species of Bartonella amplified from assays 
targeting protein-encoding genes can be identified by restriction fragment length polymorphism 
(RFLP) or DNA sequencing. The PCR assays targeting the ITS can differentiate the species of 
Bartonella by different product size that was amplified in a single run of assay. PCR assays have 
been more successful to detect infection when compared with the culture technique. They also 
provide more rapid results than those from culture. However, positive PCR results confirm 
presence of Bartonella spp. DNA, but do not prove living organisms or clinically ill caused by 
infection. Intermittent bacteremia, previous use of antibiotics, the number of organisms under the 
limit of detection, or inhibitory or interfering substances in biologic specimens can induce false-
negative results. False-positive results may occur in fluid or tissue being tested from blood 
contamination. Use of PCR assays is also limited because of the requirement of specialized 
laboratory and laboratory personnel. PCR assays are generally expensive to perform, and they 
are not standardized among laboratories.  
A combinational approach consisting of liquid pre-enrichment culture of Bartonella spp. 
in Bartonella/alpha-Proteobacteria growth medium (BAPGM), sub-inoculation of the liquid 
culture onto agar plates, followed by DNA amplification using PCR assays was shown to 
increases the sensitivity of PCR-based detection due to an increase in bacterial number. This 
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approach assists in improvement in the isolation of Bartonella spp. when compared to traditional 
inoculation of blood agar plates. This method also facilitates the detection and subsequent 
isolation of single and co-infections with B. henselae and B. vinsonii subsp. berkhoffii in the 
blood of naturally infected dogs. Therefore, the use of a combinational approach of pre-
enrichment culture and PCR may assist in the diagnosis bartonellosis in other animals, as well 
(Duncan et al., 2007). 
 
Serological Testing 
Immunofluorescent antibody assay (IFA), enzyme linked immunosorbent assay (ELISA), 
or Western blot immunoassay have been used to detect antibodies against Bartonella spp. in 
serum of cats. IFA and ELISA are commonly used in many epidemiological studies. Western 
blot immunoassay has been used to determine the Bartonella-specific immunodominant antigens 
recognized by the humoral immune response of cats (Freeland et al., 1999; Chenoweth et al., 
2004). Antibody tests are inexpensive and can be performed quickly, but they are of limited 
diagnostic value in cats. Many infected cats are likely to be seropositive against B. henselae, but 
serological testing has low positive predictive value (< 50%) for identification of bacteremia 
(Chomel et al., 1995; Fabbi et al., 2004; Guptill et al., 2004). Therefore, a positive antibody test 
result only suggests exposure to Bartonella spp., but it does not prove current infection. Due to 
high negative predictive value (> 85%) (Chomel et al., 1995; Gurfield et al., 2001; Fabbi et al., 
2004; Guptill et al., 2004), animals without antibodies against B. henselae are more likely to be 
non-bacteremic. Bacteremia in seronegative cats has been reported in some cases, thus a negative 
test result does not exclude current infection. Because antibodies against B. henselae antigens 
may cross-react with antigens of B. clarridgeiae or other species, positive test results cannot 
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discriminate Bartonella spp. that infects a cat. Because of these limitations for serologic testing, 
bacterial isolation and PCR assay are necessary to identify the species of Bartonella.  
Use of Bartonella spp. antibody tests (IgG, IgM) was attempted to determine illness, 
including uveitis, stomatitis, neurological disease, and fever, that might be potentially associated 
with Bartonella spp. infection (Pearce et al., 2006; Fontenelle et al., 2008; Lappin et al., 2009; 
Dowers et al., 2010). However, seropositivity and antibody titer did not correlate with any of 
clinical diseases. Therefore, proving feline bartonellosis by detection of antibody is not 
recommended.  
 
The Current Consensus for Clinical Diagnosis 
The consensus opinion for diagnosis of clinical bartonellosis in cats created by the AAFP 
(Brunt et al., 2006) recommends that there is no single test result from currently available assays 
that can prove clinical bartonellosis in cats. The following findings should be combined in order 
to diagnose a cat, including presence of a syndrome reported to be associated with Bartonella 
spp. infection; exclusion of other causes of the clinical syndrome; detection of a positive 
Bartonella spp. test (culture, PCR assay, or serology); and response to administration of a drug 
with presumed anti-Bartonella activity. Due to limitation of each diagnostic test, results should 
be interpreted with caution. In addition, because there is high prevalence of bacteremia in cat 
populations in endemic areas, the panel in the AAFP does not recommend testing healthy cats 




1.8.6 Treatment and Prevention 
Because the diagnosis of feline bartonellosis has not been standardized, optimal 
antimicrobial protocols for use in clinically ill cats have not been ultimately defined. The 
information of current treatment in cats was commonly obtained from human studies. In vitro, 
many strains of feline isolates were susceptible to antibiotics, but antibiotic susceptibilities 
correlated poorly with clinical efficacy in human patients with Bartonella infection (Maurin et 
al., 1995; Kordick et al., 1997b; Rolain et al., 2004a). Discrepancies between in vitro and clinical 
data may due to the pathogenesis of the individual syndrome. As found in typical CSD in 
immunocompetent people, which usually have a low number of organisms in involving lymph 
nodes. There may be different niches that Bartonella reside in the host e.g., sequestration in 
erythrocytes (Rolain et al., 2004a), or other intracellular locations. It is possible that the clinical 
manifestations of disease may relate to the immune response of the host for clearance of the 
organism. Failure of antibiotic treatment may be caused by replication rates of Bartonella spp. 
(Schulein et al., 2001, Seubert et al., 2002). It had been shown in studies of B. tribocorum 
infection of rat that the organism maintained in a non-replicating state after a short period of 
intraerythrocytic replication (Schülein et al., 2001). Many antimicrobial drugs can penetrate cells 
very well, but they may not be effective to stationary state of bacteria.  
Several antibiotics including doxycycline, enrofloxacin, amoxicillin, amoxicillin-
clavulanate, tetracycline HCl, erythromycin, and rifampin were used to treat bacteremia in 
experimentally infected cats (Greene et al., 1996; Guptill et al., 1997; Kordick and 
Breitschwerdt, 1998). Results of the studies revealed that none of the drug could completely 
clear bacteremia in all infected cats. Bacteremia was apparently eliminated in some cats. Clinical 
efficacy was also variable among each drug. In addition, relapsing bacteremia was found in some 
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cats with initially negative for blood culture results. Successful treatment with doxycycline or 
azithromycin in individual cats with uveitis was documented (Lappin and Black, 1999; Ketring 
et al., 2004). Both antibiotics have broad antibacterial spectrums and also modulate immune 
responses in human studies, therefore positive therapeutic responses may be related to anti-
inflammatory effects in cats (Culic et al., 2002; Webster and Del Rosso, 2007).  
Based upon the available data so far, the AAFP panel (2006) indicates that the most 
appropriate antibiotic treatment regimens for feline Bartonella infections have not been 
documented. The panel recommends no treatment of healthy B. henselae seropositive cats. The 
reasons of not treating healthy cats are based upon the high prevalence of bacteremia in cat 
populations in flea endemic regions, the doubtful pathogenic role of the organism, and the risk of 
antibiotic resistance of bacteria. However, a bacteremic (by positive blood culture or PCR assay) 
cat with unexplained illness related to B. henselae infection or indefinite diagnosis would 
warrant consideration of antimicrobial treatment. Doxycycline administered at 10 mg/kg, PO, 
every 12-24 hours, or amoxicillin-clavulanate at 22 mg/kg, PO, every 12 hours for 7 days (Green 
et al., 1996; Brunt et al., 2006) may be considered as the first choice for Bartonella-positive cats. 
Treatment should be continued if there is a positive response. Optimal duration of therapy for 
any drug has not been determined; however, prolonged treatment for a minimum of 2 weeks and 
at least 1 week past resolution of clinical illness may be applied. Fluoroquinolone such as 
enrofloxacin may be considered because treatment of enrofloxacin for 14 days was shown to be 
effective for the clearance of Bartonella spp. DNA in blood of all positive cats for at least 3 
months (Bradbury and Lappin, 2010). Azithromycin was previously used to treat CSD patients 
but the recent in vitro study (Biswas et al., 2010) showed that azithromycin was the least active 
antibiotic for nine feline B. henselae isolates and one human isolate when compared to 
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pradofloxacin and enrofloxacin. For five B. henselae isolates tested in this study, Azithromycin 
was active only until the second passage in our study, while pradofloxacin and enrofloxacin were 
active until at least the fifth passage. Azithromycin is currently considered contraindicated.  
Because cats with clinical bartonellosis are likely to be bacteremic, care should be taken 
to avoid being bitten or scratched while administering drugs. The optimal follow-up time for 
repeat testing has not been established. Treatment of clinically ill cats should be combined with 
eradication of fleas on all animals in the household and the premises in order to avoid re-
infection. The AAFP panel recommendations (Brunt et al., 2006) for decreasing the likelihood of 
pet cats becoming infected with Bartonella spp. include: maintain an appropriate flea-control 
program year-round; be cautious about adding stray cats or cats from shelters to the household 
without controlling fleas; and keep cats indoors to minimize exposure to fleas and other possible 
vectors. Application of effective flea control products is highly recommended. For example, 
monthly use of topical 10% imidacloprid - 1% moxidectin has demonstrated to reduce flea 
infestation and prevent flea transmission of B. henselae to cats (Bradbury and Lappin, 2010).  
Prevention of Bartonella infection by vaccination is not currently available. However, 
naturally infected cats have known to infect with various species and strains of Bartonella spp., 
and the immune responses may vary for each individual organism. Therefore, development of 
multivalent vaccine is suggested for immunizing cats (Yamamoto et al., 2003).  
Recommendations for testing and treating healthy cats were stated in the Guidelines for 
Preventing and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents 
(Kaplan et al., 2009). The Centers for Disease Control and Prevention (CDC) do not recommend 
to test healthy cats because there is not enough evidence indicating the benefit to cats or their 
owners from routine culture or serologic testing of the pet for Bartonella infection. Also, because 
34 
 
elimination of Bartonella spp. infection is difficult and because of the evidence of re-infection in 
some cats, there is no proven benefit to treat healthy cats even in cases with any Bartonella 
positive test result. In addition, the development of antimicrobial resistance should be concerned 
if the failure in clearance of the infection happens after the administration of antibiotics.  
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Research Overview and Specific Aims 
 
2.1 Research Overview 
Bartonella infections, particularly B. henselae in cats, are commonly distributed in most 
countries. Many infected cats carry the bacteria without showing clinical signs, but some cats 
may develop non-specific manifestations of disease. Bartonella henselae infection may cause 
inflammatory effects in multiple systems in the cat’s body, including eyes, mouth, and lymph 
nodes which are the most common types of diseases associated with feline bartonellosis. In rare 
cases, the disease can cause severe conditions such as hepatitis and endocarditis. Clinical signs in 
cats are frequently vague or similar to many other types of diseases. Fever is the most common 
clinical sign particularly in cats experimentally infected with B. henselae. Clinical signs alone do 
not provide enough information for diagnosis. Currently, Bartonella spp. infections in cats can 
be detected by blood culture, molecular techniques, and antibody assays, but positive or negative 
laboratory test results obtained from these available tests are usually not associated with clinical 
illness. However, high bacteremia level is thought to be a risk factor for developing clinical signs 
such as fever. The quantitative real-time PCR (qPCR) is highly sensitive and specific for 
quantification of microorganism DNA which is correlated to the number of microorganisms in a 
sample. The antigen-capture enzyme-linked immunosorbent assay (AC-ELISA) can also be a 
sensitive and specific assay that can rapidly measure antigens of interest with minimal 
specialized equipment. The quantitative information obtained from both qPCR assay and AC-
ELISA is expected to expand the knowledge and information regarding the disease association of 
B. henselae infection in cats. 
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To date, the quantitative information from qPCR assay and AC-ELISA of B. henselae in 
infected cats are not published. The research goals of this dissertation are therefore to develop 
two new diagnostic assays, the qPCR and the AC-ELISA for detection of B. henselae in blood of 
cats, and to apply both assays to a cat population in Thailand in order to determine whether or 
not the assays would aid in the diagnosis of fever caused by B. henselae. Chapter 3 (qPCR assay) 
and Chapter 4 (AC-ELISA) describe the development and titration of the assays. In order to 
determine the clinical utility of both developed assays, the optimized assays were then applied to 
a group of client-owned cats which were at risk for B. henselae infection in Thailand. Chapter 5 
is the preliminary study that determined the prevalence of Bartonella infections and other blood 
borne infections in a client-owned cat population in Bangkok, Thailand. In Chapter 6, a larger 
sample size of cats in the same area in Thailand that consisted of both febrile and afebrile cats 
were entered into the study, and the optimized qPCR assay and AC-ELISA were applied to 
selected blood samples from febrile and afebrile cats. Finally, the future research direction that 
could be taken to build on the information collected during the completion of this PhD program 
is described in Chapter 7.  
 
2.2 Specific Aim 1 (Chapter 3: qPCR Assay) 
The qPCR is a sensitive, fast, and quantitative assay for amplification of many organisms. 
The specific aim for the Chapter 3 was to develop a new qPCR assay that is optimized and 
specific for detection and determination of B. henselae bacterial load in blood samples of cats. 
The analytical performance of the assay, including analytical sensitivity and specificity were also 
assessed. The qPCR assay is expected to be highly sensitive and specific to detect B. henselae 
DNA in blood of cats. 
51 
 
2.3 Specific Aim 2 (Chapter 4: AC-ELISA) 
The AC-ELISA is a quantitative immunoassay that is usually sensitive, specific, and 
rapid to perform. The level of B. henselae antigen in blood of cats has never been assessed by 
this assay. Therefore, the specific aim of the Chapter 4 was to develop a new AC-ELISA that is 
able to accurately detect and quantify B. henselae antigen in blood of cats. The AC-ELISA is 
anticipated to be highly sensitive and specific to detect B. henselae antigen in blood of cats.  
 
2.4 Specific Aim 3 (Chapter 5: Prevalence in Thailand)  
Infections of several Bartonella spp. are transmitted among cats via fleas. Risk of flea 
infestation in cats is commonly high in tropical climate area, including Thailand. However, the 
information regarding prevalence of Bartonella infections in cats and fleas in Thailand is 
minimal. The specific aim of this chapter is to determine the prevalence of Bartonella spp. and 
other blood borne infections, including hemoplasmas and R. felis in client-owned cats and fleas 
in Bangkok, Thailand. The information of prevalence obtained from this study was used to 
design a sample size for collecting samples for the subsequent study in the Chapter 6.  
 
2.5 Specific Aim 4 (Chapter 6: qPCR and AC-ELISA with Fever) 
Bartonella henselae infection may be a cause of fever of unknown origin in cats. 
However, diagnosis using currently available techniques may be inconclusive due to high 
prevalence in the field. The clinical utility for diagnosis of feline bartonellosis using the newly 
developed qPCR assay and AC-ELISA has not been assessed. The specific aim of the Chapter 6 
is therefore to determine the association between results of qPCR assay or AC-ELISA, and fever 
in client-owned cats from Bangkok, Thailand. Other risk factors that are possibly associated with 
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fever are also evaluated in this chapter. The hypotheses for the specific aim 4 are that higher 
bacterial load or antigen level of B. henselae will exist in febrile cats compared to afebrile cats 





Development of Quantitative Real-time Polymerase Chain Reaction for                      
the Detection of Bartonella henselae in Feline Blood 
 
3.1 Summary 
Infection of Bartonella henselae in cats is commonly detected by molecular methods but 
a quantitative assay in an attempt to correlate to a clinical manifestation has never been use. A 
quantitative real-time polymerase chain reaction (qPCR) assay was developed for quantification 
of B. henselae in feline blood. The primers were designed to amplify the 85-bp PCR product of 
the groES gene, which was detected by a specific TaqMan probe. The qPCR reaction was titrated 
for optimal concentrations of oligonucleotides and reaction conditions. The analytical sensitivity 
and specificity were determined. The linear dynamic range for accurate quantification was 
between 5.2 x 10
6
 to 52 CFU/ml of blood and the level of detection was 52 CFU/ml. The qPCR 
assay did not cross-react with other cat-relevant Bartonella spp., common bacterial organisms 
that infect cats, or other bacterial contaminants. The assay was precise and reproducible since the 
intra-assay and inter-assay coefficients of variance were very low (1.48% and 0.40%, 
respectively). The recently developed qPCR described here provides a quick and accurate 
method for quantification of bacteremia level of B. henselae in feline blood. 
  







In the past few decades, polymerase chain reaction (PCR) assays have been used for 
detection of Bartonella spp. infection in humans and animals. These molecular techniques can 
detect the bacteria to the species and strain level with good analytical sensitivity and specificity 
and fast results. Because of high bacterial loads in cats, PCR assays are sufficient for bacterial 
identification while isolation or culture is not needed. Several conventional polymerase chain 
reaction (cPCR) assays targeting 16S rRNA (Bergmans et al., 1996) and protein-encoding genes, 
such as those encoding citrate synthase (gltA) (Norman et al., 1995; Birtles and Raoult, 1996), 
riboflavin synthase (ribC) (Bereswill et al., 1999; Johnson et al., 2003), 60 kDa heat shock 
protein (groEL) (Marston et al., 1999; Zeaiter et al., 2002a), cell division protein (ftsZ) (Kelly et 
al., 1998; Ehrenborg et al., 2000; Zeaiter et al., 2002b), PAP31 and 35-kDa proteins (La Scola et 
al., 2002b), as well as the 16S - 23S rRNA intergenic spacer region (ITS) (Jensen et al., 2000; 
Houpikian and Raoult, 2001; Maggi and Breitschwerdt, 2005) have been used for genetic, 
epidemiologic, and clinical studies. Most concentional PCR (cPCR) assays are sensitive for 
identification of many species of Bartonella, in which species identification can subsequently be 
performed by sequencing or restriction fragment length polymorphism (RFLP).  
Cats infected with B. henselae commonly have prolonged bacteremia for months or years 
(Kordick et al., 1995), therefore amplification of B. henselae DNA from blood of cats is usually 
straight forward and successful. Although the sensitivity of cPCR assay is ideal for the rapid 
detection of B. henselae infections, correlating results of cPCR assay and clinical illness in cats 
is difficult. This is likely because cats are major reservoirs of B. henselae and subclinical 
infections are common in cats. The current infection of an individual cat may not be associated 
with clinical signs (Quimby et al., 2008; Dowers et al., 2010). The presence or absence of 
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Bartonella spp. DNA is therefore not sufficient to conclude that cats are sick because of 
Bartonella spp. infection. The only exception was the presence of Bartonella spp. DNA in 
febrile cats (Lappin et al., 2009). Determination of bacterial counts by routine blood culture is 
time-consuming and is not sensitive enough to detect fastidious organisms, including Bartonella 
spp. Cats with PCR-positive, but culture-negative test results have often been found. To the best 
of our knowledge, no existing study addresses the association of clinical illnesses related to B. 
henselae infection and the bacteremia level in cats. Because of wide distribution of B. henselae 
infection, particularly in high flea areas, and the implications in some infected cats, a diagnostic 
assay that provides faster results and is sensitive enough for detection and quantification of B. 
henselae infection would be useful for diagnosis of feline bartonellosis. 
The advanced technology of quantitative real-time PCR (qPCR) enables both detection 
and quantification of the number of target organisms. The qPCR is at present known to be the 
most sensitive and precise method for quantification. In addition, the qPCR assay offers fast and 
reliable quantification of any target sequence in biological sample. The qPCR procedure is 
performed in the same way following the general principle of PCR, but the key feature is that the 
amplified product is detected as the reaction progresses in real time. This is beyond the cPCR 
assay, in which the PCR product is detected at the end of the assay. The amplified product in 
qPCR assay can be detected using either one of two common methods: 1) fluorescent dyes 
(SYBR Green) that bind with any double-stranded DNA, and 2) sequence-specific DNA probes 
(e.g. TaqMan, molecular beacon, minor groove binder); oligonucleotides labeled with a 
fluorescent reporter that permits detection only after hybridization of the probe with its 
complementary DNA target. Quantification can be achieved by either an absolute number or 
relative amount. The qPCR assay is more convenient to perform and quantitative. Because of its 
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high sensitivity and faster processing, qPCR assay has been chosen as a tool for diagnosis of 
many pathogenic microorganisms.  
Recently, the qPCR assay targeting the citrate synthase gene (gltA) has been used for 
detection of Bartonella spp. in feline blood (Mietze et al., 2011). Using this qPCR assay 16.6% 
of cats were positive for Bartonella spp., while only 2.2% were culture positive. The study of 
Mietze et al. (2011) supported the much higher sensitivity of qPCR assay than that of blood 
culture but did not quantify the bacterial laod. Additionally, the association between and clinical 
illness has not been determined.  
Because B. henselae is the most commonly detected Bartonella spp. in cats and appears 
to be most commonly associated with clinical illness, the current assay was designed to primarily 
detect B. henselae. This chapter describes the development of a qPCR for the detection and 
quantification of B. henselae in blood of cats. The utility of the new qPCR assay for assessing 
fever in cats is described in Chapter 6. The study hypothesis was that a sensitive and specific 
qPCR assay could be developed for detection of B. henselae in feline blood samples. The 
objectives of the study were (1) to develop and optimize a new qPCR assay for determination of 
bacterial load of B. henselae in whole blood samples of cats and (2) to assess the analytical 
sensitivity and specificity of the qPCR assay.  
 
3.3 Material and Methods 
3.3.1  Bacteria and Culture Condition 
Bartonella henselae strain CSU-1 was the reference strain for optimizing and generating 
standard curves. Genomic DNA extracted from B. henselae isolates and stored at -80 C was 
used for assay optimization. The isolates were previously confirmed by the cPCR with the 
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protocol described formerly (Jensen et al., 2000). For generating standard curves, B. henselae 
was newly grown from whole blood samples of experimentally infected cats. Blood sample (100 
µl) was plated onto trypticase soy agar with 10% sheep blood (TSA II; Becton Dickinson 
Company, Sparks, MD). The plates were then incubated at 37 C in 5% CO2 for 7 days. 
Bartonella henselae colonies were collected and suspended in phosphate-buffered saline (PBS) 
for subsequent uses. The specificity of the qPCR assay was evaluated with DNA extracts of the 
following bacteria: B. clarridgeiae, B. koehlerae, B. vinsonii subsp. berkhoffii, Mycoplasma 
haemofelis, ‘Candidatus M. haemominutum’, ‘Candidatus M. turicensis’, Ehrlichia spp., and A. 
phagocytophilum which were obtained from the Center for Companion Animal Studies; 
Escherichia coli, Enterobacter spp., Salmonella spp., Klebsiella pneumopniae, Streptococcus 
spp., Staphylococcus intermedius, Coagulase-negative Staphylococcus spp., Pseudomonas 
aeruginosa, and Enterococcus spp. which were kindly provided from the Bacteriology 
Laboratory at the Colorado State University Veterinary Diagnostic Laboratory.  
 
3.3.2  DNA Extraction 
Genomic DNA was extracted from 200 µl of each bacterial suspension using QIAamp 
DNA Mini Kit (QIAGEN, Valencia, CA) by following the manufacturer’s instructions. A 200-µl 
aliquot of feline whole blood was used for extraction of total DNA following the protocol 
described in the QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, CA). The DNA was eluted 




3.3.3  Design of Primers and Probe 
The groES gene is the target gene of the qPCR assay. The similarity of nucleotide 
sequences available at GenBank were compared among B. henselae and other Bartonella spp. 
The sequences of B. henselae groES gene from different strains were analyzed using ClustalW 
multiple alignment running through Bioedit software version 7.0.9.0 (Hall, 1999). The consensus 
sequence was subsequently used to design primers and probe by the Primer3 software (Rozen 
and Skaletsky, 2000) which is available at the Primer-Blast on the National Center for 
Biotechnology Information (NCBI) website (www.ncbi.nlm.nih.gov). Primers were selected 
corresponding to the following parameters (Hyndman and Mitsuhashi, 2003): PCR product size 
between 50 and 150 base pairs (bp); melting temperature (Tm) between 58 °C and 60 °C; length 
between 16 and 21 bp; G+C content between 40% and 60%; and avoiding 4 or more Gs or Cs at 
the 3’ end. Additionally, probe which had the following properties was designed: the length 
between 20 and 30 bp, Tm between 68 °C and 70 °C, G+C content between 40 and 60%, 
avoiding 4 or more Gs, and avoiding 5’ end G. Complimentary within the primers, between the 
primers, and between the primers and probe was also evaluated. The oligonucleotides were 
submitted to the Basic Local Alignment Search Tool (BLAST) at the NCBI website in order to 
assess the specificity.  
  
3.3.4  Screening of the Primers 
Primer sets designed by Primer3 software were initially tested with the SYBR Green 
chemistry. A standard PCR reaction mixture consisted of: 10 µl of 2X Fast SYBR Green Master 
Mix (Applied Biosystems, Carlsbad, CA), 2 µl of genomic DNA corresponding to 10 ng of total 
DNA, 0.6 µl of each primer (final concentration 0.3 µM), and 6.8 µl of PCR water. The PCR 
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assay was performed using a Mastercycler ep realplex (Eppendorf, Hamburg, Germany), which 
included an initial denaturation for 5 min at 95 C, followed by 40 cycles of: 10 s at 95 °C for 
denaturation and 30 s at 60 °C for annealing step and data acquisition step. The reactions were 
assayed in triplicates. No template controls were included in all plates. 
 
3.3.5  Optimal Annealing Temperature 
The temperature gradient mode was performed with the Mastercycler ep realplex. The 
PCR products were detected with SYBR Green I to determine the optimal annealing temperature. 
The reaction mixture was prepared as that described in section 3.3.4. The PCR conditions were at 
95 C for 5 min, followed by 40 cycles of: 10 s at 95 °C and 30 s at gradient temperatures 
between 56 C and 62 C for annealation. The most optimal temperature was subsequently 
determined by narrower gradient temperatures between 58 C and 60 C. The temperature that 
yielded high fluorescent intensity (∆Rn) and low quantification cycle (Cq) was chosen as the 
optimal annealing temperature. The threshold was automatically set at 10 times the standard 
deviations above the noise of the baseline emission calculated from cycles 3 to 15.  
 
3.3.6  PCR Product Confirmation 
The PCR products were determined by both melting curve analysis and gel 
electrophoresis. Analysis of DNA melting curves were acquired on the Mastercycler ep realplex 
by measuring the fluorescence of SYBR Green I during a linear temperature transition from       
60 °C to 95 °C at 0.2 °C/s. Fluorescence data were converted into melting peaks by the 
thermocycler software. The PCR products were loaded on 3% agarose gel and stained with EZ-
Vision (AMRESCO, Solon, OH) and Rediload dye (Invitrogen, Grand Island, NY). The gels 
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were run in 1X Tris-borate-EDTA (TBE) buffer at 120 V for 40 min before it was visualized on 
a UV transilluminator. The amplicon DNA in gels was purified using DNA 
Clean&Concentrator-5 (Zymo Research Corporation, Irvine, CA), and submitted for DNA 
sequencing at Macromolecular Resources, Colorado State University (Fort Collins, CO). The 
sequences obtained were compared with sequences in GenBank database at NCBI.  
 
3.3.7  Optimization of Primer and Probe Concentrations  
Reactions were performed using combinations of three different final concentrations, 
including 0.5, 0.6, and 0.7 µM of forward and reverse primers (Table 3-1). The TaqMan probe 
was used for detection of amplified products. Each primer combination was tested in triplicates 
which had a reaction mixture containing 10 µl of 2X TaqMan Fast Advanced Master Mix 
(Applied Biosystems, Carlsbad, CA), 2 µl of total DNA, 0.8 µl of probe (final concentration 0.2 
µM), and PCR water added up to 20 µl. The reactions were performed at 50 C for 2 min, 95 C 
for 1 min, followed by 40 cycles at 95 C for 10 s and optimal annealing temperature for 30 s, as 
determined in the section 3.3.5. The Cq value of a positive reaction was defined as the cycle 
number at which the fluorescence was first detectable above the threshold. This number 
correlates inversely to the initial amount of DNA in the template. A negative result was defined 
where no amplification occurred. For each sample, mean Cq was calculated from triplicate 
reactions. The primer concentrations were considered to be optimal when the following 
conditions were met; high fluorescence, low Cq value, low standard deviation between replicates, 




Table 3-1   Primer optimization using the checkerboard titration. Nine combinations of forward 
and reverse primer concentrations (0.5, 0.6, and 0.7 µM) were assayed in reactions using 
constant concentration (0.2 µM) of probe and same reaction condition.  
 
#1 F 0.5, R 0.5 #2 F 0.6, R 0.5 #3 F 0.7, R 0.5 
#4 F 0.5, R 0.6 #5 F 0.6, R 0.6 #6 F 0.7, R 0.6 
#7 F 0.5, R 0.7 #8 F 0.6, R 0.7 #9 F 0.7, R 0.7 
F: forward primer concentration (µM), R: reverse primer optimization (µM) 
 
Once the primer concentrations were optimized, the qPCR was further optimized with 
respect to the probe concentration. Multiple reactions were set up to provide three replicates for 
each of the reactions using probe concentration of 0.10, 0.15, or 0.20 µM. The assays were 
performed in the reaction containing optimal primer concentrations and all the other mixtures in 
the unchanged conditions. The optimal probe concentration was selected from the low 
concentration that acquired the minimum Cq value and low background. 
 
3.3.8  Generation of Standard Curves 
Suspension of B. henselae strain CSU-1 isolates which was isolated from positive feline 
blood and grown on blood agar as described in the section 3.3.1 were serially diluted. After a 10-
fold serial dilution of bacterial suspension was performed, an aliquot (100 µl) from each dilution 
was plated onto duplicated blood agar plates for viable counts. The plates were incubated in the 
condition as previously performed. The viable number of the colonies was counted on day 7 of 
incubation, and calculated for CFU/ml. An aliquot (100 µl) from each dilution of bacterial 
suspension was also spiked in 100 µl of feline whole blood. The spiked blood samples were then 
extracted for total DNA by QIAamp DNA Blood Mini Kit. The total DNA of all spiked samples 
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with known amount of B. henselae was performed in the optimized qPCR assay and condition in 
order to generate standard curves. 
The thermocycler software was used to construct standard curves in which Cq values 
were plotted on the y axis and known amount (CFU/ml) of B. henselae in spiked samples was 
plotted on the x axis. The absolute amount of B. henselae level in individual feline blood samples 
was determined by extrapolating the Cq value of unknown sample with the standard curve.  
 
3.3.9  Determination of Efficiency and Analytical Sensitivity 
The qPCR efficiency was calculated from the slope of standard curves, which was 
calculated according to the following equation: efficiency = 10
(-1/slope)
-1. Other parameters, 
including the correlation coefficient (R
2
) and Y-intercept were also determined by the analysis 
mode of the thermocycler. The linear dynamic range was determined by the range of B. henselae 
concentrations in spiked samples which had Cq values fitting on the standard curves. The limit of 
detection (LOD) was defined by the lowest amount of B. henselae on the standard curve which 
was detected by the qPCR assay, and this amount was also referred to the limit of quantification 
of the assay.  
 
3.3.10  Determination of Analytical Specificity 
The specificity of the qPCR assay was evaluated with three other Bartonella spp. that are 
genetically related or capable of infecting cats, or bacteria that are able to cause similar clinical 
signs or are clinically relevant co-infections, or bacteria that are potential contaminants in feline 
blood, as listed in the section 3.3.1. The DNA tested was either genomic DNA extracted from 
bacterial isolate of the microorganisms or total DNA extracted from feline blood positive with 
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any microorganism. The DNA was assayed with the qPCR assay in the same plate, and B. 
henselae CSU-1 was used as the positive control. 
 
3.3.11  Determination of Repeatability  
Inter-assay and intra-assay variations were determined using the spiked whole blood 
samples which were used for generation of standard curves. The samples were performed in 
triplicates within a qPCR assay to determine the intra-assay variation, and the same set of the 
samples was repeatedly performed in separate runs on 3 consecutive days in order to determine 
the inter-assay variation.  
Coefficient of variance (CV) was calculated from each of replicated samples as followed: 
standard deviation (SD) of the triplicate Cq / mean of the triplicate Cq x 100. Intra-assay CV was 
the mean of mean CVs of three separate days. The inter-assay CV was calculated by SD of the 
overall mean of three separate days / grand mean x 100. 
 
3.4 Results 
3.4.1  Selection of Primer and Probe 
The nucleotide sequences of the groES gene of B. henselae was similar to the 
corresponding gene of B. quintana (94% identity), but no significant similarity was found when 
compared to the sequence of B. clarridgeiae. The sequence identity was unable to be compared 
with B. koehlerae because of unavailability of the B. koehlerae groES sequence on the GenBank.   
Sequences of groES gene from four strains of B. henselae were available in the GenBank 
database, including accession number NC_005956, BX897699, AJ749669, and U96734. The 
ClustalW analysis showed 100% similarity among sequences (Figure 3-1). The consensus 
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sequence was used to design the primers and probe. Three sets of primers that were designed by 
Primer3 software were selected for initial screening. A probe was designed to anneal with DNA 
sequences within a specific region amplified by these sets of primers. The oligonucleotides, 
including primers and probe had 100% homology with the region of B. henselae groES gene 
when compared with sequences in the GenBank.  
All of these sets of primers amplified a single product of their expected size as 
determined by gel electrophoresis. One of the three sets of primers was chosen for assay 
optimization. The selected primer set was: forward primer, 5’ -CTC TCG ATG ACA ATG 
GGA- 3’ (18 bp) and reverse primer, 5’ -ACT TCG GTT CCA GAC CAT- 3’ (18 bp). The 
TaqMan probe was 5’ -FAM-TCC AAA CAA GAT ACG GTC CCC TG-BHQ1- 3’ (23 bp). The 
probe was labeled with FAM (6-carboxyfluorescein) as the reporter dye at the 5’ end and BHQ-1 
(Black Hole Quencher) as the quencher at the 3’ end.  
 
3.4.2  PCR Product Confirmation 
The amplification of B. henselae DNA from isolates showed a single sharp peak of the 
qPCR product at 75.3 °C (Figure 3-2). However, multiple melting peaks were produced for the 








Figure 3-1.   Nucleotide sequence alignment of the groES gene. Four sequences of B. henselae 
were obtained from the GenBank: NC005956, BX897699, AJ749669, and U96734. The 
alignment was generated using ClustalW program for maximum homology.       , forward primer;             



















Figure 3-2.   Melting curve analysis. A single peak of the PCR product of B. henselae isolates 
was produced at the temperature of 75.3 °C. 
 
 
The qPCR assay resulted in a single PCR product with the length of approximately 85 bp 
as determined by gel electrophoresis (Figure 3-3). Non-specific amplicons or primer-dimer 
formation were not detected. DNA was extracted from gel, submitted for DNA sequencing, and 
showed 95% homologous similarity with B. henselae (GenBank accession number AJ749669, 



















Figure 3-3.   Gel electrophoresis. The qPCR products of the groES gene amplified from B. 
henselae strain CSU-1 standards was analyzed on gel electrophoresis. The size of the qPCR 
product is 85 bp in length. Lane 1, 25-bp DNA ladder (Invitrogen, Grand Island, NY); lane 2-7, 
the qPCR products of B. henselae standards ranging from 52 to 5.2 x 10
6




Figure 3-4.   DNA sequence BLAST results. The DNA sequence of B. henselae strain CSU-1 
qPCR product was compared with sequences in the GenBank. BLAST result indicated that the 
qPCR product was specific to B. henselae with 95% similarity with the GenBank accession 
number AJ749669, BX897699, and U96734.   
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3.4.3  Optimal qPCR Assay Condition 
High fluorescence signal and low Cq values were observed at the gradient temperature of 
59.0 C and 60.3 C in the initial analysis (Figure 3-5). The subsequent analysis with the narrow 
gradient temperatures showed that the annealing temperature at 60 C produced the PCR product 
with the highest magnitude of fluorescence emission signal (Figure 3-6A) and the lowest Cq 
value (Figure 3-6B). After several reactions were performed using combinations of different 
primer concentrations within the same plate, these combinations resulted in a narrow range of 
fluorescence intensity (Figure 3-7A) and Cq value (Figure 3-7B). The range of Cq values was 
between 28.95 and 29.65. From the results, the primer combination of 0.6/0.6 µM was chosen 































Figure 3-5.   Gradient temperature analysis (1). The annealing temperature was varied from     
56 C to 62 C for each well (from 1 - 6) of the plate. (A) fluorescence versus cycle number 
indicate that the temperature of 56.2 C, 59.0 C, and 60.3 C generated high fluorescence signal 
(B) the lowest Cq values of the qPCR products were corresponded to the annealing temperatures 






Column Temperature (C) Cq SYBR 
1 56.2 16.96 
2 57.6 16.83 
3 59.0 13.66 
4 60.3 13.32 
5 61.5 15.93 
60 C 
59.0 C 
























Figure 3-6.   Gradient temperature analysis (2). The annealing temperature was varied from  
58.0 C to 60.0 C for each well (from column 1 - 12) of the plate. (A) Amplification plots 
showing fluorescence versus cycle number indicate that the temperature 60 C produced the 
qPCR product with the highest fluorescence signal (B) Cq values corresponding to annealing 
temperatures indicates that the lowest Cq value of the qPCR product was produced at the 
temperature 60 C. 
Column Temperature (C) Cq SYBR 
1 58.0 NTC 
2 58.1 18.33 
3 58.2 14.64 
4 58.4 14.48 
5 58.7 15.85 
6 58.9 15.07 
7 59.2 15.16 
8 59.5 15.34 
9 59.7 15.52 
10 59.9 16.04 
11 60.0 14.30 


























Figure 3-7.   Optimization of primer concentrations. Primer concentrations were optimized using 
the forward/reverse primer combination at 0.5, 0.6, 0.7 µM and the constant probe concentration 
at 0.2 µM (A) Amplification plots showing fluorescence signal versus cycle number of 9 primer 
concentration combinations indicated that the 0.6/0.6 µM combination generated the qPCR 
product with highest fluorescence intensity (B) Mean values and standard deviation (S.D.) of Cq 
values corresponding to each primer combination showed that mean Cq was similar among 
combinations. However, the 0.6/0.6 µM combination produced the qPCR product with good Cq 




Mean Cq S.D. Cq 
0.5 / 0.5 29.14 0.20 
0.5 / 0.6 29.49 0.18 
0.5 / 0.7 29.65 0.11 
0.6 / 0.5 28.95  0.18 
0.6 / 0.6 29.19 0.07 
0.6 / 0.7 29.20 0.34 
0.7 / 0.5 29.10 0.04 
0.7 / 0.6 29.13 0.05 






Among three different concentrations of probe compared (Figure 3-8), the concentration 
of 0.10 µM was too low for the assay because the fluorescent intensity was obviously lower and 
the Cq value was higher than those of 0.15 and 0.20 µM. The concentration of 0.20 µM produced 
the highest fluorescence, but high fluorescence background was also observed and triplicate 
results were not consistent. Therefore, the probe concentration of 0.15 µM was considered as the 















Figure 3-8.   Optimization of probe concentration. Probe concentration of 0.10, 0.15, and 0.2 
µM was determined in reactions with constant forward and reverse primer concentration of 0.6 
µM (A) Amplification plots showing fluorescence signal versus cycle number indicated that 
probe concentration 0.20 µM generated the qPCR product with higher fluorescence intensity 
than 0.15 and 0.10 µM (B) Mean values and standard deviation (S.D.) of Cq values 
corresponding to each probe concentration showed that mean Cq was similar among probe 
concentrations, but the mean Cq from probe concentration 0.15 µM had the lowest variation.  
Probe (µM) Mean Cq S.D. Cq 
0.10 29.86 0.11 
0.15 29.63 0.09 







The optimized qPCR assay was prepared in a 20-µl mixture of the followings: 10 µl of 
TaqMan Fast Advanced Master Mix, 1.2 µl of forward and reverse primer (final concentration 
0.6 µM), 0.6 µl of probe (final concentration 0.15 µM), 2.0 µl of template DNA, and 5 µl of 
PCR-graded water. No template controls (NTCs) were included at the same time and under the 
same conditions to detect the presence of contaminating DNA. Each of samples was assayed in 
triplicates. The thermocycling protocol included 50 C for 2 min, 95 C for 1 min, followed by 
40 cycles of 10 s at 95 °C and 30 s at 60 °C.  
 
3.4.4  CFU Determination 
By taking into account the volumes used for DNA extraction and viable cell counts, the 
number of viable colonies spiked in a volume of blood sample was calculated in CFU/ml of 
blood. The number of bacteria spiked in blood sample standards ranged from 5.2 x 10
6
 to 52 
CFU/ml of blood.  
 
3.4.5  Analytical Performance of qPCR Assay 
A log plot of standard samples is showing in Figure 3-9A. The linear dynamic range of 
the assay determined from a standard curve was composed of 6 logs of B. henselae levels 
ranging from 5.2 x 10
6
 to 52 CFU/ml (Figure 3-9B). Serial dilutions in the tested range 
demonstrated that the Cq value correlates linearly with the amount of spiked bacteria (R
2 
= 
0.994). The average slope of the standard curve was within -3.954 + .0.11. The average PCR 
efficiency was approximately 79% + 0.3%. The LOD of the qPCR assay was the minimum 






















Figure 3-9.   Standard curve for the qPCR assay. The qPCR efficiency and quantification of 
unknown blood samples of cats were determined from standard curves. Known amount of B. 
henselae (CFU/ml) was spiked in feline whole blood, in which the total DNA was subsequently 
extracted. (A) Log plot of the fluorescence intensity versus cycle number of standards ranging 
from 5.2 x 10
6
 to 52 CFU/ml: number 1 to 6 (B) Simple linear regression plot of the Cq values 
(from A) versus log of known amount of B. henselae in standards. The qPCR descriptors, 
including slope, R
2
, Y-intercept, and efficiency analyzed by the thermocycler are shown.  
 









Only B. henselae was positive in the qPCR assay (Figure 3-10). None of signals was 
observed in the reactions of other Bartonella spp. and non-Bartonella related bacteria. The 
specificity was confirmed by gel electrophoresis, and there were no PCR product of any 
organism except B. henselae found on gel.  
 
Figure 3-10.   Determination of the assay specificity. The amplification plot indicates that B. 
henselae strain CSU-1 was the only organism amplified from the qPCR, while other Bartonella 







B. henselae CSU-1 
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After the assay was replicated in three runs on three consecutive days, the intra-assay CV 
and the inter-assay CV were 1.48% and 0.40%, respectively (Table 3-2). 
Table 3-2   Repeatability determined by intra-assay and inter-assay variations. Standard samples 
ranging from 5.2 x 10
6





Day 1 Day 2 Day 3 
Mean Cq S.D. Cq CV Mean Cq S.D. Cq CV Mean Cq S.D. Cq CV 
5.2 x 10
6
 16.93 0.18 1.09 16.80 0.10 0.57 16.88 0.43 2.53 
5.2 x 10
5
 20.08 0.21 1.06 20.01 0.04 0.19 19.77 0.70 3.54 
5.2 x 10
4
 24.06 0.48 2.00 24.31 0.45 1.85 24.23 0.39 1.59 
5.2 x 10
3
 28.95 0.41 1.42 28.74 0.16 0.55 28.65 0.30 1.04 
5.2 x 10
2
 33.05 0.53 1.62 32.82 0.85 2.60 32.68 0.46 1.41 
5.2 x 10
1
 36.20 0.25 0.70 36.10 0.73 2.02 37.80 0.36 0.95 
Overall mean Cq 26.54 26.46 26.67 
Mean CV 1.31 1.30 1.84 
Grand mean  26.56 









variation: CV  
0.40% 
a
 The mean of mean CVs of three separate days 
b




B. henselae is the major species of Bartonella that infects cats, and B. henselae DNA has 
more frequently been amplified from feline blood than DNA of B. clarridgeiae and B. koehlerae. 
In addition, B. henselae appears to be the most likely Bartonella spp. to be associated with 
illness in cats. Because of their fastidious and slow growth, routine blood culture is not the 
optimal method for clinical use. Because molecular techniques are more sensitive and return 
results faster than routine blood culture, they are frequently used for identification of Bartonella 
spp. infection. Since the Bartonella-specific PCR assay was first reported, several different PCR 
77 
 
assays with high specificity and sensitivity have subsequently been developed. Recent studies 
showed the usefulness of cPCR assays for detection of Bartonella spp. DNA from blood of cats 
in many areas (Lappin et al., 2006; Solano-Gallego et al., 2006; Kamrani et al., 2008; Barrs et 
al., 2010; Juvet et al., 2010; Kelly et al., 2010; Staggemeier et al., 2010). These assays have been 
used as one-step analysis or combined with nucleotide sequencing to identify species of 
Bartonella. These assays had enough sensitivity and specificity for field studies, but most of the 
time they lacked the capability of proving the clinical illness related to the infection (Quimby et 
al., 2008; Dowers et al., 2010).  
More recently, a qPCR assay have also been used to amplify the citrate synthase gene of 
Bartonella spp. in feline blood (Mietze et al., 2011), but the quantification was not mentioned. 
Therefore, the qPCR assay described herein has the distinct advantage of being able to quantify 
the bacterial load of B. henselae in a single-step procedure.  
The qPCR assay in this study was developed to be specific to B. henselae due to its high 
prevalence and perceived clinical relevance. Primers used in previously published studies are 
commonly able to amplify many Bartonella spp. within the same PCR conditions. For example, 
the primers targeting gltA gene could amplify the DNA of four Bartonella spp. (Norman et al., 
1995), or the primers targeting ITS amplified the DNA of six Bartonella spp. (Jensen et al., 
2000). However, the new primers and the corresponding probe designed in this study were 
specific to only B. henselae.  
The DNA sequences of oligonucleotides in this study were specific to the region within a 
protein-encoding gene, the groES gene. This gene is a single-copy gene in B. henselae 
chromosomal DNA. In general, sequences of protein-encoding gene have interspecies variability, 
but are conserved at the intraspecies level. This was true with the groES gene of Bartonella spp. 
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The groES gene was chosen because this gene has higher percentage of similarity among 
different strains than other genes. All B. henselae groES sequences available in GenBank had 
100% identity (Figure 3-1), confirming that the sequences of this gene are homologous among 
known strains of B. henselae. The nucleotide sequence of the groES of B. henselae strain CSU-1, 
which is the reference strain in this study, is not available at the GenBank. However, this study 
showed that B. henselae strain CSU-1 had 95% homologous similarity with other B. henselae 
strains. 
SYBR Green I dye was used as detection system in the initial assay development for 
screening of primers because it is sensitive, easy to use, and inexpensive. The SYBR Green I is 
also a good tool for observing primer dimers or unspecific amplicons by melting curves 
generated after PCR amplification. The SYBR Green I allows for quantification, but its 
specificity is less than that of TaqMan PCR assays. In this study, using B. henselae isolates as 
template DNA, the melting curve analysis presented fluorescence signal peak around the Tm of 
the PCR products, and PCR product with the expected size was observed on gel electrophoresis. 
Primer dimers were not present. However, many non-specific amplicons were identified when 
total DNA from negative blood samples was used as the template. These non-specific amplicons 
were detected by strange peaks of fluorescent signals in melting curve analysis and the 
unpredicted sized of PCR fragments on gel electrophoresis. SYBR Green I can bind to double-
stranded DNA independently, thus specific and non-specific products amplified can be both 
detected (Deprez et al., 2002). Therefore, the use of SYBR Green I was discontinued to avoid 
non-specific detection, and the probe-based qPCR was used instead. The probe-based PCR assay 
is usually not as sensitive as the SYBR green assay, but it increases the specificity of the qPCR 
assay. The primers designed in this study were predicted to amplify a single product of 85 bp in 
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length. The qPCR assay yielded the PCR product of the predicted size (Figure 3-3), which was 
subsequently confirmed by nucleotide sequencing (Figure 3-4).  
While theoretical annealing temperatures were determined in the process of primer 
design as described above, the gradient PCR was used to determine the actual optimal annealing 
temperature and primers specificity. Using the gradient temperature mode of the thermocycler, 
various temperatures could be set up in the same assay. The annealing temperature of 60 C 
(Figure 3-5) was selected in this study because of high fluorescence signal and lowest Cq 
provided. This temperature ensured higher sensitivity of the assay than the other temperatures 
tested. 
To determine the optimal primer and probe concentrations, the checkerboard assays were 
performed. The Cq values of the qPCR assay using different primer concentrations showed a 
narrow variation of 0.7 cycles (Figure 3-6B). The observed Cq differences are due to the 
variation of primer concentrations, as these were the only variable reaction parameters. The 
concentration of the forward and reverse primers had a slight effect to the Cq values, since the Cq 
values did not change dramatically. The qPCR products were also evaluated by gel 
electrophoresis to exclude any combination that might amplify primer dimers. Each of the primer 
concentration combinations generated a specific amplicon as determined by gel electrophoresis, 
and no primer dimer was observed in any combination. As 0.6 µM of each primer generated the 
amplification curve with the highest fluorescence intensity, low Cq, and consistency results 
(Figure 3-6A). This combination was therefore chosen for the optimal reaction. After the primer 
concentrations were optimized, the optimal probe concentration was evaluated. Although the 
highest fluorescence signal was observed for the probe concentration of 0.2 µM (Figure 3-7A), 
but the Cq difference between 0.15 and 0.2 µM was only 0.08 (Figure 3-7B). The Cq values of 
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0.15 µM concentration was more consistent than that of 0.2 µM concentration, and lower 
fluorescence background was observed. Owing to the cost of a probe-based qPCR assay which is 
strongly dependent on the cost of the probe, the lower probe concentration was chosen except 
when the higher probe concentration gave a significantly lower Cq value and/or resulted in a 
significant improvement of the signal intensity. In this study, the probe concentration of 0.2 µM 
did not significantly improve the performance of the qPCR assay, so the probe 0.15 µM 
concentration was chosen for the optimal reaction.  
The qPCR assay will be used to determine the correlation of bacterial load and disease 
state, therefore quantification is necessary. In order to perform the quantification, the absolute 
quantities of the standards must first be known by some independent method. Standards with 
known amount of B. henselae are considered the critical factor for accurate quantification. In this 
study, the amount of B. henselae in the standards was measured by viable plate counts of bacteria 
(CFU/ml), in which only living bacteria are counted. This method was chosen because the 
CFU/ml is more frequently used for bacteria and is more clinically relevant for interpretation 
than the copy numbers, which are commonly used for viruses. Viable plate counts have 
advantages over other bacterial quantification methods such as turbidimetric measurement due to 
its higher sensitivity, easy to perform, and living cells being of interest. However, long 
incubation periods are needed for these fastidious bacteria. In addition, care must be taken to 
avoid pipetting errors during dilution over several orders of magnitude and plating, and plates 
may be contaminated during incubation. Once the quantity of standards was known, unknown 
samples are able to be compared with the standard curve and extrapolate a value. By performing 
the absolute quantification, the minimal optimization and validation is required. However, the 
errors from inaccurate pipetting and instability of the diluted standards must be considered.  
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In this study, the six orders of magnitude of standards created the linear dynamic range 
that provided accurate quantifications from 52 to 5.2 x 10
6
 CFU/ml of blood. The initial amount 
of DNA below this limit may be inaccurately quantified. False negative results can be occurred 
in samples containing very low amount of DNA. The sensitivity of the qPCR assay is 52 
CFU/ml. The sensitivity of the qPCR was comparable to the cPCR by Jensen et al. (2000). In 
that cPCR assay, all blood samples containing 50 to 100 CFU/ml B. henselae were detected, and 
the sensitivity decreased when the number of B. henselae was below 50 CFU/ml. The qPCR was 
shown to be similarly sensitive as the assay of Norman et al. (1995), in which the LOD was 40 
CFU/ml. The standard curves in this study were reproducible with both low intra-assay and inter-
assay variations.  
Generally, the acceptable assay efficiency is between 90% and 110%. Low efficiency 
may impact the assay sensitivity and the limit of detection. Although the qPCR in this study was 
optimized, the efficiency of the assay was approximately 79%. However, even though the 
efficiency was below the generally acceptable value, the analytical sensitivity was comparable 
with other previous assays. The efficiency of the qPCR may be not significantly problematic for 
the use of the assay in a field study. The low efficiency of a PCR assay may be caused by primer 
dimer formation, probe quality, insufficient optimization, PCR inhibitors in samples, inaccurate 
pipetting, or assay design i.e. poor primer/target binding, too long or too much secondary 
structure of PCR product. In this study, primer dimer formation and assay design were 
considered the least likely possibilities for low efficiency. Primer dimers were not detected, and 
the assay was designed following the general guidelines. If the optimization is not sufficient, 
nonspecific products or insufficient product may be produced, which directly impact the PCR 
efficiency. The primers and probe were only the reagents optimized in this study because a 
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commercially available master mix was used for convenience. It is possible that additional 
reaction optimization may be needed such as magnesium concentration. Otherwise, the use of 
different commercially available master mixes should be compared. Since the spiked whole 
blood samples were used for preparing standards, PCR inhibitors may be left over from the DNA 
extraction, leading to the low assay efficiency. Poor laboratory technique, particularly pipetting 
errors can also increase variation of Cq values.  
When evaluating the specificity of the qPCR assay, no cross-reactivity with other species 
of Bartonella or other bacterial microorganisms was found. Because co-infection with more than 
one organism in healthy or sick cats is commonly found, this probe-based qPCR assay ensures 
that no false positive results will occur. Other Bartonella spp. such as B. quintana were 
unavailable at the time of testing, thus the cross-reactivity with the species beyond the list was 
incomplete.  
In conclusion, the qPCR assay in this study has been a successful method providing a 
new diagnostic tool for detecting and quantifying B. henselae in feline blood. This chapter 
described the development procedures, optimization, analytical sensitivity, and analytical 
specificity of the qPCR. Optimizing the qPCR assay is very important to ensure its efficiency as 
well as specificity. The sensitivity of the qPCR has shown to be comparable with cPCR assays. It 
is believed that the assay described here would be useful in clinical purposes for diagnosis of B. 
henselae in cats. However, some limitations of the qPCR assay, including low efficiency and the 
quality of standards should be considered for interpretation of results. The question of whether 
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Development of Antigen-Capture Enzyme-linked Immunosorbent Assay for                
the Detection of Bartonella henselae in Feline Blood 
 
4.1 Summary 
A polyclonal-based antigen-capture enzyme-linked immunosorbent assay (AC-ELISA) 
was developed for antigen detection of B. henselae in blood of cats. Rabbit polyclonal antibodies 
against B. henselae strain CSU-1 were produced. The optimized assay consists of 25 µg/ml of 
coating IgG and 10 µg/ml of horseradish peroxidase-conjugated IgG per microELISA plate well. 
Because of non-specific binding between IgG antibodies and non-relevant proteins, preparation 
of blood samples by hemolysis and subsequent filtration was necessary. The accuracy of the 
assay was evaluated. The AC-ELISA test results of six experimentally infected cats were 
compared to results of cPCR assay, qPCR assay, and routine culture. The AC-ELISA appeared 
to be much less sensitive than the PCR assays because only 50% of the samples positive by both 
PCR assays were positive by the AC-ELISA. However, the AC-ELISA had high specificity with 
the false positive rate of <10%. The present format of AC-ELISA is not valid for the clinical use, 
but the results would be useful for designing more sensitive assays in the future.  
 









Persistent bacteremia in host-adapted reservoirs is a typical characteristic of Bartonella 
spp. infection as well as B. henselae infection in cats. Bartonella henselae usually colonizes and 
replicates in a primary niche shortly after animals are infected. Once B. henselae is released into 
blood circulation, bacteria can adhere and invade red blood cells where bacteria replicate and 
persist for the remaining lifespan of infected cells (Dehio, 2001). Bartonella henselae can escape 
from the immune system of the host because of the intra-cellular location. The antibodies are 
able to clear extracellular bacteria from bloodstream and prevent bacterial re-invasion into the 
primary niche or red blood cells (Koesling et al., 2001). Bacteremia in naturally infected cats 
may last for months or years (Kordick et al., 1995).  
Detection of a current B. henselae infection in cats is commonly based on culture or 
amplification of B. henselae DNA from blood. Polymerase chain reaction (PCR) assays are 
reliable methods that have shown to be more sensitive and are more rapid to perform than culture 
method. However, the laboratory testing using PCR assays can be expensive and requires 
specialized laboratory facilities and well-trained staffs. Determination of serum antibodies 
against Bartonella spp. by means of immunofluorescence assay (IFA) or enzyme-linked 
immunosorbent assay (ELISA) can be performed quickly and inexpensively. However, these 
serological tests prove only the previous exposure and neither of them is highly correlated with 
bacteremia. In addition, none of available tests is associated with clinical manifestations related 
to B. henselae infection (Brunt et al., 2006). This chapter introduces a newly developed assay 
that is simple to perform, is able to reduce the turnaround time, and could potentially be used to 




Several antigen detection assays have been widely used for diagnosis of feline infectious 
diseases such as feline leukemia virus and Dirofilaria immitis. These assays are commercially 
available, can be performed at the point-of-care, are easy-to-perform, inexpensive, and reliable 
due to good performances (high sensitivity and high specificity) for diagnosis of particular 
infections. Detection of antigens can be based on ELISA technique, in which the antigen levels 
are corresponded to the amount of agent burdens. Because of adequate sensitivity and specificity 
to produce accurate and reliable results therefore additional tests are generally not required for 
confirmation. An antigen detection test has never been used for detection of B. henselae in cats. 
The objective of this study is to develop a new antigen capture ELISA for the purpose of 
detecting B. henselae antigens in blood samples of cats. To the best of my knowledge, this is the 
first polyclonal-based AC-ELISA developed and compared to the currently available assays for 
the diagnosis of B. henselae infection.  
 
4.2.1 General Considerations for the Design and Conduct of Antigen Detection ELISA 
Types of ELISA for antigen detection  
Typically, there are two different types of ELISA that can be used for antigen detection; 
antigen-capture ELISA (AC-ELISA) and competitive ELISA (Paulie et al., 2001). The AC-
ELISA ELISA (also called sandwich ELISA) is commonly used for detecting specific analyte 
within complex mixture. Antigens of a targeted analyte are bound between two layers of 
antibodies, including capture and detection antibodies. The analyte to be measured then must 
contain at least two antigenic binding sites. The AC-ELISA is therefore confined to the detection 
of multivalent antigens such as proteins or polysaccharides. The assay also requires that binding 
of one antibody must not interfere or compete for binding of the other antibody.  
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The competitive ELISA is an alternative assay for antigen detection. The assay is 
commonly used if the matched-paired antibodies are not available or the analyte is too small for 
the AC-ELISA. The competitive ELISA is also used to increase the specificity of an assay when 
samples contain cross-reacting species. There are several different features for competitive 
ELISA, and each of these features requires that either antigen or primary antibody must be 
conjugated to a detection enzyme. The sample is then mixed with the conjugated antigens or 
conjugated antibodies prior to incubation on the plate. If the plate is coated with unlabeled 
antigens, the sample antigens compete with coated antigens on the solid phase for binding to the 
conjugated antibodies. When the plate is coated with unlabeled antibodies, the sample and 
conjugated antigens compete each other to bind the coating antibodies. Because of the 
competition between analyte and conjugated reagent, the amount of analyte in the sample is 
reciprocal to the signal generated.  
The AC-ELISA is more frequently used than the competitive ELISA because of higher 
level of sensitivity and specificity. The sensitivity of the AC-ELISA depends on the affinity of 
the capture and detection antibodies, while the sensitivity of the competitive ELISA is influenced 
by the affinity and the amount of antibody used. The AC-ELISA is more specific than the 
competitive ELISA since it involves at least two antibody recognition sites.  
 
Monoclonal antibody versus polyclonal antibody 
The choice of antibody is the primarily important consideration for assay development. 
Due to the versatility of the AC-ELISA, either monoclonal or polyclonal antibodies can be used 
in the assay (Leenaars and Hendriksen, 2005). Monoclonal antibodies recognize only single 
epitope of an antigen therefore they provide high specificity and allow detection of small 
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differences in an antigen. However, the sensitivity of the assay may be low due to antibody 
molecules can bind to only one antigenic site. The production of monoclonal antibodies is 
generally more complicated and time-consuming than polyclonal antibody production.  
Conversely, polyclonal antibodies provide higher sensitivity because multiple antibodies 
can possibly bind to different epitopes on a single antigen molecule. The production of 
polyclonal antibodies is simple, inexpensive, and requires short period. In order to detect large 
molecules that have many epitopes, such as bacteria molecules, polyclonal antibodies produced 
from an animal can be used as a “self-sandwich” ELISA for both capture and detection. 
However, polyclonal antibodies have a higher risk of cross-reactivity since the epitope is less 
precisely defined.  
Depending on reagents availability, monoclonal antibodies or polyclonal antibodies or 
combinations of them can be used. Monoclonal antibodies are often used as the capture antibody 
to generate the highest level of specificity in an assay, and polyclonal antibodies are applied as 
the detection antibody to enhance the signal to noise ratio. In a different way, coating with 
polyclonal antibodies can pull down as much of the antigens as possible to increase the 
sensitivity. Then monoclonal antibodies are used to detect the bound antigens to provide higher 
specificity. However, the choices of antibodies are empirically selected.  
 
4.2.2 Considerations for Polyclonal Antibody Production 
Animal selection 
Selection of the animal species for polyclonal antibody production commonly depends on 
the specific purpose of the experiment, the amount of antiserum needed, and the ease of 
obtaining blood samples. Rodents and rabbits are often used to produce antibodies for many 
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research objectives. Female animals are preferred over males for handling, and they are less 
aggressive in social interactions. Young adults should be used because the immune response is 




This is one of critical steps in antibody production. The quality and quantity of antigen 
should be considered. The purity and method of preparation of the immunizing antigens is very 
important. The antigen to be immunized should have no contamination with endotoxins (i.e. 
lipopolysaccharide, pyrogens), toxic substances (i.e. urea, citric acid), chemical residues that are 
used to inactivate the organism (i.e. sodium azide, formaldehyde, β-propiolactone), or extreme 
pH that can be a risk of toxicity to animals. The quantity of antigen usually depends on the 
inherent properties of the antigen, the purity of the antigen, the adjuvant used, and the route and 
frequency of the injection.  
 
Choice of adjuvant 
Adjuvants are frequently used to boost the immune response. Freund’s Completed 
Adjuvant containing mycobacteria is used in the polyclonal antibody production because high 
antibody titers can be induced to almost all types of antigens, especially small peptides with poor 
immunogenicity. Freund’s adjuvants also play a role in depot effect for prolonged exposure of 
the immune cells by slowly releasing of the antigen from the injection sites (Stills, 2005). 
However, the inflammatory responses at the sites of injection and the distress in animals are 
sometimes found after immunization. Adjuvants containing mycobacteria or their components 
such as cell walls should only be used once per animal because re-exposure to mycobacteria may 
93 
 
result in severe hypersensitivity reactions. Therefore, FCA is limited used for only the initial 
immunization. The FCA preparation with a low concentration of mycobacteria (0.1 mg/ml) and 
limited injection dose (0.1 ml per site) are also recommended to minimize subsequent 
inflammation (Leenaars and Hendriksen, 2005). Alternative adjuvants such as TiterMax, Ribi, 
Aluminum salts, Quil A, Adjuvax are optional for minimizing side effects on animals, but the 
immune responses vary by each adjuvant and immunizing antigens.  
 
Immunization protocol 
There are several essential issues to be considered (Leenaars et al., 1999; Leenaars and 
Hendriksen, 2005), including (1) use of an adjuvant (2) route of injection (3) volume to be 
injected and (4) the immunization schedule. Suggested injection routes depend on the antigen 
mixture with or without adjuvants and the species of animals. The intramuscular and 
subcutaneous are major routes of injection. Antigen can be absorbed by lymphatics in this 
region, but the mixture of antigen and adjuvant may result in local inflammation. The 
intramuscular route should be avoided for small rodents such as mice. Intravenous administration 
should be the route of choice for small particulate antigens, including viruses, bacteria, or cells 
that do not induce anaphylaxis because of wide distribution and increased capture of the antigen 
by lymphoid tissues. Booster injections should not be administered by the same route used for 
the primary immunization, and booster injection sites should be distant from previous injection 
sites. The injection volume should be as small as possible to avoid the adverse reactions and 
discomfort to animals. The volumes to be injected are based on the use of an adjuvant, and the 
inoculum should be spread among multiple injection sites in larger animals. Primary injections 
with very low amounts of antigen (in picograms) are not recommended, since this does not 
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stimulate the immunologic memory sufficiently, and might induce tolerance to the antigen. The 
immunization schedule has an influence on the result of the immunization. The time interval 
between each immunization can affect both the induction of B memory cells and the class switch 
of B cells from IgM to other antibody classes and subclasses. A booster is generally considered 
after the antibody titer has plateaued or begun to decline. The endpoint of polyclonal antibody 
production should be judged when the antibody titer has reached an acceptable level. This should 
usually occur after a maximum of two boosters.  
 
Blood collection 
Because a booster injection into an animal that has previously established a memory 
response will usually induce a high antibody titre, intermittent bleeding of an immunized animal 
can help maintaining a high serum antibody level and facilitates the collection of adequate 
amounts of antibodies. Thus, regular interval blood collections should be performed after a 
sufficient serum antibody titer has been reached. The volume to be removed per bleeding should 
not exceed 15% of the total blood volume, which in practice, an amount up to 1% of the total 
body weight can safely be removed. Animals should not be bled more frequently than once every 
14 days when maximum blood volumes are collected. A collection method that does not require 
anesthesia should be preferred when possible. In a species in which blood sampling in conscious 
animals is not easy for the operator and stressful for the animal, the use of a sedative to facilitate 




4.2.3 Assay Development Procedure  
Assay optimization 
Optimization is the process of evaluating and adjusting the physical, chemical and 
biological parameters of an assay to ensure that the performance characteristics of the assay are 
best for the intended application. The optimizing process is fundamental and critical to achieve a 
good quality assay, particularly if the assay is for routine diagnostic use in multiple laboratories. 
The capture and detection antibodies should be titered in order to select the concentration of each 
antibody that provides the most excellent results for the assay. 
 
Assay validation 
Assay validation is usually performed after the assay has been optimized. This is the 
process that determines the fitness of an assay for an intended purpose and the performance 
characteristics of the assay (Jacobson, 1996; OIE, 2010). A number of reference samples are 
used. Selection, collection, preparation and management of reference samples are essential for 
the validation. The steps of the assay validation include estimates of the analytical performance 
characteristics, which are primarily consist of analytical specificity, analytical sensitivity, linear 
operating range, and repeatability. Analytical specificity is important to determine the ability of 
the assay to distinguish between the target analyte and other components that may be potentially 
cross-reactive to antibodies. Analytical sensitivity, synonymous with the lower limit of detection 
of an analyte, is also required to determine the smallest amount of analyte in a sample that can be 
detected and distinguished from the result of a matrix background. The preliminary estimate of 
repeatability is necessary to warrant the precision for further assay development. Two types of 
precision should be considered, intra-assay and inter-assay repeatability. Intra-assay repeatability 
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is the reproducibility between wells within an assay. This allows the researcher to run multiple 
replicates of the same sample on one plate and obtain similar results. Inter-assay repeatability is 
the reproducibility between assays. Inter-assay precision guarantees that the results obtained will 
be reproducible over a period of time.  
The next step of assay validation is to evaluate the diagnostic performance characteristics 
which primarily are the establishment of diagnostic sensitivity and diagnostic specificity. 
Diagnostic sensitivity is the proportion of samples from known infected reference animals that 
test positive in an assay. Diagnostic specificity is the proportion of samples from known 
uninfected reference animals that test negative. These estimates are the basis for calculation of 
other parameters from which inference is made regarding test results such as predictive values. 
Therefore, it is important that estimate of diagnostic sensitivity and diagnostic specificity are as 
accurate as possible. These parameters are derived from testing a panel of samples from 
reference animals of known history and infection status relative to the disease or infection in 
question, and relevant to the region in which the test is to be used.  
 
4.3 Materials and Methods 
4.3.1 Buffers and Reagents 
Complete and Incomplete Freund’s Adjuvant (Sigma-Aldrich, St. Louis, MO) were used 
in immunization. The antigen coating buffers assessed in the AC-ELISA were phosphate-
buffered saline (PBS), pH 9.0 and carbonate buffer, pH 9.4. The solutions tested for blocking the 
plate consisted of 2 and 4% bovine serum albumin (BSA) (A-7030; Sigma-Aldrich, St. Louis, 
MO) and 0.5, 3, and 5% non-fat dry milk (NFDM) (BioRad, Hercules, CA) in coating buffer. 
The washing buffer was PBS (pH 9) containing 0.05% Tween 20 (Fisher Scientific, Pittsburgh, 
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PA). The substrate was 3,3’,5,5’-tetramethylbenzidine (TMB) (Kirkegaard and Perry 
Laboratories, Gaithersburg, MD). In addition, 0.18 M sulfuric acid was used for stopping the 
reaction. The reagents used in SDS-PAGE included Laemmli sample buffer, -mercaptoethanol, 
10X Tris/Glycine/SDS buffer, and Bio-Safe Coomassie Stain (Biorad, Hercules, CA).  
 
4.3.2 Production of Rabbit Polyclonal Antibodies 
Rabbits 
Two, 4-kg, female New Zealand White rabbits were used for immunization. The rabbits 
were housed in individual cages and maintained at the Painter Center at Colorado State 
University. The immunization protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC). The rabbits were acclimatized for 2 weeks before immunization.  
 
Preparation of B. henselae antigens  
Bartonella henselae strain CSU-1 was used for immunizing the rabbits. The bacteria 
were previously isolated from blood samples of experimentally infected cats. Positive colonies of 
B. henselae were collected into sterile PBS, and stored at -80 C until used. After being thawed, 
bacterial cells were disrupted by 30% pulsed sonication for 10 min. The tube was placed in ice 
water during sonication. The sonicate suspension was centrifuged at 10,000 g for 10 min. The 
supernatant was discarded, and the pellet was resuspended in sterile deionized water. After 
vortexing, an aliquot of the crude antigen suspension was removed for measurement of total 
protein concentration. The rest of the crude antigen suspension was then diluted to an anticipated 





Each rabbit was immunized with 100 µg of crude antigen for each injection. An equal 
volume (0.5 ml each) of the antigen suspension and adjuvant was mixed vigorously until the 
water-in-oil emulsion was formed. The mixture was immediately administered to the rabbits. 
Freund’s Complete Adjuvant was used in the initial immunization to enhance antibody 
responses. Thereafter, Freund’s Incomplete Adjuvant was used in booster injections. Each rabbit 
was inoculated subcutaneously in multiple sites with a total of 1 ml of antigen/adjuvant mixture 
at week 0. Two booster immunizations with the same quantity of antigens were injected to the 
rabbits by the intramuscular route at weeks 2 and 4. Details of dose, route, quantity, and 
frequency of immunization are displayed in Table 4-1. The rabbits were adopted in the end of the 
immunization procedure. 
Table 4-1    Immunization protocol of rabbit polyclonal antibody production. Each rabbit was 
inoculated subcutaneously in multiple sites with a total of 1 ml of antigen/FCA mixture at week 
0 of immunization. An equal amount of antigens mixed with FIA was injected to the rabbits by 
the intramuscular route at weeks 2 and 4 of immunization. A small volume of blood (2 ml) was 
collected periodically for determination of antisera after immunization. Antisera were collected 
at week 8, 12, 16, 20 of immunization  
 
Week Immunization/booster Dose Route Blood volume  Antibody testing 




S.C. 2 ml  AGID 




I.M. 2 ml AGID 




I.M. 2 ml AGID 
6 NA   2 ml AGID 
8 NA   40-60 ml AGID  
12 NA   40-60 ml AGID  
16 NA   40-60 ml AGID  
20 NA   40-60 ml  AGID  
FCA; Freund’s Completed Adjuvant, FIA; Freund’s Incompleted Adjuvant, AGID; agar gel 




Blood collection and processing 
Two milliliter of whole blood was collected from each rabbit by lateral ear venipuncture 
every other week after immunization. Serum was separated by centrifugation at 1,500 g for 20 
min, and evaluated for antibodies to B. henselae by agar gel immunodiffusion (AGID) test. An 
approximate 40-60 ml of blood (1% of body weight) was collected from each rabbit at week 8, 
12, 16, and 20 of immunization. Serum samples were separated by centrifugation as described 
above and stored at -20 C for subsequent processes.  
 
Agar gel immunodiffusion test  
Polyclonal antibodies against B. henselae were monitored every 2 weeks (from week 0 to 
12), followed by once a month (week 16 and 20) with an AGID test following the procedure of 
the previous studies (Lappin et al., 1989; Simard et al., 2000). The B. henselae antigens, positive 
and negative control sera, and test sera were filled into each individual well on a gel plate. The 
plate was incubated in a humid chamber at room temperature, and was examined at 24 and 48 h 
of incubation. A test serum was considered positive if there was an appearance of clearly 
definable white precipitation line where serum and antigens met each other. Absence of any 
precipitation lines was recorded as a negative test result. 
 
Polyclonal IgG purification  
Total IgG was purified from rabbit serum samples by a commercially available kit 
(Melon Gel IgG Purification Kit; Thermo Fisher Scientific, Rockford, IL). The procedure was 
performed following the manufacturer’s instructions. The purified IgG solutions of two rabbits 
were pooled, aliquoted, and stored at -20 C until used. The pooling of antibody ensured 
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consistency in reagent quality, and reduced variability between assays over time. The protein 
concentration of the pooled IgG solution was assessed by NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
The purity of IgG preparations was determined using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), as previously described (Laemmli, 1970). The 
IgG sample was diluted in the ratio 1:1 in running buffer. The diluted sample was mixed with an 
equal volume of solubilizing solution (Laemmli sample buffer) containing 5% -
mercaptoethanol, and the mixture was subsequently boiled for 5 min. After protein denaturation, 
samples were loaded onto 12.5% polyacrylamide gel (Criterion Tris-HCl gel, Bio Rad, Hercules, 
CA), and electrophoresed in 1X Tris/Glycine/SDS buffer at 180 V for 1 h and 20 min. The gel 
was stained overnight with Coomassie brilliant blue (Bio-Safe Coommassie) on a rocking 
shaker. The gel was destained in distilled water to remove the excessive stain, and visualized 
with epi-white light illumination by ChemiDoc MP system (Biorad, Hercules, CA). Molecular 
weight of IgG was compared with a protein ladder (Precision Plus Protein Dual Color Standards, 
Bio Rad, Hercules, CA).  
 
Conjugation of IgG with peroxidase  
Fractions of pooled IgG were conjugated with horseradish peroxidase (HRP) by a 
commercially available kit (EZ-Link Plus Activated Peroxidase Kit; Thermo Fisher Scientific, 
Rockford, IL), following the manufacturer’s instructions. The conjugate was preserved in 50% 
glycerol solution, and stored at -20 C until assayed. 
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4.3.3 AC-ELISA Procedure  
A microtiter plate was coated overnight at 4 C with 100 µl of rabbit anti-B. henselae IgG 
diluted in coating buffer. The next day, the coating IgG was discarded, and the plate was washed 
for 4 times with 200 µl of PBS containing 0.05% Tween 20 (PBS-TW). Unoccupied space in 
wells of the plate was blocked with a blocking reagent for 1 h at 37 C, followed by washing. 
Samples were applied to the plate in duplicates, and the plate was incubated at 37 C for 30 min. 
After washing, 100 µl of rabbit HRP-conjugated IgG was added. The plate was incubated again 
at 37 C for 30 min before the excessive conjugate was removed by washings. The colorimetric 
reaction was developed by incubation with 100 µl of TMB substrate for 10 min at room 
temperature. The reaction was stopped with 100 µl of sulfuric acid solution. The optical density 
(OD) values were read at 450 nm wavelength by a microplate reader. Blank and substrate 
controls were included in each plate to determine any signal generated from non-binding of 
























Figure 4-1.   AC-ELISA procedure. A microtiter plate is coated with the rabbit anti-B. henselae 
IgG at 4 C overnight. After 4 times of washing with PBS-TW, the plate is blocked with a 
blocking reagent for 1 h at 37 C, followed by washing. Samples are pipetted into the plate in 
duplicates, and the plate is incubated at 37 C for 30 min. After washing, the rabbit HRP-
conjugated IgG is added. The plate is further incubated at 37 C for 30 min before it is washed. 
The TMB substrate is added, and the plated is incubated at room temperature for 10 min. The 
reaction is stopped with sulfuric acid solution. The OD values are read at 450 nm wavelength by 
a microplate reader.  
 
4.3.4 Assay Optimization 
Titration of capture antibody and conjugated antibody  
Different dilutions of rabbit IgG from 1:20 to 1:160 (corresponding to IgG concentrations 
of 100, 50, 25, and 12.5 µg/ml, respectively) were titrated against 3 different dilutions from 1:20, 
1:40 and 1:80 of rabbit conjugated IgG (corresponding to IgG concentrations of 40, 20, and 10 
µg/ml, respectively) on the same ELISA plate. The titrated plate layout is shown in Figure 4-2. 
B. henselae antigen 20 ng/µl was applied to each sample well of all combinations. The optimal 
dilutions of capture IgG and conjugated IgG were determined by the well that gave the highest 
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Figure 4-2.   The microtiter plate layout for titration of capture antibody and conjugated 
antibody. The rabbit IgG was diluted to 1:20 in row A, and 2-fold dilution was made from row B 
to D. After overnight incubation at 4 C, the plate was washed and the equal amount of B. 
henselae antigen was added into each sample well. After 30 incubation at 37 C and washing, the 
HRP-conjugated rabbit IgG at the dilution 1:20, 1:40, and 1:80 was added into the column 2-3, 
4-5, and 6-7, respectively. After incubation and washing, the substrate was added, and then the 
reaction was stopped. SC, substrate control; B, blank well; dark circle, sample well.  
 
Microtiter plate 
Immulon 1B and 2HB (Thermo Scientific, Rochester, NY) were used to compare the 
optimal plate for the assay.  
  
Coating buffer 
Carbonate buffer (pH 9.4) and PBS buffer (pH 9.0) were compared to determine the 




























BSA (2 and 4%) and NFDM (0.5, 3, and 5%) in PBS were used to determine the 
appropriate blocking reagent for the assay.  
 
4.3.5 Sample Preparation 
Step 1: Lysis of red blood cells 
Red blood cells were lyzed to maximize the release of B. henselae into blood sample. 
Deionized water and RPMI 1640 medium (Gibco-Invitrogen, Grand Island, NY) were compared 
to determine the proper lysis reagent. A whole blood sample was lysed with 20 volume of a lysis 
reagent. The tube was vortexed for 10 s and left to stand for 10 min before assayed.  
Step 2: Removal of non-relevant proteins from hemolysate samples 
Non-specific binding between antibodies and blood components in negative samples was 
observed. Hemolysate samples were therefore subsequently processed in different ways in order 
to evaluate the best method that can reduce as many non-relevant proteins as possible and result 
in high signal-to-noise ratio. Three different methods were determined. 
a) Dilution: Hemolysate samples were serially diluted 2-fold from 1:10 to 1:80 with PBS-TW 
before they were assayed.  
b) Centrifugation: The hemolysate was centrifuged at 10,000 g for 10 min. The supernatant was 
discarded, and the pellet was resuspended with PBS-TW before assayed. 
c) Filtration: Hemolysate was loaded into a centrifugal filter unit with 5-µm pore size 
(Ultrafree-MC, Millipore, Billerica, MA). The tube was centrifuged at 10,000 g for 10 min to 
remove cell debris and large molecular particles. The filtrate was gently pipetted out and 
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discarded while precipitate was left at the bottom of the tube. The precipitate was 
resuspended with PBS-TW before applied to the plate.  
 
4.3.6 Assay Validation 
Calculation of the positive cut-off value 
Negative blood samples from 10 known uninfected cats were assayed with the AC-
ELISA to calculate a cutoff, which was calculated from average OD value of the negative 
samples plus 3 times of standard deviations (SD). Samples with absorbance above this value 
were considered positive. 
 
Determination of analytical sensitivity  
A known concentration of B. henselae antigen was spiked into a negative blood sample, 
and serial 2-fold dilutions ranging from 20 to 0.1325 ng/µl was made. Standard curves were 
generated from these serial dilutions after they were assayed. The concentrations of B. henselae 
antigen (ng/µl) were plotted on the x axis and the corresponding absorbance was plotted on the y 
axis. The limit of detection (LOD) was determined by the lowest concentration of B. henselae 
antigen within the linear operating range that was detected by the assay.  
 
Determination of analytical specificity  
The specificity was determined using blood samples positive for organisms that maybe  
potentially cross-reactive with B. henselae antigens such as B. clarridgeiae and B. koehlerae, or 
those that are causative of bacteremia or as similar clinical illnesses as B. henselae infection (i.e. 
Mycoplasma haemofelis, ‘Candidatus Mycoplasma haemominutum’), or cultivated organisms 
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that are possibly contaminated in feline blood samples (i.e. E. coli, Enterobacter spp., 
Salmonella spp., Klebsiella pneumopniae, Streptococcus spp., Staphylococcus intermedius, 
Pseudomonas aeroginosa, and Enterococcus spp.). The cultivated organism spiked in a negative 
blood sample was used when infective blood samples of particular organisms were not available.  
 
4.4 Results 
4.4.1 Rabbit Polyclonal Antibodies 
There was no evidence of adverse reaction in both rabbits during immunization period. 
Both rabbits produced polyclonal antibodies against B. henselae strain CSU-1 as determined by 
the AGID test (Figure 4-3). The AGID test was negative in both rabbits on week 0 and 2. Serum 
of the rabbit A was found positive in AGID test at week 4, 6, 8, 10, and 12 (duration 8 weeks). 
Weak positive reaction was observed at week 4, and test results were found strong positive in the 
following weeks. The rabbit B was positive by AGID test at week 6, 8, 10, 12, 16, and 20 
(duration 14 weeks). AGID test results were strongly positive from week 8 to 16, followed by 
weak positive reaction on week 20.  
The SDS-PAGE analysis (Figure 4-4) has shown that many non-relevant proteins were 
eliminated from rabbit antisera after they were purified using the purification kit (Melon Gel). 
Typically, rabbit IgG molecules were degraded into IgG heavy chain and IgG light chain in the 
SDS-PAGE analysis. The distinct bands which corresponded to protein with molecular weight of 
50 kDa were IgG heavy chains, and the diffused bands corresponding to protein with molecular 
weight of 25 kDa were IgG light chains. Purified total IgG samples of rabbit A (week 8 and 12) 
and rabbit B (week 8, 12, or 16) clearly presented the bands of proteins of IgG heavy and light 












Figure 4-3.   AGID test for B. henselae antibodies in rabbit sera. A serum sample was 
considered positive when a white precipitation line appeared between test serum and B. henselae 
antigens. Sera of rabbit A and B were positive for B. henselae antibodies, as well as positive 
controls. Absence of any precipitation lines was recorded as a negative test result, as shown on 
negative control. Ag, B. henselae strain CSU-1 antigens; PC, positive serum control; NC, 











Figure 4-4.   Analysis of rabbit purified total IgG by SDS-PAGE. Protein molecular weight 
marker is shown in lane 1 and 8. The bands corresponding to the molecular weight of 50 kDa, 
and 25 kDa were IgG heavy chain and light chain, respectively. Lane 2: unpurified serum 
(control); lane 3-4: IgG fractions of rabbit A from week 8 and 12; lane 5-7: IgG fractions of 
rabbit B from week 8, 12, 16, respectively.   
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The pooled IgG was made from the IgG fractions of rabbit A and rabbit B. The 
concentration of the pooled IgG was 2 mg/ml. A fraction of IgG pool was used for conjugation 
with HRP, and the final concentration of conjugated IgG was 0.8 mg/ml. 
 
4.4.2 Optimized Assay 
A plateau of signal was obtained between the dilution of 1:20 and 1:160 of capture IgG 
(Figure 4-5). The similar pattern of saturating level was seen in all dilutions of conjugate. The 
results demonstrated that the capture IgG was saturated on a microtiter plate when the dilution 
was at least 1:160, and any dilution of capture IgG within this range should generate a similar 
signal. The 1:20 and 1:40 dilutions of conjugated IgG produced very high OD values at 
approximately 3.2 and 2.4, respectively. The plateau of OD value generated by the 1:80 dilution 
of conjugate was about 1.8, which was within an acceptable value. The plate background OD 
values, developed in wells where there was no antigen, for the 1:20 (mean OD value, 0.6) and 
1:40 (mean OD value 0.4) dilutions of conjugated IgG were obviously high, while that of the 
1:80 dilution was lower (mean OD value, 0.2). Based on the results the optimized titration for 







Figure 4-5.   Titration of capture and conjugated IgG concentrations. A plate was coated with 
different dilutions of rabbit IgG at 1:20, 1:40, 1:80, and 1:160. Three different dilutions of rabbit 
conjugated IgG at 1:20, 1:40, and 1:80 were used as detection antibody.  
 
 
Comparison of 2 types of microtiter plates revealed that Immulon 2 HB plate provided 
higher overall absorbance than that of Immulon 1B plate (Figure 4-6). This result confirmed 
higher binding of capture IgG on Immulon 2HB plate. Using PBS as the coating buffer was 
likely to provide slightly higher signals on Immulon 2HB than carbonate. In contrast, carbonate 
gave slightly higher signals than PBS on Immulon 1B plate (Figure 4-6). In addition, PBS 
generated lower plate background (OD: 0.05 on Immulon 1B; 0.07 on Immulon 2HB) than that 
of carbonate (OD: 0.07 on Immulon 1B; 0.09 on Immulon 2HB). From the results, PBS was 
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Figure 4-6.   Selection of the microtiter plate and coating buffer. The rabbit IgG diluted from 
1:20 to 1:160 in either PBS or carbonate buffer was coated on an Immulon 1B plate. The 
duplicated reaction was performed on an Immulon 2HB. Both plates were subsequently assayed 
at the same time within the same condition. 
 
Blocking the plate with BSA yielded the plate background OD values ranging from 0.13 - 
0.17. However, the plate background OD less than 0.10 was observed when the plate was 
blocked with NFDM. Among 3 different concentrations of NFDM tested, 0.5% NFDM gave 
lower OD value about 0.05 - 0.07. 
    
4.4.3 Sample Preparation 
Lysis buffer  
Lysis of red blood cells with RPMI did not differentiate negative (mean OD, 0.72 + 0.10) 
from positive samples (mean OD, 0.65 + 0.18). The signals were also not different from those 
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positive samples) (Figure 4-7). Using deionized water obviously yielded higher OD value in 
positive samples (1.26 + 0.25) than that in negative samples (0.96 + 0.29). The signals were also 




Figure 4-7.   Determination of lysis buffer. Positive and negative blood samples were lysed with 
20 volume of deionized water and RPMI 1640 medium before they were assayed in AC-ELISA. 
The results were compared to samples diluted with PBS-TW without hemolysis.  
 
Removal of non-relevant proteins from hemolysate samples 
a) Dilution 
The absorbance of diluted negative samples were high (OD value, 0.7 - 0.9) for all 
dilution levels. The absorbance of positive samples (OD value, 0.9 - 1.2) was not much different 

































The absorbance of negative samples was between 0.3 - 0.5 and that of positive samples 
was 0.4 - 0.9. Using the centrifugation technique could remove more cross-reactive substances 
from samples than the dilution method. However, the background signal in negative samples was 
still unacceptably high.  
 
c) Filtration  
The non-specific binding was obviously reduced by the filtration method. The absorbance 
of negative samples was between 0.2 - 0.4 and that of positive samples was 0.4 - 0.9.  
In order to indicate that filtration method was effective for the assay. The samples from 6 
experimentally infected cats with known uninfected and infected status were performed. Samples 
were collected from cats on week 0, 4, 8, 10, and 12 of infection. All samples tested were 
previously assayed by Bartonella specific-cPCR, the qPCR described in Chapter 3, and blood 
culture.  
Results were demonstrated in Table 4-2. The AC-ELISA identified 7 positive samples 
among the total samples tested (24.1%), culture identified 6 positive samples (20.7%), and both 
qPCR and cPCR assays identified 12 positive samples (41.4%). Among the 12 samples positive 
by both PCR assays, 6 were also positive by AC-ELISA. These samples were considered truly 
positive (sensitivity 50%). The remaining 6 samples negative by AC-ELISA were considered 
false negative. There were 6 samples positive for both PCR assays and culture. These were also 
true positives.  
For 17 samples found to be negative by both PCR assays, 16 were also negative by AC-
ELISA (specificity 94.1%). These samples were considered truly negative. Only 1 sample was 
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negative by both PCR assays but positive by AC-ELISA. This sample was considered false 
positive. None of these 17 samples was positive by culture.  
Table 4-2   AC-ELISA results of 6 experimentally infected cats compared with results of qPCR 
assay, cPCR assay, and blood culture.  
 
Cat Week AC-ELISA qPCR cPCR Culture 
A 0 - - - - 
 4 -  - - - 
 8 - - - - 
 10 - + (8)
a
 + - 
 12 + + (122) + + 
B 0 - - - - 
 4 - - - - 
 8 + + (20) + - 
 10 - + (4) + - 
 12     
C 0 - - - - 
 4 - - - - 
 8 - - - - 
 10 + + (40) + + 
 12 + + (35) + + 
D 0 - - - - 
 4 - - - - 
 8 + - - - 
 10 + + (49) + - 
 12 + + (23) + + 
E 0 - - - - 
 4 - - - - 
 8 - + (10.5) + + 
 10 - + (0.3) + + 
 12 - + (0.4) + - 
F 0 - - - - 
 4 - - - - 
 8 - - - - 
 10 - - - - 
a








The results showed that the filtration method could discriminate positive and negative 
samples better than dilution or centrifugation method. The filtration method was as sensitive as 
culture method, but less sensitive than PCR assays. The AC-ELISA was less specific than both 
PCR assays and culture. 
 
4.4.4 Analytical Performance Characteristics of AC-ELISA 
Cut-off value 
A cutoff was assessed from a total of 10 negative blood samples, which OD values 
ranged from 0.217 - 0.396 (mean + SD, 0.292 + 0.05). The cutoff was calculated as the average 
OD value of the selected negative samples plus 3 SDs. This yielded a cutoff value of 0.459. 
  
Analytical sensitivity 
A serial dilution of B. henselae antigen was used to establish a standard curve (Figure 4-
8). Seven doubling dilutions over the range of 0.31 to 20 ng/µl had mean OD values between 
0.229 and 1.806. The cutoff was set at 0.459 (from above). Using these criteria, the assay can 
measure antigens at the range of 1.25 - 20 ng/µl. The result ensures that the amount of B. 
henselae antigen in a sample within this range will be accurately measured. The limit of 
detection of this assay was 1.25 ng/µl. The linear regression curve was based on OD values 
between 1.25 and 20 ng/µl; OD = 0.064 (antigen concentration) + 0.619. The standard curve was 
linear with correlation coefficient (R
2 












Figure 4-8.   Standard curve of for the AC-ELISA. Various concentrations of B. henselae 
antigen over a range between 0.31 and 20 ng/µl were measured from three separate plates run 
under same conditions. Data points represent the means of OD values, and error bars represent 




To determine the analytical specificity, blood samples positive with other Bartonella spp. 
and hemoplasmas, and cultivated organisms of non-related Bartonella bacteria were analyzed by 
the assay. None of these bacteria was positive in the AC-ELISA. These findings indicated that 
the AC-ELISA would be specific for B. henselae and had no cross-reaction with other bacteria. 
 
4.5 Discussion 
An ELISA-based assay has been known as a rapid, reliable, easy-to-perform, and 
inexpensive test. The AC-ELISA described here was developed for the detection of B. henselae 
in blood samples of cats. Because B. henselae mostly resides within erythrocytes, evaluation of 
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considered as the choice for this pilot study, due to simplicity, inexpensiveness, and rapidity in 
antibody production. Additionally, higher sensitivity of the assay may be acquired than using 
monoclonal antibodies. The rabbits were preferable for antibody production because of the ease 
of manipulation and the amount of antisera required. This study did not evaluate for predominant 
antigens of B. henselae, therefore the whole-cell antigens were used for immunizing rabbits. 
Because bacterial cells consist of multivalent antigens, rabbit polyclonal antibodies can be 
simultaneously used as capture and detection antibodies. Bacterial cells were lysed by sonication 
before immunizing rabbits for safety and prevention of infection in animals. B. henselae strain 
CSU-1 is the local strain, which was used as the reference strain for antibody production.  
Rabbit antisera were screened for antibodies against B. henselae by AGID test, but this 
test cannot evaluate titer of the antibodies. However, the reactivity of antibodies was determined 
by density of precipitation line in the AGID test. After rabbit antisera were collected, they were 
purified for total IgG using a commercially available kit, the Melon Gel IgG Purification. The kit 
provides the affinity method in which IgG can be isolated from serum proteins by negative 
selection. The gel column contains a proprietary ligand that holds on most non-relevant proteins 
in serum, while allowing IgG to pass through the column support. Albumin and transferrin are 
removed by this method. This kit is simple, convenient to perform, and suitable for rabbit serum. 
Total IgG was highly purified (Figure 4-4). Many proteins were removed from purified IgG 
solution compared to unpurified serum. Moreover, the reactivity of IgG is stable because elution 
is not needed.  
The AC-ELISA was optimized to ensure high signal, low background, and the highest 
sensitivity. In this study, the 1:80 dilution (25 µg/ml) of IgG was used for coating the plate, and 
the 1:80 dilution (10 µg/ml) of conjugated antibody was optimized for detection of antigen-
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antibody complex. The selected concentrations in which the capture antibody optimally pairs 
with the detection antibody would ensure that the assay provides the best signal-to-noise ratio. 
Several other empirical experiments were performed to optimize the assay. The use of Immulon 
2HB plate yielded higher reactivity than Immulon 1B. This is because the hydrophilic surface of 
Immulon 2HB increases the ability to bind with hydrophilic IgG molecules, while the 
hydrophobic surface of Immulon 1B primarily binds with hydrophobic molecules. The 
appropriate coating buffer was determined in this study. The results showed that coating plates 
with PBS resulted in higher reactivity and lower plate background than carbonate buffer for 
Immulon 2HB plate. Background caused by non-specific binding of the conjugated antibody to 
plate can be reduced by using a blocking reagent. Selection of the optimal blocking reagents is 
empirical for each assay. Protein blockers such as BSA and NFDM are permanent blocker and 
stabilize surface bound biomolecules. BSA is typically effective on medium and high binding 
surfaces, as well as many covalent surfaces, but 0.5% NFDM had shown to be stronger blocking 
reagent than BSA in this study. It is possible that BSA was not optimally functional in the high 
pH buffer used in the experiments. 
Bartonella spp. are intra-erythrocytic organisms. Lysis of red blood cells is capable of 
releasing organisms and increasing the sensitivity for detection of organisms in samples. 
Deionized water is hypotonic reagent resulting in hemolysis and leakage of B. henselae. In this 
study, hemolysate could discriminate positive from negative samples, while no difference was 
found with RPMI-1640 medium. RPMI-1640 medium has been used for the culture of human 
lymphoid cells for aid in utilizing a bicarbonate buffering system. However, it did not help for 
lysis of red blood cells in this system.  
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High background in negative samples was observed from the analysis of hemolysed 
samples. Negative blood samples which do not have B. henselae antigens are supposed to yield 
low absorbance in the assay. However, OD values of negative blood samples were obviously 
high (> 0.50). This effect was less likely to result from non-specific binding of conjugated IgG 
on the plate because the plate background signal was low (< 0.10). There are 2 possibilities that 
can explain this phenomenon: 1) binding of non-specific IgG and non-relevant antigens in blood 
samples or 2) cross-reaction between B. henselae-specific IgG and non-relevant antigens in 
blood samples that have as similar epitopes as B. henselae. The rabbit IgG used in this study 
contains B. henselae-specific antibodies, and may contain antibodies reactive to impurities in the 
immunogen, as well as naturally induced antibodies to a variety of non-B. henselae antigens 
from previous exposure. In general, rabbit serum normally contains 5 - 10 mg/ml of total IgG, 
and only 1 - 2% of the total IgG is specific for the antigen used for immunization to animals. 
Approximately 50 - 200 µg of specific IgG has been found in 1 ml of serum. Therefore, non-
specific antibodies commonly exist in total IgG and might be a primary cause of high non-
specific background signal, particularly in samples containing blood or serum. In this study, it is 
possible that the immunogen may be contaminated with blood components received during 
bacterial isolate collection from blood agar plate. Contaminants might exist although several 
washings were applied. Cross-reaction of B. henselae-specific IgG and bacteria other than B. 
henselae was determined. The results showed that none of organisms were cross-reactive with 
the rabbit IgG in the assay. The specificity of rabbit IgG increases the reliability of positive 
results of the assay.  
Non-specific binding of rabbit IgG and non-relevant proteins can affect both analytical 
specificity and analytical sensitivity of the assay. Analytical specificity would be low because of 
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false positives in negative samples that have a lot of non-relevant antigens. In order to increase 
the analytical specificity, a high cutoff is necessary. Thus, analytical sensitivity will be 
decreased, and higher proportion of false negative results will be troublesome. The total IgG is 
usually enough for most assays, but it was not sufficient for this study. In this case, the non-
specific antibody binding should be removed by separation of specific antibodies from other 
non-specific antibodies or using monoclonal antibodies instead. The affinity purification of 
antibody (Roque et al., 2007) is considered as a method of choice for polyclonal antibody 
purification in which antiserum contains antibodies with the ultimate in specificity and 
sensitivity. The affinity purification eliminates all other potentially interfering serum proteins 
and antibodies that will increase the background and cause cross-reactivity. It leaves behind a 
population of antibodies that only react with the epitopes chosen for inclusion on the affinity 
matrix. Therefore, the specific antibody is selected and highly purified while non-specific 
antibody is discarded. Furthermore, simple sample processing such as hemolysis may only be 
needed. However, the affinity purification requires a variety of optimization particularly the 
elution step and a lot of reagents, such as antibody and antigen of interest. Furthermore, antibody 
reactivity may be lost from elution step in the affinity purification. Modification of the assay by 
using monoclonal antibody is another option that can reduce the non-specific binding and 
increase the specificity of the assay. Although polyclonal antibodies have an advantage over 
monoclonal antibodies for higher sensitivity and versatility; however, in this circumstance, 
monoclonal antibodies should be the antibody of choice for enhancing the analytical specificity 
of the assay. Since monoclonal antibodies had distinct advantages over polyclonal antibodies for 
specific binding to their antigenic determinants.  
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Due to non-specific binding of the rabbit IgG, subsequent experiments were performed in 
order to find a method that can remove as many non-relevant molecules as possible while 
leaving B. henselae antigens in samples. Sample processing after lysis of red blood cells, 
including dilution, centrifugation, or filtration method was performed. The dilution method was 
not able to decrease the reactivity of non-specific binding. The centrifugation method removed 
some non-relevant molecules. However, the filtration method of the hemolysate using centrifugal 
filter unit with a pore size of 5 µm removed more cross-reactive molecules than the 
centrifugation method, and the signal of negative samples were within an acceptable level. The 
size of B. henselae is 0.3-0.6 x 0.3-1.0 µm (Stramer et al., 2009). Bacterial cells are therefore 
easily passed through the filter, while molecules bigger than 5 µm were separated out of samples. 
Molecules in the supernatant which are smaller than bacterial cells are further removed from 
samples; thus, only molecules that have similar size to B. henselae were co-precipitated in the 
sample to be assayed.  
Of 29 known positive and negative samples with PCR assays and blood culture, 
discordant results of AC-ELISA were found in 20.7% of all samples. Because culture is not 
practical in many laboratories, and PCR assay has been known as highly sensitive and specific 
technique. PCR assay was then used for comparison of results of the AC-ELISA. However, 
viability of bacteria cannot be determined by either PCR assay or AC-ELISA. The samples 
positive with PCR are thought to be truly positive, as well as samples negative with PCR are 
thought to be truly negative. The AC-ELISA had a false negative rate of 50% and a false positive 
rate of 5.9% of when compared to results of PCR assays (Table 4-2). These findings on small 
number of samples shows that the AC-ELISA has lower diagnostic sensitivity and specificity 
than the PCR assays. False positivity might be caused by non-specific binding of rabbit IgG and 
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non-relevant proteins remaining in the processed samples rather than the cross-reactivity with 
other organisms.  
The AC-ELISA was shown to have lower diagnostic sensitivity than the PCR assays. 
These findings are expected because a high cutoff was selected. Samples that have very low 
levels of B. henselae are detected but the signals are not high enough to be positive. However, 
other possibilities may result from low analytical sensitivity of the AC-ELISA itself. Low 
analytical sensitivity may be caused by insufficient optimization of the assay or low avidity of 
antibodies. In addition, false negativity may be caused by interference of the antigen-antibody 
interaction by sample matrix, or quality of sample tested because of degradation of antigen 
during storage. The capture and detection antibodies were already optimized, and the acceptance 
results were obtained. Therefore, the results highly suggest that low avidity of rabbit IgG for 
binding with B. henselae antigens exist and may be an explanation for the low analytical 
sensitivity of the assay. If this circumstance is true, substitution with other antibodies will be the 
solution. The sample matrix probably prevents antibodies for recognizing its designated analyte 
or the antigen of interest. The antibody is then masked by binding to some matrix component. 
Antigen degradation might also be possible due to multiple freeze-thaw cycles. 
A limitation of the AC-ELISA is the availability of antibodies. Polyclonal antibodies 
were obtained from only 2 rabbits, and titer of them was unknown. Thus, only one pair is 
available for the assay. Because the reactivity of antibodies from both rabbits was observed to be 
similar in the AGID test, they were pooled and the pooled antibodies were used. This study 
showed that the pooled antibodies may have low avidity causing low sensitivity of the assay. It is 
suggested that different sources of antibodies should be obtained in order to find a perfect match 
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of antibodies. At least 3 rabbits should be immunized, and 3 matches of these antibodies would 
be compared.  
The AC-ELISA described here was optimized and initially validated for detection of B. 
henselae in blood samples of cats. The major advantage of the AC-ELISA is the ability to obtain 
quick results because it is easy-to-perform and requires only simple laboratory facilities. The 
weakness of the assay is the non-specific binding of IgG that causes high background in negative 
blood samples. Therefore, it took a lot of time and creativity until the most acceptable 
performance characteristics of the assay were achieved. However, the accuracy of the AC-
ELISA was not acceptable when compared with the PCR assays. Because of low analytical 
sensitivity of the AC-ELISA, truly infected cats cannot be detected by this assay, and the AC-
ELISA should not be used alone for screening of B. henselae infection. It is highly suggested that 
the AC-ELISA be improved by substitution of the current antibodies with another perfect match 
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5.1  Summary  
Flea infestations are common in Thailand, but little is known about the flea-borne 
infections. Fifty flea pools and 153 blood samples were collected from client-owned cats 
between June and August 2009 from veterinary hospitals in Bangkok, Thailand. Total DNA was 
extracted from all samples, and then assessed by conventional PCR assays. The prevalence rates 
of Bartonella spp. in blood and flea samples were 17% and 32%, respectively, with DNA of 
Bartonella henselae and Bartonella clarridgeiae being amplified most commonly. Bartonella 
koehlerae DNA was amplified for the first time in Thailand. Hemoplasma DNA was amplified 
from 23% and 34% of blood samples and flea pools, respectively, with ‘Candidatus Mycoplasma 
haemominutum’ and Mycoplasma haemofelis being detected most frequently. All samples were 
negative for Rickettsia felis. Prevalence rate of B. henselae DNA was increased 6.9 times in cats 
with flea infestation. Cats administered flea control products were 4.2 times less likely to be 
Bartonella-infected. 
 




5.2 Introduction   
Ctenocephalides felis (C. felis) has been recognized as the vector of several infectious 
agents that cause disease in cats and humans. The most common pathogens detected in C. felis 
include Bartonella spp., hemoplasmas, and Rickettsia felis. Bartonella henselae and Bartonella 
clarridgeiae are associated with cat-scratch disease and other syndromes in humans and are 
thought to be the most common species of Bartonella in cats (Breitschwerdt et al., 2010). More 
recently, Bartonella koehlerae has been amplified from cats and humans but information 
concerning its prevalence in cats or fleas is minimal (Droz et al., 1999; Avidor et al., 2004). Most 
cats with natural B. henselae infection are clinically normal. However, clinical findings such as 
fever, lymphadenopathy, endocarditis, myocarditis, gingivitis, stomatitis, and uveitis have been 
reported in some cats (Fontenelle et al., 2008; Quimby et al., 2008; Lappin et al., 2009; Perez et 
al., 2009; Bradbury and Lappin, 2010). 
Mycoplasma haemofelis, ‘Candidatus Mycoplasma haemominutum’, and ‘Candidatus 
Mycoplasma turicensis’ are three hemoplasma species that can reside on the surface of feline 
erythrocytes. Some cats with hemoplasma infections develop hemolytic anemia (Sykes et al., 
2007), with M. haemofelis appearing to be the most pathogenic (Foley et al., 1998). ‘Candidatus 
M. haemominutum’ can be pathogenic in some cats, particularly when co-infections with feline 
leukemia virus occur (Reynolds and Lappin, 2007). ‘Candidatus M. turicensis’ was originally 
identified in the blood of a Swiss cat with anemia, and has recently been amplified from the 
blood of client-owned cats in other countries. It has been proven experimentally to induce 
anemia in some cats (Willi et al., 2005). 
R. felis was identified in C. felis for the first time in 1990, and it is closely related to the 
spotted fever group. People infected with R. felis may develop signs of fever, headache, myalgia, 
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and macular rash. Recently, it was suspected that an Australian family had an illness due to R. 
felis infection after contact with their cats (Williams et al., 2011). However whether clinical 
illness is associated with natural infection with R. felis in cats is unclear (Bayliss et al., 2009). 
Since C. felis serves as a potential vector of many pathogens, the number of prevalence 
studies in cats and fleas have been increasing worldwide. The prevalence rates can differ among 
cat populations and geographical locations. Thailand is a tropical country where C. felis 
infestations are common in cats. Although cats are likely to be exposed to fleas and these flea-
borne pathogens, only a few prevalence studies have been reported to date (Maruyama et al., 
2001; Parola et al., 2003 and Inoue et al., 2009) and to our knowledge, hemoplasmas have never 
been reported in Thailand. To provide further information concerning these organisms among 
cats living in this area, the objective of this study was to determine the prevalence of Bartonella 
spp., hemoplasmas, and R. felis in client-owned cats and fleas in Bangkok, Thailand. 
 
5.3 Materials and Methods  
5.3.1 Cats and Fleas 
This study was approved by the Institutional Animal Care and Use Committee at 
Colorado State University and the owner of each cat gave permission to use the samples. 
Samples were obtained from client-owned cats that were presented to veterinary hospitals in 
Bangkok between June and August 2009. Whole blood and serum samples and at least one flea 
were collected from each cat. Fleas were brushed off each cat and immediately placed into a 
tube. Questionnaires related to demographic data, body temperature, and health history were 
completed by the attending veterinarians. All samples were stored at -20 °C and then shipped on 
cold packs to Colorado State University for assay. The species of fleas were identified by a 
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veterinarian (SA) using morphology criteria (Menier and Beaucournu, 1998) before 
deoxyribonucleic acid (DNA) was extracted for analysis in the polymerase chain reaction (PCR) 
assays. 
 
5.3.2 DNA Extraction and PCR Assays 
Total DNA was extracted using the QIAamp DNA Blood Mini Kit (QIAGEN). Fleas 
from each cat were pooled and total DNA extracted as previously described (Shaw et al., 2004). 
The DNA of blood and pooled-flea samples were assayed in conventional PCR assays for 
Bartonella spp. (Jensen et al., 2000) targeting a fragment of the 16S-23S rRNA intergenic spacer 
region, hemoplasma spp. (Jensen et al., 2001) targeting a fragment of 16S rRNA gene, and 
Rickettsia spp. (Shaw et al., 2004) that amplified a fragment of gltA gene. Samples with a band 
of 170 base pairs (bp) were differentiated for M. haemofelis and ‘Candidatus M. turicensis’ by 
DNA sequencing. The 161-bp PCR products for B. henselae and B. koehlerae were differentiated 
by assaying the DNA extracts by a B. koehlerae specific PCR assay (unpublished data) and 
confirmed by DNA sequencing (Macromolecular Resources, Colorado State University, Fort 
Collins, CO). Because R. felis IFA slides to use with serology are not commercially available in 
the USA, PCR alone was used in this study. The amplified products were identified by 
electrophoresis on agarose gels as described for each assay. 
 
5.3.3 Bartonella spp. IgG Enzyme-linked Immunosorbent Assay 
Bartonella spp. IgG was measured in sera using an indirect ELISA as previously 
described (Lappin et al., 2009). Briefly, 100 μl of a 1:64 dilution of each serum sample, a 
positive serum control, and a negative serum control were pipetted into quadruplicate wells of a 
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microtitre plate coated with B. henselae antigen. Substrate and enzyme control wells were 
included on each plate. The plates were incubated for 30 min at 37 °C, and subsequently washed 
three times with 200 μl of PBS solution containing 0.05% Tween-20. One hundred milli liter of a 
1:3000 dilution of peroxidase-labeled goat anti-cat IgG (gamma) (Kirkegaard and Perry 
Laboratories) in PBS-Tween solution was pipetted into appropriate wells. The plate was 
incubated for 30 min at 37 °C and after another wash step, 100 μl of substrate (TMB; SureBlue 
Reserve TMB Substrate, Kirkegaard and Perry Laboratories) was pipetted into each well. The 
enzyme reaction was stopped after 10 min. The optical density of each well was read at 450 nm 
with an automated micro-ELISA reader. A sample was considered positive for B. henselae IgG if 
the mean OD value was greater than the mean OD value plus 3SD of negative samples at the titer 
> 64. Titers were estimated by comparison to a standard curve generated from the positive and 
negative control sample results. 
 
5.3.4 Statistical Analysis 
Associations between PCR results and risk factors were assessed with Pearson’s chi-
square or Fisher’s exact test. Significance was defined as P < 0.05. 
 
5.4 Results  
5.4.1 Client-Owned Cats 
A total of 153 blood and serum samples were collected from cats at various ages. Gender 
and neuter status were classified into intact female (18.3%), spayed female (29.4%), intact male 
(27.5%), and castrated male (24.8%) groups. The majority of the cats lived in single cat 
households (75.2%), and most (54.9%) lived exclusively indoors. Approximately 50% of the cats 
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had been exposed to fleas but only 32.7% were currently infested. Flea control products had been 
applied to 44.4% (68 of 153) of the cats; however 20.6% (14 of 68) of these cats had fleas. 
Conversely, 43.4% (36 of 83) of the cats without flea control had a current flea infestation. 
Fever (> 102.5 °F) was detected in 5.9% of the cats when they presented at the hospitals. 
A number of other health issues were reported in 56.2% of the cats. Problems associated with the 
urinary system, injuries, the gastrointestinal system, the respiratory system, the integument, and 
gingivitis were most commonly recorded. 
 
5.4.2 Flea Identification 
A total of 226 fleas were collected from 50 cats, and 99% of the individual fleas were C. 
felis. One Ctenocephalides canis and one Pulex irritans were co-infested on two different cats 
with C. felis. 
 
5.4.3 PCR Results 
Of the 153 blood samples, DNA of at least one target organism was amplified from 
37.3% with the distribution of results presented in Table 5-1. Rickettsia spp. DNA was not 
amplified from any cat blood sample or flea pool. The overall prevalence of Bartonella spp. 
DNA was 17.0% (26 cats). Of the 50 C. felis pools, DNA of at least one target organism was 
amplified from 56.0%. The overall prevalence of Bartonella spp. DNA was 32.0% (16 pools) 





Of the 26 Bartonella-positive cats, 12 had Bartonella-positive fleas, five had Bartonella-
negative fleas, and nine had no fleas. Flea control products had previously been applied to seven 
of these 26 cats. A topical product containing fipronyl (Frontline Plus, Merial) was applied to 
four cats, selamectin (Revolution, Pfizer Animal Health) to one cat, and a non-specified flea 
product to two cats. The products were administered consistently in only one of the seven cats. 
Table 5-1   Bartonella spp. and hemoplasma spp. DNA in feline blood samples and cat fleas.  
 
PCR assays     Number of PCR positive samples (%) 
  Cat blood  Flea pool 
  (n = 153)   (n = 50) 
All assays negative 96 (62.7)  22 (44) 
Any assay positive 57 (37.3) 28 (56) 
Any Bartonella spp. positive 26 (17.0) 16 (32) 
B. henselae alone 12 (7.8)  5 (10) 
B. clarridgeiae alone 6 (3.9)  5 (10) 
B. koehlerae alone 1 (0.7) 0 (0) 
Any hemoplasma positive 35 (22.9) 17 (34) 
‘Candidatus M. haemominutum’ alone 22 (14.4) 11 (22) 
M. haemofelis alone 4 (2.6) 1 (2) 
B. henselae and B. koehlerae positive 1 (0.7) 1 (2) 
B. henselae and B. clarridgeiae positive 1 (0.7) 0 (0) 
B. henselae and M. haemofelis positive 1 (0.7) 0 (0) 
B. henselae and ‘Candidatus M. haemominutum’ positive 2 (1.3)  1 (2)  
B. clarridgeiae and ‘Candidatus M. haemominutum’ positive 1 (0.7) 2 (4) 
M. haemofelis and ‘Candidatus M. haemominutum’ positive 5 (3.3) 0 (0) 





Of 12 cats with Bartonella spp. DNA amplified from blood and fleas from the same cat, 
four paired samples were positive for B. henselae, three paired samples were positive for B. 
clarridgeiae, and one paired sample was co-infected with B. henselae and B. koehlerae. Four 
cats had negative blood, but positive flea extracts, for DNA of B. henselae or B. clarridgeiae. B. 
koehlerae DNA was amplified from the blood of two cats and extract of one flea pool. By DNA 
sequencing, the homology percentage of these B. koehlerae-positive PCR products ranged from 
96% to 99% with the B. koehlerae GenBank accession No. AF312490. 
Overall, hemoplasma DNA was amplified from 22.9% of the cats; both M. haemofelis 
and ‘Candidatus M. haemominutum’ were identified. Haemoplasma spp. DNA was amplified 
from 34.0% of the flea pools (Table 5-1). Of the 35 hemoplasma-positive cats, seven had 
hemoplasma-positive fleas. Four of the seven cats had agreement of the hemoplasma species 
(‘Candidatus M. haemominutum’). The remaining hemoplasma-positive cats had no fleas or 
fleas infected with different organisms. 
All PCR assays were negative using DNA from C. canis and P. irritans. However, the 
cats infested with C. canis and P. irritans were positive for B. clarridgeiae and M. haemofelis 
DNA, respectively. 
 
5.4.4 Bartonella spp. IgG ELISA 
The overall prevalence of Bartonella spp. IgG antibodies in serum was 65.4%. The 
reciprocal titers ranged from 64 to 1024. When the Bartonella spp. IgG and PCR assay results 
were paired, 44.4% had agreement between ELISA and PCR assay results (20 cats were both 
IgG and PCR positive and 48 cats were both IgG and PCR negative). Of the 153 cats, 52.3% 
were IgG positive but PCR negative, and 3.3% were IgG negative but PCR positive. 
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5.4.5 Risk Factors Associated with Bartonella spp. and Hemoplasma Infections 
Based on the PCR results, the odds of having B. henselae DNA were 4.3 times higher in 
young cats (< 1 year) than older cats (> 1 year) (95% CI = 1.37 - 13.80; P = 0.003). The odds of 
having B. henselae DNA were 6.9 times higher in flea-infested cats than cats without flea 
infestation (95% CI = 2.09 - 26.05; P < 0.001). Cats administered flea control products had 4.2 
times lower odds of having B. henselae DNA (95% CI = 1.20 - 16.46; P = 0.010). Lastly, febrile 
cats had higher odds of having B. henselae DNA than cats without fever but the result was not 
statistically different (OR = 4.3; 95% CI = 0.62 - 22.47; P = 0.073). None of risk factors were 
associated with the PCR results for B. clarridgeiae or hemoplasmas. 
 
5.5 Discussion  
B. henselae, B. clarridgeiae, and B. koehlerae are transmitted by C. felis and so while 
prevalence rates for Bartonella spp. infection in cats can vary among areas, it often parallels the 
flea prevalence rates. This is the first study to determine the prevalence of Bartonella spp. DNA 
in both feline blood samples and fleas in Bangkok. In this study, cats with flea infestation were 
seven times more likely to be infected with B. henselae than flea-free cats. The overall 
prevalence rate (17%) of Bartonella spp. DNA in the blood of cats in this study is similar to 
other studies in which rates varied from 19% to 22% (Jensen et al., 2001; Maruyama et al., 2001; 
Inoue et al., 2009). The prevalence is lower than that reported by others (Lappin et al., 2006). 
The prevalence of 32% of Bartonella spp. DNA in flea pools is similar to the Australian study of 
Barrs et al. (2010), lower than the study from the United States (Lappin et al., 2006), but higher 
than the studies from the United Kingdom and Canada (Shaw et al., 2004; Kamrani et al., 2008). 
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There was agreement between the Bartonella spp. amplified from blood and the 
corresponding flea pools in 67% of the paired samples. The data support the likelihood of the 
transmission of Bartonella spp. from fleas to cats. However, some Bartonella spp. infected cats 
were infested by Bartonella-negative fleas or fleas positive with different Bartonella spp. This 
may due to the fleas feeding on different cats in the same vicinity with different infections 
(Lappin et al., 2006; Barrs et al., 2010). 
Monthly use of an imidacloprid was proven experimentally to prevent the transmission of 
B. henselae among cats (Bradbury and Lappin, 2010). In this study, seven cats owned by 68 
clients had Bartonella spp. infection although they had received flea control products. The 
owners may not have complied with optimal treatment recommendations for the products and the 
cats may have been infected by low level exposure to Bartonella spp. infected fleas. It is also 
possible that some products may not reduce transmission amongst cats, as reported for 
imidacloprid, or that the cats were infected before the products were administered. Owners 
should be advised of the potential risks of flea-associated illnesses and instructed in the 
application of effective flea control products. 
This is the first report of Bartonella spp. antibodies in cats in Thailand. The 
seroprevalence rate of 65% is similar to those reported from other areas with high C. felis 
infestation rates (Chomel et al., 1999; Marston et al., 1999; Nasirudeen and Thong, 1999). The 
ELISA and PCR assay results were in agreement for only 44.4% of the cases and when the PCR 
assay result was used as the reference test, the positive predictive value and negative predictive 
value for ELISA were 20% and 90%, respectively. Like previous other studies (Barrs et al., 




This study is the first report of B. koehlerae infection in cats and C. felis in Thailand. Cats 
are considered to be the reservoir for B. koehlerae, but the prevalence rates appear to be low in 
both cats and fleas (Droz et al., 1999). 
B. henselae and B. clarridgeiae were commonly amplified in both cats and fleas. Since B. 
henselae is predominant among cats in the area, B. henselae infection should be suspected as an 
underlying cause when cats present with clinical signs associated with bartonellosis. We found 
that 6% of the cats had fever and 44% were positive for Bartonella spp. DNA. A subsequent 
study will be performed to further assess whether Bartonella spp. infections are associated with 
fever in cats in Thailand. 
Just as with Bartonella spp., hemoplasma prevalence rates in cats and fleas are 
increasingly being studied worldwide. Prevalence rates vary among cat populations and 
geographical areas, ranging from 27% to 40% (Shaw et al., 2004; Tasker et al., 2004; Lappin et 
al., 2006). In this study, ‘Candidatus M. haemominutum’ is the major species found in cats and 
fleas, while M. haemofelis is the subpopulation. Only 11% of hemoplasma-positive cats had the 
same hemoplasma species in blood and fleas, suggesting that the fleas may be feeding on more 
than one cat as discussed for the Bartonella spp. In addition, current flea infestation did not 
increase the risk of hemoplasma infection in these cats. C. felis may play a minor role on 
transmission of hemoplasmas in cats, and fleas may merely obtain hemoplasmas via the 
hematophagous activity. Fighting and biting are proposed to be the natural route of hemoplasma 
transmission (Sykes, 2010). 
The failure to amplify R. felis DNA from feline blood has been reported in other studies 
(Hawley et al., 2007; Barrs et al., 2010). Bacteremia may be transient and intermittent, or R. felis 
could be sequestered in tissues other than blood. R. felis antibodies have been detected in serum 
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of some cats suggesting exposure may be relatively common (Case et al., 2006; Bayliss et al., 
2009). However, additional seroprevalence work is needed to further determine the range of R. 
felis exposure in cat populations. Cat fleas are a natural vector for R. felis, and the prevalence in 
C. felis has commonly been reported (Parola et al., 2003; Shaw et al., 2004). In this study, R. felis 
DNA was not amplified from any of the fleas. In the only other study of R. felis in C. felis in 
Thailand (Parola et al., 2003), the prevalence rate was not reported. Why R. felis DNA was not 
amplified from fleas in this study is unclear. It is possible that R. felis infection is very rare or the 
organism was present but was below the limit of detection of the assay. 
In conclusion, cats and fleas in Bangkok are commonly positive for DNA of Bartonella 
spp., hemoplasmas, or a combination of these flea-associated organisms. Because of the potential 
for illness to be induced by these agents in the cats or humans, flea control for cats is highly 
suggested in the area. 
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Determination of Bartonella henselae Bacterial Load and Antigen Level in                 
Blood Samples of Febrile and Afebrile Client-owned Cats 
 
6.1 Summary  
Some cases of fever of unknown origin in cats may be probably caused by B. henselae 
infection, but correlation of fever and infection has not been clearly documented. A quantitative 
real-time polymerase chain reaction (qPCR) assay and an antigen-capture enzyme linked 
immunosorbent assay (AC-ELISA) were recently developed for detecting B. henselae infection 
in cats. The objectives of this study were to determine whether bacterial DNA load and antigen 
levels of B. henselae are associated with fever, and to identify risk factors that might be 
associated with fever in cats presenting to veterinary hospitals in Thailand. Blood and serum 
samples were collected from client-owned cats, including 22 with fever of unknown cause and 
178 without fever. Total DNA was extracted from each sample and evaluated in Bartonella and 
hemoplasma conventional PCR assays and the new B. henselae qPCR assay. Each blood sample 
was assayed in the AC-ELISA, and each serum sample was tested for Bartonella spp. IgG, feline 
leukemia virus antigen, and feline immunodeficiency virus antibodies. Febrile cats had 
significantly higher prevalence of B. henselae DNA than those of afebrile cats. Higher bacterial 
load in febrile cats than afebrile cats was detected, but the finding was not statistically 
significant. Because of low sensitivity of the AC-ELISA, the presence of B. henselae antigen 
was not associated with fever. The present study supports that B. henselae infection is associated 
with fever, and B. henselae-infected cats with high bacterial DNA levels are most likely to 
develop fever.  
Keyword: B. henselae; Fever; Cat; qPCR; Antigen  
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6.2 Introduction  
Fever is a common clinical sign developed in cats during infections, inflammations, and 
immunologic or idiopathic diseases. A number of infectious agents, including viruses, bacteria, 
fungi, and protozoa have been found to be causes of fever in cats. Among these organisms, 
Bartonella spp., hemoplasmas, feline leukemia virus (FeLV), and feline immunodeficiency virus 
(FIV) are the common organisms that infect cats. They are also included in the lists of diagnosis 
for febrile cats presenting to the veterinary practitioner. Bartonella henselae has been known to 
commonly infect cats as the primary animal reservoir and results in subclinical infection with 
prolonged intra-erythrocytic bacteremia. However, some infected cats may develop clinical 
signs; fever appears to be common and is reported in both experimentally and naturally infected 
cats. Lymphadenopathy, inflammatory skin lesions, lethargy, anorexia, mild neurologic signs, 
and reproductive disorders also develop in some experimentally infected cats (Guptill et al., 
1997; Guptill et al., 1998; Kordick et al., 1999; O'Reilly et al., 1999; Bradbury and Lappin, 
2010). Uveitis, stomatitis, gingivitis, lymphadenopathy, hyperglobulinemia, and urological 
diseases have been documented in naturally-infected cats (Ueno et al., 1996; Glaus et al., 1997; 
Lappin et al., 2000; Lappin et al., 2009; Whittemore et al., 2012). Hemoplasmas are the causative 
agents of infectious anemia in cats. Acute infection with Mycoplasma haemofelis and 
‘Candidatus Mycoplasma turicensis’ can cause fever, lethargy, anorexia, and anemia (Foley et 
al., 1998; Willi et al., 2005). Cats infected with ‘Candidatus Mycoplasma haemominutum’ are 
subclinical or develop only minimal clinical signs of acute disease (Foley et al., 1998; Foley and 
Pedersen, 2001). Fever is also a common clinical sign presenting in cats infected with the 
retroviruses, FeLV and FIV. Cats may not show any clinical signs in the initial state, but sickness 
is obviously seen in the chronic state, particularly FeLV which may lead to cancer. Both FeLV 
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and FIV may cause severe immune suppression in cats resulting in increased risk of 
opportunistic infections (Pedersen et al., 1989; Hoover and Mullins, 1991).  
Diagnosis of Bartonella spp. in cats mostly relies on amplification of bacterial DNA from 
blood of animals due to the high sensitivity and specificity of molecular assays. Routine culture 
of blood is less frequently used clinically because of delayed turnaround time for results and 
some culture techniques are less sensitive than some of the PCR assays. Antibody testing by 
means of immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), or 
western blot can be performed quickly and inexpensively, but results often are not correlated 
with current infection or disease manifestations. A recent study revealed higher prevalence of 
Bartonella spp. DNA in febrile cats than afebrile cats (Lappin et al., 2009). Fever caused by 
infection is an inflammatory response of the host’s immune system triggered by exogenous 
pyrogens. This raises a question regarding level of bacteremia that can stimulate fever. In order 
to determine estimate the level of bacteremia, a quantitative real-time polymerase chain reaction 
(qPCR) assay and an antigen-capture enzyme-linked immunosorbent assay (AC-ELISA) were 
recently developed for the amplification of B. henselae DNA and antigen, respectively. The 
hypothesis to be tested is that higher levels of B. henselae DNA or antigen will be detected in the 
blood of febrile cats than those of afebrile cats. The objectives of this study were to determine 
whether bacterial load and antigen level of B. henselae are associated with fever, and to identify 







6.3 Materials and Methods 
6.3.1 Client-owned Cats and Sample Collection 
Whole blood samples were collected from febrile and aferile client-owned cats presenting 
to veterinary practitioners in the Small Animal Teaching Hospital of Chulalongkorn University 
and 6 private veterinary hospitals in Bangkok, Thailand between June 2010 and October 2010. 
Physical examination was performed by attending practitioners on all cats. Fever was defined as 
body temperature > 102.5 F. Only febrile cats with unknown cause of fever on physical 
examination were included in the study. Cats diagnosed with hyperthermia of known causes, and 
cats previously treated with antibiotics within two weeks were excluded. One ml of EDTA-
anticoagulated whole blood sample and 0.5 ml of serum sample from each cat were stored at -20 
C and shipped on ice packs to the Center for Companion Animal Studies at Colorado State 
University, where total DNA was extracted from the whole blood, and PCR assays were 
performed. A questionnaire was completed by the owner and veterinarian at the time of sample 
collection. The questionnaire provided information concerning signalment, housing location, 
presence or absence of flea infestation, and flea control.  
 
6.3.2 DNA Extraction  
The total DNA was extracted from 200 µl of each blood sample using a commercially 
available kit (QIAamp DNA Blood Mini Kit, QIAGEN, Valencia, CA) that was performed 
following the manufacturer’s instructions. The extracted DNA was eluted in 200 µl of Tris-




6.3.3 Conventional PCR Assays 
The conventional PCR assays described previously (Jensen et al., 2000; Jensen et al., 
2001) were performed to detect Bartonella spp. and hemoplasmas in the total DNA samples. The 
positive results were detected by electrophoresis on a 3% agarose gel, stained and visualized 
with UV light. The PCR products of B. henselae and B. koehlerae yielded the same size of the 
band, as well as M. haemofelis and ‘Candidatus M. turicensis’. The species were confirmed by 
DNA sequencing, which was performed at Macromolecular Resources, Colorado State 
University, Fort Collins, CO. 
 
6.3.4 Bartonella henselae-specific Quantitative Real-time PCR Assay 
All samples positive for B. henselae DNA in cPCR assay were subsequently analyzed in 
the qPCR assay. In addition, cPCR-negative samples from 6 febrile and 6 afebrile cats were also 
randomly selected for testing with the qPCR assay. All reactions were performed in triplicates in 
the PCR mixture consisted of 10 µl of commercially available master mix (2X TaqMan Fast 
Advanced Master Mix, Applied Biosystems, Carlsbad, CA), 0.6 µM of each primer (forward: 5’ 
CTC TCG ATG ACA ATG GGA 3’ and reverse: 5’ ACT TCG GTT CCA GAC CAT 3’), 0.15 
µM of probe (5’ FAM-TCC AAA CAA GAT ACG GTC CCC TG-BHQ1 3’), 2 µl of template 
DNA in a final 20 µl reaction mix. The PCR was carried out with a thermocycler (Mastercycler 
ep realplex, Eppendorf, Hamburg, Germany) under the following conditions: incubation at 50 C 




6.3.5 Estimation of Bacterial Load by qPCR assay  
A standard curve was performed from a blood sample set spiked with known initial 
amount of B. henselae, ranging from 5.2 x 10
6
 to 52 CFU/ml. The absolute amount of B. 
henselae in unknown samples was extrapolated from quantification cycle (Cq) values with the 
standard curve by a simple linear regression model. 
 
6.3.6 Rabbit Polyclonal Antibody Production  
Bacterial cells of B. henselae strain CSU-1 were disrupted by 30% pulsed sonication for 
10 min. After centrifugation of the sonicate suspension at 10,000 g for 10 min, the supernatant 
was discarded. The pellet was suspended in sterile deionized water. The crude antigen 
suspension was then diluted, aliquoted into single doses, and stored at -80 C until used. 
The immunization protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC). Two female, 4-kg, New Zealand White rabbits were used for 
immunization. The rabbits were first inoculated subcutaneously in multiple sites with 100 µg of 
crude antigen mixed with Freund’s Complete Adjuvant. They were boosted twice in 2-week 
intervals by intramuscular injection of the same quantity of antigen emulsified in Freund's 
Incomplete Adjuvant. Antibodies against B. henselae were evaluated every 2 weeks by agar gel 
immunodiffusion test, as previously described (Lappin et al., 1989; Simard et al., 2000). 
Approximately, 40 - 60 ml of blood was collected by lateral ear venipuncture for serum 
separation at week 8, 12, and 16 of immunization. Total IgG was purified from antisera using a 
commercially available kit (Melon Gel IgG Purification Kit; Thermo Fisher Scientific, Rockford, 
IL). The procedure was performed following the manufacturer’s instructions. The purity of IgG 
preparations was determined using sodium dodecyl sulfate polyacrylamide gel electrophoresis 
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(SDS-PAGE), as previously described (Laemmli, 1970). Purified IgG solutions of two rabbits 
were pooled, and fractions of the pooled IgG were conjugated with horseradish peroxidase 
(HRP) by a commercially available kit (EZ-Link Plus Activated Peroxidase Kit; Thermo Fisher 
Scientific, Rockford, IL), following the manufacturer’s instructions. The conjugate was 
preserved in 50% glycerol solution. Pooled IgG and conjugate were stored at -20 C until 
assayed. 
 
6.3.7 Blood Sample Preparation for AC-ELISA 
Whole blood samples were lysed with 20 volume of deionized water. Suspension was 
vortexed for 10 s and left to stand for 10 min. Hemolysate was loaded into a centrifugal filter 
unit with 5-µm pore size (Ultrafree-MC, Millipore, Billerica, MA). The tube was centrifuged at 
10,000 g for 10 min.  The filtrate was gently pipetted out and discarded. The precipitate was 
resuspended with PBS-TW before applied to the assay. 
 
6.3.8 AC-ELISA Procedure 
The same sample set that was tested in the qPCR assay was also tested with the AC-
ELISA. A microtiter plate was coated at 4 C overnight with rabbit anti-B. henselae IgG (25 
µg/ml) diluted with PBS (pH 9.0). The plate was washed for 4 times with PBS containing 0.05% 
Tween 20 (PBS-TW) after incubation, and then blocked at 37 C for 1 h with 0.5% NFDM. 
Following 4-time washing, samples in quadruplicates were applied to the plate. The plate was 
incubated at 37 C for 30 min. After washing, the rabbit HRP-conjugated IgG (10 µg/ml) with 
PBS-TW was added into wells, and the plate was incubated at 37 C for 30 min. Washing was 
applied, and TMB substrate was added into wells. The plate was incubated at room temperature 
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for 10 min before the reaction was stopped with sulfuric acid solution (0.18 M). The optical 
density (OD) value was read at 450 nm wavelength by a microplate reader. Blank and substrate 
controls were included in each plate and each run of the assay. 
 
6.3.9 Calculation of the Positive Cut-off for the AC-ELISA 
A sample was determined to positive when OD value was higher than a cutoff which was 
calculated by average OD value of known negative samples plus 3 times of standard deviations 
(SD).  
 
6.3.10 Bartonella spp. IgG ELISA 
Serum samples were analyzed for Bartonella spp. IgG using the protocol described 
previously (Lappin et al., 2009). 
 
6.3.11 Detection of Retroviral Infection 
Serum was used to identify feline leukemia virus (FeLV) and feline immunodeficiency 





6.3.12 Data Analysis  
Continuous variables, including age and bacterial load were expressed as median (range), 
while body temperature were expressed as mean + SD. Comparison of continuous variables 
between cats with and without fever was analyzed by two sided t-test or Wilcoxon Rank Sum 
Test. Associations between categorical variables and fever were determined by Pearson’s Chi-
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square test and Fisher’s exact test, and P-value < 0.05 was considered as significant. Logistic 
regression analyses were used to evaluate factors that might be associated with fever. The 
dependent variable was the clinical sign of fever (y/n), and the independent variables included 
age (> 1 year/< 1 year), sex (male/female), housing location (indoor/indoor and outdoor), flea 
infestation (y/n), and flea control (y/n), B. henselae DNA (positive/negative), B. henselae antigen 
(positive/negative), Bartonella spp. IgG (positive/negative), “Candidatus M. haemominutum” 
DNA (positive/negative), FIV antibody (positive/negative), and FeLV antigen 
(positive/negative). Variables with a critical  of 0.25 in univariable models were entered as 
predictor variables in the multivariable model. The final model was identified using backwards 
selection with a critical  of 0.05. Confounding and interactions were also evaluated. Odds ratios 
(OR) and 95% confidence intervals (CI) were calculated from logistic regression models. 
Statistical significance was set as P < 0.05. Analyses were accomplished using statistical 
software (SAS 9.1, SAS Institute, Cary, NC). 
 
6.4 Results  
6.4.1 Client-owned cats 
Two hundred cats were included in the study, of which 22 were febrile and 178 were 
afebrile. The median age of febrile cats (1.2 years, range 0.4 - 10) was not significantly different 
from afebrile cats (2 years, range 0.2 - 17; P = 0.20). The majority (169/200) of cats presented to 
the Small Animal Teaching Hospital of Chulalongkorn, and the other cats were recruited from 
private veterinary hospitals. The mean body temperature in febrile cats (103.6 + 0.9 F) was 
significantly higher than afebrile cats (100.8 + 1.01 F; P < 0.001). The age, sex, housing 
location, flea infestation, and flea control of client-owned cats with and without fever are 
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described in Table 6-1. There was no significant difference in the proportions of these variables 
between both groups of cats (Table 6-2).  
Table 6-1   Characteristics of client-owned cats. Twenty-two febrile and 178 afebrile client-
owned cats presented to one of 7 veterinary hospitals in Bangkok, Thailand in 2010. Data 
presented as number (%). 
 
Characteristic 
Fever (n=22) No fever (n=178) 




































































Table 6-2   Univariable logistic regression analysis of variables that are associated with fever. 
Characteristics of cats and laboratory findings of 200 client-owned cats that were presenting to 
one of 7 veterinary hospitals in Bangkok, Thailand in 2010 were analyzed for risk factors of 
fever.  
 
Variable  Category OR [95% CI] P-value 
Age  
 
> 1 year 
<1 year  






























1.21 [0.47, 3.13]  
Ref. 
0.69 
B. henselae DNA 
 






2.80 [0.99, 7.96]  
Ref. 









0.59 [0.16, 1.79]  
Ref. 
0.32 
































6.4.2 cPCR Results 
Overall prevalence rates of Bartonella spp. DNA and hemoplasma DNA were 20% 
(40/200) and 22% (44/200), respectively. Only DNA of B. henselae and ‘Candidatus M. 
haemominutum’ was detected in febrile cats. Five febrile cats were positive for B. henselae only, 
2 were positive for ‘Candidatus M. haemominutum’ only, and 1 was positive for both B. 
henselae and ‘Candidatus M. haemominutum’ (Table 6-3). Prevalence rates of B. henselae DNA 
in febrile cats were 27.3%. Of 63 afebrile cats positive for any organism, the majority were 
positive for ‘Candidatus M. haemominutum’ only (20 cats), followed by B. henselae only (14 
cats). Some afebrile cats were positive for only M. haemofelis or B. clarridgeiae. B. koehlerae or 
‘Candidatus M. turicensis’ was detected from each of 2 afebrile cats. The DNA of more than one 
species was also detected in afebrile cats. The prevalence rate of B. henselae DNA in afebrile 
cats was 11.8%. Febrile cats had significantly higher prevalence of Bartonella spp. DNA than 
afebrile cats (P = 0.05), but prevalence rate of ‘Candidatus M. haemominutum’ DNA was not 
significantly different between groups (P = 0.58) (Table 6-2). The odds of having Bartonella 
spp. DNA in blood was 2.5 times higher for cats infested with fleas compared with those without 
flea infestation (P = 0.04). Age was not significantly associated with the prevalence of B. 
henselae DNA (OR 1.07, 95% CI 0.42 - 2.72; P = 0.89); neither was sex (OR 0.88, 95% CI   
0.36 - 2.20; P = 0.77), housing location (OR 1.66, 95% CI 0.70 - 3.92; P = 0.25), or flea control 







Table 6-3   Prevalence of Bartonella spp. and hemoplasma DNA determined by cPCR assays in 
blood samples of 22 febrile and 178 afebrile client-owned cats.  
 
Assay 
Fever (n=22) Non-fever (n=178) 
Number (%) Number (%) 
Negative 14 (63.6) 115 (64.6) 
B. henselae  5 (22.7) 14 (7.8) 
B. clarridgeiae  0 (0) 7 (3.9) 
B. koehlerae  0 (0) 1 (0.6) 
‘Candidatus M. haemominutum’  2 (9.1) 20 (11.2) 
M. haemofelis  0 (0) 6 (3.4) 
‘Candidatus M. turicensis’  0 (0) 1 (0.6) 
Co-infections 
‘Candidatus M. haemominutum’ and M. haemofelis 
B. henselae and ‘Candidatus M. haemominutum’ 
B. henselae and M. haemofelis 
B. henselae, ‘Candidatus M. haemominutum’, and 
M. haemofelis 
B. clarridgeiae and ‘Candidatus M. haemominutum’  



































6.4.3 qPCR Results 
The quantitative performance of the qPCR assay was established by the standard curve 
which is shown in Figure 6-1. The plot of the log of bacterial load (CFU/ml) versus the Cq 
showed a linear correlation (R
2 
= 0.997). The efficiency of the qPCR was 79%, and the limit of 
detection (LOD) was 52 CFU/ml.  
 
Figure 6-1.   Standard curve for the qPCR assay. Six orders of magnitude of B. henselae, 
ranging from 52 (a) to 5.2 x 10
6
 (f) CFU/ml, were spiked in feline whole blood samples.  
 
All of the samples that tested positive for Bartonella cPCR, including 6 febrile and 21 
afebrile cats were also positive by the qPCR assay. Of 6 febrile cats that were positive with 
qPCR assay, only 1 had bacterial load below the LOD. The median bacterial load of 6 febrile 
cats was 2470 CFU/ml (range 21 - 7467 CFU/ml). Whereas 11 of 21 afebrile cats positive with 
qPCR assay had bacterial load which was below the detection limit. The median bacterial load of 
21 afebrile cats was 49 CFU/ml (range 19 - 3494 CFU/ml). The median bacterial load of febrile 
cats was 50 times higher than that of afebrile cats (Figure 6-2), although the difference was not 
statistically significant (P = 0.15). The cPCR-negative samples were all negative with the qPCR 












Figure 6-2.   Comparison of B. henselae bacterial load between febrile and afebrile cats. Box 
plots of B. henselae bacterial load (CFU/ml) in blood samples of 21 afebrile and 6 febrile client-
owned cats presenting to one of 7 veterinary hospitals in Bangkok, Thailand in 2010. The box 
represents the interquartile range (25-75%), the horizontal line represents the median, and the T-

































6.4.4 AC-ELISA Results 
The AC-ELISA was shown to be specific to B. henselae since other Bartonella spp. and 
unrelated Bartonella bacteria tested for specificity were all negative in the assay. Blood samples 
of 27 febrile and afebrile cats that were tested positive by both PCR assays were also tested in 
the AC-ELISA. Overall, 29.6% of cats were positive by the AC-ELISA. The results showed that 
the AC-ELISA was less sensitive than both PCR assays. Of 6 febrile cats positive with PCR 
assays, only one (16.7%) was positive with AC-ELISA. Seven of 21 (33.3%) afebrile cats that 
were positive by PCR assays were also positive with AC-ELISA. The cPCR-negative samples 
tested were all negative with the AC-ELISA. The odds of developing fever were not significantly 
different between cats positive and negative with B. henselae antigen (Table 6-2). 
 
6.4.5 Bartonella spp. IgG 
Sixty-four cats (32%) were positive for Bartonella spp. IgG, in which 13 were B. 
henselae DNA positive, 3 were B. clarridgeiae DNA positive, 1 were B. henselae and B. 
clarridgeiae DNA positive, and 47 were negative for Bartonella spp. DNA. The cat that was 
positive for B. koehlerae DNA was negative for Bartonella spp. IgG.  
 
6.4.6 FeLV and FIV Results 
Overall prevalence rates of FeLV antigen and FIV antibody was 11% (22 cats) and 9% 
(18 cats), respectively. Of 22 febrile cats, 5 (22.7%) were positive for FeLV antigen, and 2 
(9.1%) were positive for FIV antibody. Among 178 afebrile cats, 17 (9.6%) were positive for 
FeLV antigen, and 16 (9.0 %) were positive for FIV antibody. Neither FeLV (P = 0.07) nor FIV 
(P = 0.99) was associated with fever (Table 6-2). Three cats (1.5%) were positive for both FeLV 
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and FIV, and these cats were not febrile. Of 40 cats that were Bartonella spp. DNA positive, 5 
(12.5%) were concurrently positive for FeLV, and 2 (5%) were also positive for FIV. The 
prevalence of FeLV antigen was not associated with the presence or absence of Bartonella spp. 
DNA (OR 1.20, 95% CI 0.32 - 3.7; P = 0.78). The FIV antibody was not associated with the 
prevalence of Bartonella spp. DNA (OR 0.47, 95% CI 0.05 - 2.16; P = 0.54).  
 
6.4.7 Risk Factors for Fever  
Of all variables described in Table 6-2, the variables of sex, FeLV, and B. henselae DNA 
passed screening (P < 0.25), and they were included in multivariable model building. However, 
the final model included only B. henselae DNA because this was the main risk factor of interest 
and was the only significant factor. The odds of developing fever was 2.8 times greater for cats 
that were positive for B. henselae DNA compared with those that were negative (95% CI 0.99 - 
7.96; P = 0.05).  
 
6.5 Discussion 
Cats are prone to develop feline bartonellosis during infection with B. henselae, and fever 
is the most clinical sign documented. In this study, the prevalence of B. henselae DNA was 
almost 3 times higher in febrile than afebrile cats (P < 0.05). The results of this study are 
consistent with those of the previous study which was performed with samples of cats in the 
United States (Lappin et al., 2009). Fever has been reported in B. henselae-infected cats (Guptill 
et al., 1997; Guptill et al., 1998; Kordick et al., 1999; O'Reilly et al., 1999; Mikolajczyk and 
O'Reilly, 2000; Bradbury and Lappin, 2010), and has also been documented in B. henselae-
infected people (Chomel et al., 2006). Although B. henselae infection cannot be proved to be the 
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cause of fever, this study suggests that presence of B. henselae DNA in blood is related to fever 
in cats. The overall prevalence of Bartonella spp. DNA was similar to that of the recently 
published study of cats within the same area (Assarasakorn et al., 2012). Bartonella clarridgeiae 
and B. koehlerae were rarely amplified from blood of cats, and those samples were from afebrile 
cats. Both species of Bartonella may be minimal pathogenic organisms for cats. Cats of this area 
are prone to be infected with many feline Bartonella spp.; however, the qPCR assay was 
designed to be specific to only B. henselae due to the highest prevalence rate and clinical 
relevance in cats.  
This study proposes the qPCR assay which is capable of estimating B. henselae bacterial 
load in feline blood. The assay is very specific to B. henselae, and the analytical sensitivity is 
comparable to the currently used cPCR assay (Jensen et al., 2000). The advantage of the new 
assay is the quantification of bacteria that would be detected earlier than routine culture. Levels 
of Bartonella henselae DNA between cats with and without fever are compared for the first time 
in this study. The qPCR results demonstrated 100% concordance with the cPCR results. These 
findings show that the qPCR assay has equivalent diagnostic sensitivity to the cPCR assay. There 
were 44% (12/27) of the samples tested that had bacterial load lower than the limit of detection 
of the assay. The least amount of bacterial load detected in these samples was 19 CFU/ml. All of 
these samples were considered truly positive due to high specificity of the assay, but the 
detectable bacterial load beyond the detection limit may have risk for inconsistence and 
imprecision. However, all qPCR-positive results were included for comparing between groups of 
cats. That is because at least 2 of 3 replicates of each sample were found to be positive. This 
study suggests that very low bacterial load should be interpreted with caution because the actual 
quantity was difficult to acquire between replicates with unacceptably large variation. Samples 
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with very low bacterial load may originally have very low amount of B. henselae, but it is 
possible that DNA might be lost over the period of storage due to the degradation of DNA.  
Despite febrile cats had approximately 50 times higher B. henselae bacterial load than 
afebrile cats, there was no significantly different in bacterial load between groups. Lack of 
statistical significance should be caused by inadequate number of studied cats. Repeating an 
analysis with a larger sample size is strongly recommended in order to increase the statistical 
power. The results of the present study suggest that fever is more likely to develop in cats that 
have high level of bacterial load detected by the qPCR assay. However, cats are natural reservoir 
for B. henselae, afebrile cats can also have estimated bacterial loads. The pathogenesis of fever is 
generally triggered by endogenous pyrogens (cytokines) that are released from phagocytic cells 
after they are activated by exogenous pyrogens such as bacterial infection. The higher number of 
B. henselae may be able to induce higher responses of phagocytic cells, and these cats are prone 
to develop fever. If the bacterial load was proved to be associated with fever, the qPCR assay 
would be used for diagnosis of fever related to B. henselae infection in cats. 
The AC-ELISA is an immunoassay that was developed for detection of B. henselae 
antigen in order to evaluate whether antigenemia level is associated with fever induced by B. 
henselae infection. The performance of this AC-ELISA is not adequate for detection of B. 
henselae antigen in feline blood. Of all PCR positive-samples tested, about 30% were found 
positive with AC-ELISA. The results document that the PCR assays tested have higher 
sensitivity or better ability to identify cats with B. henselae infection than the AC-ELISA. 
Negative results in PCR assays suggest the absence of infection, but negative results in AC-
ELISA may be falsely negative. The results suggest that low analytical sensitivity of the assay 
may result in low diagnostic sensitivity and low negative predictive value, as well.  
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The limited analytical sensitivity of the AC-ELISA may be caused by the avidity of the 
rabbit antibodies used. The antibodies produced from the 2 rabbits showed similar reactivity in 
the screening test (AGID test). The antibodies of both rabbits were then pooled and used for 
coating the plate and detecting the antigen of bacteria. In spite of adequate optimization, the 
pooled antibody itself may not have enough avidity for antigen binding. Antigen, particularly 
with low amount of antigen will be separated from antibody on the solid phase, and no signal 
will be generated. The result of this study suggested that selection of a perfect match pair of 
antibody should be performed using different sources of antibodies. False negatives may result 
from the degradation of antigen during transport and storage of samples. Results would be more 
accurate if fresh samples are tested.  
Because cross-reaction of polyclonal antibodies and non-relevant antigens in blood 
sample may occur, the high cutoff value was selected to avoid false positivity from non-specific 
binding. Concurrently, the high cutoff then decreased the analytical sensitivity that may affect 
the diagnostic sensitivity of the assay. If the level of analyte to be tested is below the detection 
limit, the assay will detect that sample as a false-negative test result. Cats infected with B. 
henselae commonly have prolonged, intermittent bacteremia for months or years. It is possible 
that antigen-negative cats may be experiencing chronic infection with low level bacteremia and 
antigenemia. Otherwise, cats may be within the window period of B. henselae infection, which is 
the time between first infection and when the test can reliably detect that infection. Because of 
higher sensitivity of PCR assays, B. henselae DNA may be detected earlier than the detection of 
B. henselae antigen. The advantage of the assay is the specificity to B. henselae antigens. Low 
rates of false positive test results should be found. The presence of B. henselae antigen in feline 
blood was shown to be not associated with fever for this sample set. However, because of limited 
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performance of the AC-ELISA, the assay did not provide enough information to determine an 
association with fever. In addition, the present AC-ELISA is not suitable for clinical use. 
Improvement of the sensitivity of the assay is highly suggested, and the performance should be 
determined by a larger number of the cat population. 
In this study, seroprevalence of Bartonella spp. IgG was not associated with the 
prevalence of B. henselae DNA. Similar results were documented in a previous study (Lappin et 
al., 2009). The Bartonella spp. ELISA may be used to recognize whether a cat was exposed to B. 
henselae, but it should not be used to test for current infection. In addition, seroprevalence of 
Bartonella spp. IgG was not associated with fever in the cats described here which is the same as 
the result in the previous study (Lappin et al., 2009). However, there were 29% (47 cats) of PCR-
negative cats that were positive by the Bartonella ELISA. The combination of PCR and ELISA 
results resulted in the detection of Bartonella in a total of 43.5% (87 cats) in this sample set, 
while only 20% of the cases could be identified by the PCR alone. The combined tests of PCR 
and ELISA were suggested to increase the detection of Bartonella-infected cats.  
 The overall prevalence of hemoplasma DNA was similar to the prevalence in cats in the 
previous study (Assarasakorn et al., 2012). Hemoplasma DNA of either ‘Candidatus M. 
haemominutum’ or M. haemofelis was commonly found in afebrile cats. ‘Candidatus M. 
turicensis’ was first identified in a healthy cat in Thailand in this study. Cats with hemoplasma 
infections may develop hemolytic anemia, particularly M. haemofelis that is more pathogenic 
(Foley et al., 1998; Sykes et al., 2007), and ‘Candidatus M. turicensis’ was recently been proven 
to be cause hemolytic anemia in cats (Willi et al., 2005). ‘Candidatus M. haemominutum’ was 
found to be associated with anemia in client-owned cats (Reynolds and Lappin, 2007). Anemic 
cats having hemoplasma DNA should be considered to be treated with antihemoplasma drug.  
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No association was found between the prevalence of Bartonella spp. DNA and the 
prevalence of FIV or FeLV in this study. The absence of association between Bartonella spp. 
IgG and FIV infection is not surprised, and the result is consistent with previous studies (Glaus et 
al., 1997; Maruyama et al., 1998; Dubey et al., 2009). Rather, a negative association between 
seroprevalence of Bartonella spp. and the prevalence of FeLV antigen was found in this study. 
Care should be taken in interpreting this result because it was based on a low number of 
observations (2 cats were positive for Bartonella spp. IgG and FeLV).  
Logistic regression analysis showed that no risk factors, but B. henselae DNA was 
associated with fever in cats. Bartonella henselae-infected cats of any age, sex, housing location, 
with or without flea infestation, and with or without flea control can develop fever. Infection 
with hemoplasmas, FeLV, and FIV was evaluated as possible contributing factors to the 
development of fever in this study. However, none of these infections was associated with fever 
in these cats. There were 8 febrile cats that were negative in all assays. The predisposing cause of 
fever in these cats was unknown.  
In conclusion, the findings of this study strongly support that B. henselae should be 
considered as an etiologic agent of cats with fever of unknown origin, particularly cats with high 
bacterial load of B. henselae. The qPCR assay is suggested to be used for diagnosis of fever 
associated with B. henselae infection. Because of low sensitivity, the AC-ELISA is not 
appropriate for clinical use.  
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Conclusions and Future Directions 
 
7.1 Conclusions  
Bartonella henselae infection is important in cats for both clinical and zoonotic issues. 
Due to vague clinical signs which may develop in infected cats, diagnostic tests are necessary to 
help formulate the optimal treatment plan. A major goal of this work was to develop new 
quantitative assays which have adequate sensitivity and specificity for aid in diagnosis of 
diseases associated with B. henselae infection in cats. This dissertation described how these two 
new assays, the qPCR and the AC-ELISA were developed and demonstrated the performance of 
the assays. The qPCR assay performed very well with feline blood. The sensitivity and 
specificity of the qPCR assay was equivalent to the cPCR assay which is commonly used and 
considered a reference test. Moreover, the qPCR assay provides advantages over the cPCR assay, 
including rapidity and quantitative measurement. For the polyclonal-based AC-ELISA, the 
performances of the assay are not adequate to apply to clinical cases. The sensitivity of the AC-
ELISA is inferior to that of the qPCR and the cPCR assays. The results of this study provide 
additional infectious disease agent prevalence information for cats in Bangkok, Thailand. The 
application of the qPCR assay to the samples of febrile and afebrile cats in Thailand suggest that 
using PCR to estimate bacterial load may aid in the diagnosis of fever associated with B. 
henselae infection. The results also provided additional information that B. henselae infection in 
cats can be associated with fever. The AC-ELISA applied to feline blood samples from Thailand 
did not show the association with fever and this assay should not be used for this purpose at this 
time. All of the work in this dissertation shows that the qPCR results are superior to non-
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quantitative test results to make an association between B. henselae and fever. Quantification of 
B. henselae bacterial load in feline blood appears to be helpful for diagnosis of fever in cats and 
the qPCR should be used to assess for other disease associations. The AC-ELISA in this 
dissertation was a prototype assay and these results can be used to aid in the development of a 
more sensitive assay in the future.  
 
7.2 Future Directions 
7.2.1 The qPCR assay 
While the qPCR assay described here has only moderate efficiency, its sensitivity was 
adequate for detecting B. henselae infection in cats, and is comparable with another currently 
being used PCR assay. However, if the efficiency of the assay can be improved, the limit of 
detection could be lower than the present assay. A higher number of samples with very low DNA 
quantities would likely be detected and additional information would be potentially gained. 
Several approaches can be performed in order to increase the stringency of assay, such as using 
different master mixes, adjusting the magnesium concentration, or using PCR 
enhancer/additives. The qPCR assay showed its ability for being used as a diagnostic tool. 
Although the statistical power of the study is not enough due to the limited number of samples 
from the cat population of interest (fever), it is suggested that bacterial load of B. henselae is 
likely to be associated with fever in some cats. A larger sample size is highly required in the next 
study. A qPCR cutoff value that consistently associated with fever was not determined in this 
work, but that will be evaluated further when additional samples are collected. The results of the 
qPCR assay may be evaluated in other clinical problems like uveitis to extend the clinical utility 
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of the assay. This work suggests that the qPCR assay can be a sensitive and cost-effective tool 
for diagnosis of feline bartonellosis. 
 
7.2.2  The AC-ELISA 
The performance characteristics, particularly the sensitivity of the AC-ELISA in this 
dissertation, are not adequate to detect B. henselae infection in cats. The assay is also not a 
reliable tool for diagnosis of B. henselae associated fever. The most important consideration to 
improve the assay is the efficiency of antibody. In this dissertation, the rabbit polyclonal 
antibodies used appeared to contain cross-reactive antibodies that increased the background 
signal of the assay. This finding significantly reduced the sensitivity and specificity of the assay. 
Sample processing can only improve the specificity, but the low sensitivity still exists. The use 
of monoclonal antibodies assay should be the antibody of choice for the AC-ELISA because 
cross-reaction can ultimately be eliminated. Due to high specificity between specific monoclonal 
antibodies and antigen, use of monoclonal antibodies is anticipated to decrease background as 
well as increase the sensitivity of the assay. Monoclonal antibody-based ELISA might be a cost-
effective test for B. henselae antigen detection. Furthermore, the assay may be developed in the 
format of a point-of-care test. 
